,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,AATK,"AATYK, AATYK1, KIAA0641, LMR1, LMTK1, PPP1R77",ENSG00000181409,Apoptosis associated tyrosine kinase,17,81117295-81166077,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA009073,Enhanced,,Uncertain,Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 36.4;duodenum: 23.4,small intestine: 18.3,Group enriched,5.0,CACO-2: 35.4;SH-SY5Y: 15.1
1,ABAT,GABAT,ENSG00000183044,4-aminobutyrate aminotransferase,16,8674565-8784575,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041528, HPA041690",Enhanced,Supported,Supported,Mitochondria,"Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 164.5;kidney: 135.3;liver: 175.2,thyroid gland: 47.5,Cell line enhanced,,Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1
2,ABC7-42404400C24.1,,ENSG00000277758,,10,47750864-47763592,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA036971, HPA036972, HPA064559",Approved,,Approved,Golgi apparatus,,Not detected,Tissue enhanced,,cerebral cortex: 13.8;lung: 19.3,skin: 5.7,Cell line enriched,7.0,SK-BR-3: 45.1
3,ABCC8,"ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2",ENSG00000006071,ATP binding cassette subfamily C member 8,11,17392885-17476845,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB011451, HPA042318",Approved,,Approved,Nucleoli<br>Golgi apparatus<br>Cytosol,,Tissue enriched,Tissue enhanced,,cerebral cortex: 11.3,adrenal gland: 7.5,Cell line enhanced,,A549: 1.7;AN3-CA: 1.8;SCLC-21H: 9.0
4,AC006486.9,,ENSG00000268643,,19,42234583-42255132,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 7.8,endometrium: 5.1,Cell line enhanced,,RT4: 21.6
5,AC007325.4,,ENSG00000278817,,Unmapped,131494-137392,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,cerebral cortex: 27.4;heart muscle: 34.4;skeletal muscle: 40.5,thyroid gland: 14.9,Cell line enhanced,,A549: 14.5;T-47d: 10.8
6,ACOT7,"ACH1, ACT, BACH, CTE-II, hBACH, LACH1, MGC1126",ENSG00000097021,Acyl-CoA thioesterase 7,1,6264269-6394391,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA025735, HPA025762",Enhanced,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:2.55e-6 (unfavourable), Liver cancer:2.31e-5 (unfavourable), Lung cancer:1.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 129.2,small intestine: 62.3,Expressed in all,,
7,ACSBG1,"BG1, BGM, FLJ30320, hBG1, hsBG, KIAA0631, MGC14352",ENSG00000103740,Acyl-CoA synthetase bubblegum family member 1,15,78167468-78245688,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041642, CAB045955, HPA058869",Approved,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 25.6;skin: 13.3,adrenal gland: 8.1,Cell line enhanced,,NTERA-2: 3.3
8,ADAM11,MDC,ENSG00000073670,ADAM metallopeptidase domain 11,17,44759031-44781846,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA074550,Enhanced,,,,,Mixed,Tissue enhanced,,cerebral cortex: 19.8,heart muscle: 4.0,Cell line enhanced,,HEK93: 18.5
9,ADAM22,MDC2,ENSG00000008277,ADAM metallopeptidase domain 22,7,87934143-88202889,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA050325,,,Approved,Cell Junctions,,Mixed,Tissue enhanced,,cerebral cortex: 47.6,prostate: 18.2,Cell line enhanced,,Karpas-707: 58.7;SH-SY5Y: 81.7
10,ADAP1,"CENTA1, GCS1L",ENSG00000105963,ArfGAP with dual PH domains 1,7,897901-955407,Predicted intracellular proteins,Evidence at protein level,"HPA007033, HPA012049",Enhanced,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:4.13e-5 (favourable), Colorectal cancer:5.25e-4 (unfavourable), Head and neck cancer:9.13e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 80.4,colon: 37.9,Cell line enhanced,,A-431: 97.9;CAPAN-2: 69.1;HMC-1: 64.7;THP-1: 87.7
11,ADCY1,"AC1, DFNB44",ENSG00000164742,Adenylate cyclase 1,7,45574140-45723116,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB018364, HPA068274",Uncertain,,Approved,Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 35.0,"cervix, uterine: 8.2",Cell line enhanced,,hTERT-HME1: 17.5;SCLC-21H: 16.1;SH-SY5Y: 27.5;SK-MEL-30: 23.8;WM-115: 17.1
12,ADCY2,"AC2, HBAC2, KIAA1060",ENSG00000078295,Adenylate cyclase 2,5,7396208-7830081,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB031482, HPA038015, HPA038483",Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 57.2;skeletal muscle: 23.6,prostate: 8.4,Group enriched,7.0,AF22: 5.6;NTERA-2: 4.3;SK-MEL-30: 3.8
13,ADCYAP1,PACAP,ENSG00000141433,Adenylate cyclase activating polypeptide 1,18,904943-912172,Predicted secreted proteins,Evidence at protein level,HPA065887,,Approved,,,Renal cancer:2.91e-6 (favourable),Tissue enhanced,Tissue enhanced,,appendix: 19.3;cerebral cortex: 16.0;gallbladder: 15.7,testis: 5.6,Cell line enriched,17.0,SCLC-21H: 20.8
14,ADCYAP1R1,"PAC1, PAC1R, PACAPR",ENSG00000078549,ADCYAP receptor type I,7,31052461-31111479,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA030739, HPA049877",Enhanced,,Supported,Vesicles,Endometrial cancer:5.78e-4 (favourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 137.1;fallopian tube: 46.8,"cervix, uterine: 20.7",Group enriched,6.0,AF22: 3.6;NTERA-2: 4.9;SCLC-21H: 4.8;SH-SY5Y: 7.8
15,ADGRA1,"GPR123, KIAA1828",ENSG00000197177,Adhesion G protein-coupled receptor A1,10,133070929-133131675,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA042773,Approved,,,,,Tissue enriched,Tissue enhanced,,adrenal gland: 4.9;cerebral cortex: 22.4,fallopian tube: 3.1,Cell line enriched,24.0,RH-30: 6.1
16,ADGRL1,"CIRL1, KIAA0821, LEC2, LPHN1",ENSG00000072071,Adhesion G protein-coupled receptor L1,19,14147743-14206187,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA037974,Uncertain,,,,"Pancreatic cancer:1.14e-4 (favourable), Renal cancer:4.45e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 60.1,parathyroid gland: 24.2,Cell line enhanced,,AN3-CA: 66.4;SCLC-21H: 64.6
17,ADGRL3,"KIAA0768, LEC3, LPHN3",ENSG00000150471,Adhesion G protein-coupled receptor L3,4,61201258-62078335,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA015027, HPA015762, CAB022698",Uncertain,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 42.0;parathyroid gland: 30.6,"cervix, uterine: 8.5",Cell line enhanced,,AF22: 41.2;EFO-21: 10.2
18,ADORA1,RDC7,ENSG00000163485,Adenosine A1 receptor,1,203090654-203167405,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA044383,,,Supported,Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 50.2;testis: 25.4,parathyroid gland: 18.9,Cell line enhanced,,CACO-2: 33.2;RH-30: 62.4;RPTEC TERT1: 23.7;SK-BR-3: 26.3
19,ADRA1B,,ENSG00000170214,Adrenoceptor alpha 1B,5,159916783-159972544,"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA074416,,,Supported,Plasma membrane,"Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 14.8;spleen: 17.0,ovary: 4.8,Cell line enhanced,,EFO-21: 12.8;TIME: 10.9;U-2 OS: 9.6
20,AGBL4,"CCP6, FLJ14442",ENSG00000186094,ATP/GTP binding protein like 4,1,48532855-50023913,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA037994,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 7.9,fallopian tube: 4.6,Cell line enhanced,,NTERA-2: 1.1;SCLC-21H: 1.9
21,AGPAT4,"dJ473J16.2, LPAAT-delta",ENSG00000026652,1-acylglycerol-3-phosphate O-acyltransferase 4,6,161129979-161274061,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA053287, HPA060525",Approved,,Approved,Nucleoli<br>Golgi apparatus<br>Vesicles,"Cervical cancer:1.45e-4 (unfavourable), Renal cancer:4.08e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 24.7,placenta: 12.3,Cell line enhanced,,AF22: 25.4
22,AGT,SERPINA8,ENSG00000135744,Angiotensinogen,1,230702523-230714297,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001557, CAB025798",Supported,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 226.5;liver: 649.6,gallbladder: 133.7,Cell line enhanced,,CACO-2: 60.4;Hep G2: 401.1;THP-1: 150.6
23,AIFM3,"AIFL, FLJ30473",ENSG00000183773,"Apoptosis inducing factor, mitochondria associated 3",22,20965108-20981360,Predicted intracellular proteins,Evidence at protein level,HPA001271,,,Enhanced,Mitochondria,Urothelial cancer:7.13e-5 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 18.5;colon: 18.7,rectum: 9.0,Cell line enhanced,,Hep G2: 5.1;HMC-1: 9.5;T-47d: 5.0;THP-1: 5.1
24,AJAP1,"MOT8, SHREW-1, SHREW1",ENSG00000196581,Adherens junctions associated protein 1,1,4654732-4792534,Predicted membrane proteins,Evidence at protein level,,,,,,Renal cancer:1.89e-7 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 11.3;ovary: 6.0,"kidney,seminal vesicle: 3.2",Cell line enhanced,,BEWO: 7.2;EFO-21: 6.2;RPTEC TERT1: 18.3
25,AKAP6,"ADAP6, AKAP100, KIAA0311, mAKAP, PRKA6",ENSG00000151320,A-kinase anchoring protein 6,14,32329273-32837681,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB001983, HPA048741",Enhanced,,,,,Mixed,Tissue enhanced,,cerebral cortex: 49.0;heart muscle: 36.0,skeletal muscle: 16.6,Cell line enhanced,,fHDF/TERT166: 12.2
26,ALK,CD246,ENSG00000171094,Anaplastic lymphoma receptor tyrosine kinase,2,29192774-29921566,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010694,Approved,,Supported,Plasma membrane,,Group enriched,Tissue enhanced,,cerebral cortex: 2.7;testis: 2.0,adrenal gland: 0.5,Cell line enriched,6.0,SH-SY5Y: 28.3
27,AMZ1,KIAA1950,ENSG00000174945,Archaelysin family metallopeptidase 1,7,2679522-2775500,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA020233,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 4.0,endometrium: 1.5,Cell line enhanced,,BEWO: 6.7;MCF7: 5.8;T-47d: 26.0
28,ANK2,LQT4,ENSG00000145362,Ankyrin 2,4,112818109-113383740,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA008007, CAB015178, HPA035970",Enhanced,,Supported,Plasma membrane,Renal cancer:2.41e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 184.4,kidney: 125.1,Cell line enhanced,,RH-30: 60.5;SH-SY5Y: 33.1
29,ANKRD13B,FLJ25555,ENSG00000198720,Ankyrin repeat domain 13B,17,29589769-29614761,Predicted intracellular proteins,Evidence at protein level,"HPA051886, HPA063748",Uncertain,,Supported,Vesicles,"Renal cancer:5.92e-6 (unfavourable), Pancreatic cancer:7.58e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 25.9,testis: 17.6,Cell line enhanced,,SCLC-21H: 75.3;SH-SY5Y: 76.2
30,ANKRD24,KIAA1981,ENSG00000089847,Ankyrin repeat domain 24,19,4183354-4224814,Predicted intracellular proteins,Evidence at protein level,"HPA041534, HPA048498",Uncertain,,Uncertain,Microtubules<br>Cytosol,Liver cancer:9.13e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 13.5;testis: 7.0,prostate: 3.2,Cell line enhanced,,Karpas-707: 3.5;U-266/70: 12.3
31,ANKRD34C,,ENSG00000235711,Ankyrin repeat domain 34C,15,79293285-79298235,Predicted intracellular proteins,Evidence at protein level,HPA045329,Uncertain,,Approved,Mitochondria,,Not detected,Tissue enhanced,,cerebral cortex: 1.9,skin: 0.9,Cell line enriched,29.0,SCLC-21H: 10.0
32,ANLN,"ANILLIN, scra, Scraps",ENSG00000011426,Anillin actin binding protein,7,36389806-36453791,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA005680, CAB033902, HPA050556, CAB062547, CAB068175",Enhanced,,Enhanced,Nucleoplasm<br>Midbody,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.97e-7 (unfavourable), Pancreatic cancer:2.00e-6 (unfavourable), Lung cancer:6.99e-5 (unfavourable), Endometrial cancer:1.73e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 87.2,bone marrow: 23.1,Expressed in all,,
33,ANO8,"KIAA1623, TMEM16H",ENSG00000074855,Anoctamin 8,19,17323223-17334829,Predicted membrane proteins,Evidence at protein level,"HPA031787, HPA049206",Uncertain,,Uncertain,Nucleoplasm<br>Nucleoli fibrillar center,,Expressed in all,Tissue enhanced,,cerebral cortex: 34.5,skin: 19.9,Mixed,,
34,APBA1,"D9S411E, MINT1, X11",ENSG00000107282,Amyloid beta precursor protein binding family A member 1,9,69427530-69672306,Predicted intracellular proteins,Evidence at protein level,HPA061287,,,Supported,Golgi apparatus,,Mixed,Tissue enhanced,,cerebral cortex: 18.4,parathyroid gland: 11.8,Cell line enhanced,,HAP1: 18.1;SCLC-21H: 7.9;U-138 MG: 7.0
35,APBA2,"D15S1518E, HsT16821, LIN-10, MGC:14091, MINT2, X11L",ENSG00000034053,Amyloid beta precursor protein binding family A member 2,15,28884483-29118315,Predicted intracellular proteins,Evidence at protein level,CAB037065,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 12.2,spleen: 3.3,Cell line enhanced,,HEL: 7.6;SH-SY5Y: 21.2;U-937: 11.6
36,APBB3,FE65L2,ENSG00000113108,Amyloid beta precursor protein binding family B member 3,5,140558268-140564781,Predicted intracellular proteins,Evidence at protein level,HPA005571,Uncertain,,Supported,Actin filaments<br>Cytosol,"Renal cancer:2.06e-6 (unfavourable), Pancreatic cancer:6.79e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 11.5,testis: 6.6,Cell line enhanced,,SCLC-21H: 7.1
37,APC,"DP2, DP2.5, DP3, PPP1R46",ENSG00000134982,"APC, WNT signaling pathway regulator",5,112707498-112846239,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA013349,Supported,,,,,Expressed in all,Tissue enhanced,,cerebral cortex: 60.1,parathyroid gland: 19.9,Expressed in all,,
38,ARFGEF3,"BIG3, C6orf92, dJ171N11.1, KIAA1244, PPP1R33",ENSG00000112379,ARFGEF family member 3,6,138161921-138344663,Predicted intracellular proteins,Evidence at protein level,HPA036350,Uncertain,,,,Breast cancer:8.20e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 23.7;parathyroid gland: 29.7,prostate: 19.2,Cell line enhanced,,RH-30: 13.0;RT4: 15.4;SK-BR-3: 16.6
39,ARHGDIG,RHOGDI-3,ENSG00000242173,Rho GDP dissociation inhibitor gamma,16,268727-283010,Predicted intracellular proteins,Evidence at protein level,HPA078260,,,Approved,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 131.1;duodenum: 44.2,small intestine: 17.9,Cell line enhanced,,HEK93: 24.6;MCF7: 27.2;SCLC-21H: 14.0;SH-SY5Y: 15.7
40,ARHGEF4,"ASEF, KIAA1112, STM6",ENSG00000136002,Rho guanine nucleotide exchange factor 4,2,130836916-131047263,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA018267,Approved,,,,Testis cancer:7.00e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 61.6;skin: 44.1,esophagus: 14.5,Cell line enhanced,,HaCaT: 31.5;hTCEpi: 52.8;SCLC-21H: 52.6
41,ASPDH,,ENSG00000204653,Aspartate dehydrogenase domain containing,19,50511600-50514690,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042631, HPA042654",Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 17.9;kidney: 27.9;liver: 34.6,duodenum: 6.9,Cell line enhanced,,HEK93: 12.4;MOLT-4: 13.3;SH-SY5Y: 9.8
42,ASPHD1,,ENSG00000174939,Aspartate beta-hydroxylase domain containing 1,16,29900375-29919864,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045175,Uncertain,,,,Pancreatic cancer:7.38e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 53.5,gallbladder: 11.9,Mixed,,
43,ASPHD2,FLJ39838,ENSG00000128203,Aspartate beta-hydroxylase domain containing 2,22,26429273-26445015,Predicted membrane proteins,Evidence at protein level,HPA000820,Uncertain,,,,Renal cancer:4.06e-5 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 12.8,stomach: 7.8,Cell line enhanced,,Karpas-707: 15.8
44,ATL1,"AD-FSP, FSP1, SPG3, SPG3A",ENSG00000198513,Atlastin GTPase 1,14,50532509-50633068,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA027550,Enhanced,,,,,Mixed,Tissue enhanced,,cerebral cortex: 96.9,smooth muscle: 22.0,Cell line enhanced,,HDLM-2: 18.1;SCLC-21H: 20.2;SiHa: 19.9
45,ATP1A3,DYT12,ENSG00000105409,ATPase Na+/K+ transporting subunit alpha 3,19,41966582-41997497,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB033630, HPA045367, HPA056446",Enhanced,,,,"Renal cancer:3.02e-6 (unfavourable), Pancreatic cancer:6.15e-5 (favourable), Ovarian cancer:3.44e-4 (unfavourable)",Group enriched,Tissue enhanced,,cerebral cortex: 378.4;heart muscle: 86.0,testis: 54.5,Cell line enhanced,,Daudi: 39.5;SCLC-21H: 148.3;SH-SY5Y: 57.8
46,ATRNL1,"ALP, FLJ45344, KIAA0534",ENSG00000107518,Attractin like 1,10,115093365-115948992,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA038070,Uncertain,,Approved,Nucleus<br>Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 33.9,testis: 22.7,Cell line enhanced,,AN3-CA: 27.6;RH-30: 19.2
47,B3GALT1,beta3Gal-T1,ENSG00000172318,"Beta-1,3-galactosyltransferase 1",2,167868948-167874041,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.2;colon: 3.7;rectum: 4.0,skeletal muscle: 1.8,Cell line enriched,7.0,AN3-CA: 33.1
48,B3GALT2,beta3Gal-T2,ENSG00000162630,"Beta-1,3-galactosyltransferase 2",1,193179045-193186654,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 29.0;gallbladder: 26.0,heart muscle: 14.9,Group enriched,5.0,AF22: 19.6;ASC TERT1: 6.1;LHCN-M2: 11.4;WM-115: 23.5
49,B3GNT4,"B3GN-T4, beta3Gn-T4",ENSG00000176383,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4",12,122203543-122208952,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA055261,Uncertain,,Approved,Nucleoli<br>Mitochondria,Renal cancer:3.52e-6 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 4.3;skin: 2.9,kidney: 1.9,Cell line enhanced,,HDLM-2: 4.5;hTCEpi: 4.9;T-47d: 5.0
50,B4GALNT4,"FLJ25045, NGalNAc-T1",ENSG00000182272,"Beta-1,4-N-acetyl-galactosaminyltransferase 4",11,369796-382116,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA053126,Uncertain,,Approved,Nucleoplasm<br>Microtubules<br>Cytokinetic bridge<br>Mitotic spindle,,Mixed,Tissue enhanced,,cerebral cortex: 30.9;ovary: 11.7,"endometrium,fallopian tube: 6.9",Cell line enhanced,,AF22: 38.5;NTERA-2: 34.8;SCLC-21H: 50.7;SH-SY5Y: 55.6
51,B4GAT1,"B3GN-T1, B3GNT1, B3GNT6, BETA3GNTI, iGAT, iGNT",ENSG00000174684,"Beta-1,4-glucuronyltransferase 1",11,66345372-66347692,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA015484,Uncertain,,,,Pancreatic cancer:3.55e-5 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 185.2,adrenal gland: 52.4,Expressed in all,,
52,BAIAP3,"BAP3, KIAA0734",ENSG00000007516,BAI1 associated protein 3,16,1333601-1349441,Predicted intracellular proteins,Evidence at protein level,HPA015627,Uncertain,,,,Renal cancer:1.52e-5 (favourable),Mixed,Tissue enhanced,,adrenal gland: 24.9;cerebral cortex: 25.1;fallopian tube: 42.4,testis: 13.8,Cell line enhanced,,CAPAN-2: 17.3
53,BASP1,"CAP-23, CAP23, NAP-22, NAP22",ENSG00000176788,Brain abundant membrane attached signal protein 1,5,17065598-17276843,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA045218, HPA050333",Enhanced,,Enhanced,Plasma membrane,"Renal cancer:5.25e-11 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 419.0;epididymis: 369.1,placenta: 130.6,Cell line enhanced,,HeLa: 555.7;SiHa: 845.8
54,BCAS1,"AIBC1, NABC1",ENSG00000064787,Breast carcinoma amplified sequence 1,20,53936777-54070594,Predicted intracellular proteins,Evidence at protein level,"CAB033558, HPA051816, HPA054745",Enhanced,,Approved,Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 108.7;stomach: 155.8,rectum: 80.7,Group enriched,6.0,RT4: 143.2;SK-BR-3: 277.9
55,BDNF,,ENSG00000176697,Brain derived neurotrophic factor,11,27654893-27722058,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB009564, HPA031440, HPA056104",Enhanced,,Supported,Nuclear speckles<br>Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 11.9,epididymis: 4.9,Cell line enhanced,,BJ: 37.3;BJ hTERT+ SV40 Large T+: 30.7;HBF TERT88: 30.4;U-138 MG: 45.3
56,BEST3,"MGC13168, MGC40411, VMD2L3",ENSG00000127325,Bestrophin 3,12,69643360-69699476,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA054582,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 16.3;skeletal muscle: 12.2,testis: 5.6,Group enriched,13.0,REH: 32.4;RPMI-8226: 26.4;U-698: 43.2
57,BEX1,,ENSG00000133169,Brain expressed X-linked 1,X,103062651-103064240,Predicted intracellular proteins,Evidence at protein level,HPA045384,Approved,,,,"Renal cancer:8.16e-8 (favourable), Breast cancer:6.43e-4 (favourable), Thyroid cancer:6.88e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 505.2,parathyroid gland: 154.3,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 525.2;HBF TERT88: 582.7;HL-60: 1113.6;SCLC-21H: 490.1
58,BEX2,DJ79P11.1,ENSG00000133134,Brain expressed X-linked 2,X,103309346-103311046,Predicted intracellular proteins,Evidence at protein level,HPA045384,Uncertain,,,,"Renal cancer:3.05e-13 (favourable), Endometrial cancer:8.54e-7 (unfavourable), Lung cancer:1.52e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 226.5,thyroid gland: 156.9,Cell line enhanced,,hTCEpi: 64.4;NTERA-2: 86.5;SCLC-21H: 148.6;SH-SY5Y: 61.1
59,BEX5,NGFRAP1L1,ENSG00000184515,Brain expressed X-linked 5,X,102153708-102156057,Predicted intracellular proteins,Evidence at protein level,HPA059058,Enhanced,,,,"Renal cancer:1.97e-4 (favourable), Lung cancer:3.09e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 96.0,epididymis: 34.8,Cell line enhanced,,HAP1: 14.7;Karpas-707: 39.3
60,BHLHB9,"GASP3, KIAA1701, p60TRP",ENSG00000198908,"Basic helix-loop-helix domain containing, class B, 9",X,102720688-102753540,Predicted intracellular proteins,Evidence at protein level,HPA000887,,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 18.8,parathyroid gland: 8.4,Mixed,,
61,BHLHE22,"Beta3, BHLHB5, bHLHe22, CAGL85, TNRC20",ENSG00000180828,Basic helix-loop-helix family member e22,8,64580367-64583628,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA064128, HPA064872, HPA067500",Enhanced,,,,,Mixed,Tissue enhanced,,cerebral cortex: 12.2,seminal vesicle: 3.3,Cell line enriched,15.0,THP-1: 52.6
62,BRINP3,"DBCCR1L, DBCCR1L1, FAM5C",ENSG00000162670,BMP/retinoic acid inducible neural specific 3,1,190097662-190478404,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA054693,Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 44.5;small intestine: 19.6,prostate: 10.9,Cell line enriched,6.0,SCLC-21H: 17.0
63,BRSK2,"C11orf7, PEN11B, STK29",ENSG00000174672,BR serine/threonine kinase 2,11,1389899-1462689,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA073690,,,Approved,Golgi apparatus,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 61.7;pancreas: 19.2,testis: 9.5,Cell line enhanced,,NTERA-2: 27.4;SCLC-21H: 74.9
64,C10orf105,FLJ00245,ENSG00000214688,Chromosome 10 open reading frame 105,10,71711702-71737824,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 2.3;spleen: 3.2,testis: 1.4,Cell line enriched,6.0,BJ hTERT+: 2.6
65,C10orf35,,ENSG00000171224,Chromosome 10 open reading frame 35,10,69630251-69633599,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA034591,Enhanced,,Approved,Nucleus<br>Centrosome<br>Cytosol,"Liver cancer:1.03e-4 (unfavourable), Head and neck cancer:8.64e-4 (unfavourable), Urothelial cancer:9.72e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 27.6,testis: 20.2,Cell line enhanced,,PC-3: 53.3
66,C14orf132,C14orf88,ENSG00000227051,Chromosome 14 open reading frame 132,14,96039324-96093889,Predicted membrane proteins,Evidence at transcript level,,,,,,"Pancreatic cancer:3.54e-4 (favourable), Urothelial cancer:4.95e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 82.6,fallopian tube: 35.8,Cell line enhanced,,SCLC-21H: 62.1;SH-SY5Y: 55.5;U-87 MG: 45.2
67,C15orf59,"INSYN1, LOC388135, MGC131524",ENSG00000205363,Chromosome 15 open reading frame 59,15,73735431-73752747,Predicted intracellular proteins,Evidence at transcript level,HPA041563,Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:5.38e-9 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 55.9,seminal vesicle: 19.8,Cell line enhanced,,ASC diff: 6.2;fHDF/TERT166: 4.8;HEK93: 5.9;U-2 OS: 5.5
68,C16orf45,FLJ32618,ENSG00000166780,Chromosome 16 open reading frame 45,16,15434295-15625028,Predicted intracellular proteins,Evidence at protein level,HPA041114,Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Liver cancer:1.53e-4 (favourable), Renal cancer:1.75e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 171.9,"cervix, uterine: 59.6",Cell line enhanced,,fHDF/TERT166: 72.2;U-87 MG: 109.4
69,C17orf51,"FLJ12977, FLJ31874, FLJ33618",ENSG00000212719,Chromosome 17 open reading frame 51,17,21524790-21574458,Predicted intracellular proteins,Evidence at protein level,HPA052106,Enhanced,,Approved,Nucleoplasm<br>Nuclear bodies<br>Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 16.6,testis: 8.2,Mixed,,
70,C1orf216,FLJ38984,ENSG00000142686,Chromosome 1 open reading frame 216,1,35713875-35719472,Predicted intracellular proteins,Evidence at protein level,"HPA028299, HPA031343",Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:7.68e-10 (unfavourable), Liver cancer:2.15e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 60.6,smooth muscle: 18.6,Expressed in all,,
71,C21orf140,,ENSG00000222018,Chromosome 21 open reading frame 140,21,34400317-34401072,Predicted intracellular proteins,Evidence at transcript level,HPA045123,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 2.6;testis: 4.0,esophagus: 1.1,Not detected,,
72,C2orf72,LOC257407,ENSG00000204128,Chromosome 2 open reading frame 72,2,231037490-231049719,Predicted intracellular proteins,Evidence at protein level,HPA044962,Uncertain,,Approved,Nucleus<br>Plasma membrane,"Renal cancer:4.74e-4 (unfavourable), Pancreatic cancer:5.27e-4 (favourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 2.8;colon: 2.9;liver: 4.7,stomach: 1.3,Cell line enhanced,,BEWO: 8.2;CACO-2: 1.7;EFO-21: 2.9
73,C3orf49,,ENSG00000163632,Chromosome 3 open reading frame 49,3,63819362-63848636,Predicted intracellular proteins,Evidence at transcript level,HPA053582,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.2;testis: 2.1,skin: 0.5,Not detected,,
74,C3orf80,,ENSG00000180044,Chromosome 3 open reading frame 80,3,160225496-160228213,Predicted membrane proteins,Evidence at transcript level,HPA047439,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 9.8,esophagus: 2.7,Cell line enriched,6.0,HMC-1: 126.0
75,C4orf48,,ENSG00000243449,Chromosome 4 open reading frame 48,4,2041993-2043970,Predicted secreted proteins,Evidence at protein level,HPA052447,Uncertain,,Supported,Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 22.1,testis: 11.2,Cell line enhanced,,HEK93: 145.6;PC-3: 318.4
76,C9orf172,,ENSG00000232434,Chromosome 9 open reading frame 172,9,136844415-136848801,Predicted intracellular proteins,Evidence at protein level,HPA021200,Uncertain,,Approved,Focal adhesion sites<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 7.4,spleen: 3.3,Mixed,,
77,CA10,"CA-RPX, CARPX, HUCEP-15",ENSG00000154975,Carbonic anhydrase 10,17,51630313-52160017,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA054825, HPA057837",Supported,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 56.7;cervix, uterine: 32.1",testis: 10.7,Cell line enhanced,,RT4: 1.6;SCLC-21H: 7.3
78,CA11,"CARP2, CARPX1",ENSG00000063180,Carbonic anhydrase 11,19,48637942-48646312,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA041778,,,Approved,Vesicles<br>Microtubules,"Lung cancer:2.11e-5 (favourable), Pancreatic cancer:8.60e-5 (favourable), Cervical cancer:4.33e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 244.1,ovary: 49.5,Cell line enhanced,,AN3-CA: 39.9;SCLC-21H: 35.8
79,CA14,,ENSG00000118298,Carbonic anhydrase 14,1,150257159-150265078,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008482,Approved,,Approved,Plasma membrane,,Group enriched,Tissue enhanced,,cerebral cortex: 10.6;seminal vesicle: 21.2,skeletal muscle: 9.4,Group enriched,23.0,AF22: 83.4;AN3-CA: 46.6;NTERA-2: 65.8;SK-MEL-30: 134.5
80,CABP7,MGC57793,ENSG00000100314,Calcium binding protein 7,22,29720084-29731839,Predicted membrane proteins,Evidence at protein level,HPA016439,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,adrenal gland: 2.5;cerebral cortex: 3.4,small intestine: 1.4,Group enriched,13.0,HEL: 9.4;SCLC-21H: 11.7;SH-SY5Y: 3.3;U-2 OS: 3.4
81,CACNA1A,"APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6",ENSG00000141837,Calcium voltage-gated channel subunit alpha1 A,19,13206442-13633025,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA064258, HPA071902",Enhanced,,Uncertain,Endoplasmic reticulum,Pancreatic cancer:4.32e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 15.1,stomach: 3.5,Group enriched,7.0,SCLC-21H: 56.1;U-87 MG: 26.1
82,CACNA1G,"Cav3.1, NBR13",ENSG00000006283,Calcium voltage-gated channel subunit alpha1 G,17,50561068-50627474,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA004714,Uncertain,,,,,Mixed,Tissue enhanced,,"cerebral cortex: 10.5;cervix, uterine: 8.5",endometrium: 5.2,Cell line enhanced,,A549: 8.5;SCLC-21H: 3.3
83,CACNA1I,Cav3.3,ENSG00000100346,Calcium voltage-gated channel subunit alpha1 I,22,39570753-39689737,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 4.7;thyroid gland: 2.7,adrenal gland: 2.3,Cell line enhanced,,SK-BR-3: 1.4;T-47d: 1.0
84,CACNA2D3,HSA272268,ENSG00000157445,Calcium voltage-gated channel auxiliary subunit alpha2delta 3,3,54122547-55074557,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA030849, HPA030850",,,Uncertain,Nucleus<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 16.2,adrenal gland: 5.4,Cell line enhanced,,BJ hTERT+: 3.3;HAP1: 1.9;HeLa: 6.3
85,CACNB4,EJM4,ENSG00000182389,Calcium voltage-gated channel auxiliary subunit beta 4,2,151832768-152099475,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA015601,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 25.9,skin: 8.0,Cell line enhanced,,HMC-1: 17.7
86,CACNG4,"MGC11138, MGC24983",ENSG00000075461,Calcium voltage-gated channel auxiliary subunit gamma 4,17,66964910-67033398,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA005803, HPA065370",Enhanced,,Approved,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 48.6;prostate: 20.3,lung: 9.2,Cell line enriched,7.0,SH-SY5Y: 436.5
87,CACNG5,,ENSG00000075429,Calcium voltage-gated channel auxiliary subunit gamma 5,17,66835117-66885486,Predicted membrane proteins,Evidence at protein level,HPA050115,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 1.2,lymph node: 0.6,Not detected,,
88,CADM3,"BIgR, FLJ10698, IGSF4B, Necl-1, NECL1, SynCAM3, TSLL1",ENSG00000162706,Cell adhesion molecule 3,1,159171609-159203313,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA002981, CAB025746",Enhanced,,,,"Renal cancer:1.03e-5 (unfavourable), Urothelial cancer:5.75e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 278.5;placenta: 113.9,"cervix, uterine: 44.7",Group enriched,7.0,HHSteC: 54.6;HSkMC: 158.9;hTERT-HME1: 91.2;U-2 OS: 34.5;WM-115: 59.5
89,CADM4,"IGSF4C, Necl-4, SynCAM4, TSLL2",ENSG00000105767,Cell adhesion molecule 4,19,43622368-43639839,Predicted membrane proteins,Evidence at protein level,HPA012612,Enhanced,,Approved,Nucleus<br>Nuclear membrane,Renal cancer:2.28e-6 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 163.6,parathyroid gland: 59.1,Cell line enriched,5.0,WM-115: 552.4
90,CALHM1,FAM26C,ENSG00000185933,Calcium homeostasis modulator 1,10,103453387-103458888,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA018317,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.8,kidney: 0.6,Cell line enhanced,,U-266/70: 1.0;U-266/84: 1.2
91,CAMK1D,CKLiK,ENSG00000183049,Calcium/calmodulin dependent protein kinase ID,10,12349482-12835545,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA007266,Enhanced,,Approved,Nucleus<br>Cytosol,Lung cancer:1.67e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 52.0,"skin,thyroid gland: 21.9",Cell line enhanced,,HDLM-2: 105.6;U-266/70: 38.2
92,CAMK1G,"CLICKIII, dJ272L16.1, VWS1",ENSG00000008118,Calcium/calmodulin dependent protein kinase IG,1,209583717-209613938,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 32.3;ovary: 27.7,seminal vesicle: 7.4,Cell line enhanced,,hTEC/SVTERT24-B: 7.0;SK-MEL-30: 1.6
93,CAMK2B,"CAM2, CAMK2, CAMKB",ENSG00000058404,Calcium/calmodulin dependent protein kinase II beta,7,44217150-44334577,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB006849, HPA026307, HPA051783, HPA051785, HPA053973",Enhanced,Supported,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 214.1,skeletal muscle: 46.1,Cell line enriched,12.0,SCLC-21H: 88.9
94,CAMK2N1,CaMKIINalpha,ENSG00000162545,Calcium/calmodulin dependent protein kinase II inhibitor 1,1,20482391-20486220,Predicted intracellular proteins,Evidence at protein level,,,,,,"Head and neck cancer:1.37e-7 (unfavourable), Lung cancer:1.66e-4 (unfavourable), Liver cancer:5.49e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 321.1,small intestine: 95.6,Cell line enhanced,,AN3-CA: 195.3;CAPAN-2: 173.9
95,CAMK2N2,CaM-KIIN,ENSG00000163888,Calcium/calmodulin dependent protein kinase II inhibitor 2,3,184259213-184261463,Predicted intracellular proteins,Evidence at protein level,HPA050835,,,Supported,Nucleus<br>Centrosome,Cervical cancer:9.77e-4 (favourable),Mixed,Tissue enhanced,,adrenal gland: 12.2;cerebral cortex: 40.4,pancreas: 5.6,Cell line enhanced,,REH: 28.6;SCLC-21H: 37.1;U-138 MG: 32.1
96,CAMK4,CaMK-GR,ENSG00000152495,Calcium/calmodulin dependent protein kinase IV,5,111223653-111494886,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB004347, HPA011753, HPA017206",Approved,,Supported,Nucleoplasm<br>Nucleoli fibrillar center,,Mixed,Tissue enhanced,,cerebral cortex: 16.5;testis: 17.0,lymph node: 9.7,Cell line enhanced,,HDLM-2: 83.9;SH-SY5Y: 35.7
97,CAMKK1,"CAMKKA, DKFZp761M0423, MGC34095",ENSG00000004660,Calcium/calmodulin dependent protein kinase kinase 1,17,3860315-3894891,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009111, HPA028062",Approved,,Supported,Cytosol,Pancreatic cancer:2.65e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 51.5,seminal vesicle: 14.7,Cell line enhanced,,U-87 MG: 27.3
98,CAP2,,ENSG00000112186,"CAP, adenylate cyclase-associated protein, 2 (yeast)",6,17393216-17557792,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA050530, HPA054147",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 125.1;skeletal muscle: 220.8,heart muscle: 70.1,Mixed,,
99,CARMIL3,"BC008134, C14orf121, crml-1, LRRC16B",ENSG00000186648,Capping protein regulator and myosin 1 linker 3,14,24052000-24069728,Predicted intracellular proteins,Evidence at protein level,HPA030596,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 6.7;skin: 6.2,testis: 3.0,Cell line enhanced,,Daudi: 7.8;HMC-1: 6.5;Karpas-707: 4.8;SCLC-21H: 12.8;SH-SY5Y: 5.6
100,CBARP,"BARP, C19orf26, DOS, MGC40084",ENSG00000099625,CACN beta subunit associated regulatory protein,19,1228287-1238027,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012777,,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,adrenal gland: 2.4;cerebral cortex: 7.0,skin: 1.1,Cell line enhanced,,SH-SY5Y: 5.6
101,CBLN4,"CBLNL1, dJ885A10.1",ENSG00000054803,Cerebellin 4 precursor,20,55997440-56005472,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA051496, HPA074497",,Supported,Approved,Midbody ring,,Mixed,Tissue enhanced,,adrenal gland: 24.5;cerebral cortex: 15.6;epididymis: 11.2,fallopian tube: 6.8,Cell line enriched,51.0,SH-SY5Y: 10.2
102,CBSL,,ENSG00000274276,Cystathionine-beta-synthase like,21,6444869-6468040,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001223,Supported,,Approved,Nucleoli<br>Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 45.9;liver: 27.3,thyroid gland: 22.2,Cell line enhanced,,AN3-CA: 123.4;NTERA-2: 245.4;SH-SY5Y: 82.5
103,CCDC177,"C14orf162, PLPL",ENSG00000267909,Coiled-coil domain containing 177,14,69569816-69574837,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 2.2,epididymis: 0.6,Cell line enhanced,,SCLC-21H: 1.9
104,CCDC184,"C12orf68, LOC387856",ENSG00000177875,Coiled-coil domain containing 184,12,48183584-48185926,Predicted intracellular proteins,Evidence at protein level,"HPA039947, HPA041715",Uncertain,,Approved,Mitochondria<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 15.3,adrenal gland: 6.7,Cell line enhanced,,AF22: 6.1;SH-SY5Y: 4.4;U-2 OS: 2.5;U-87 MG: 3.0
105,CCDC85A,KIAA1912,ENSG00000055813,Coiled-coil domain containing 85A,2,56184123-56386173,Predicted secreted proteins,Evidence at protein level,"HPA043106, HPA057020",Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 21.0,thyroid gland: 15.9,Cell line enhanced,,Daudi: 34.0;fHDF/TERT166: 59.7;U-266/70: 25.2
106,CCDC85B,DIPA,ENSG00000175602,Coiled-coil domain containing 85B,11,65890112-65891635,Predicted intracellular proteins,Evidence at protein level,HPA054415,Uncertain,,,,Renal cancer:3.78e-5 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 27.6,adipose tissue: 21.1,Cell line enhanced,,WM-115: 340.7
107,CCSAP,"C1orf96, CSAP, FLJ41471",ENSG00000154429,"Centriole, cilia and spindle associated protein",1,229321005-229343294,Predicted intracellular proteins,Evidence at protein level,"HPA028402, HPA043443",Enhanced,,Supported,Nucleus<br>Plasma membrane<br>Microtubule ends,"Renal cancer:4.50e-13 (unfavourable), Liver cancer:1.41e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 54.0,placenta: 18.6,Expressed in all,,
108,CDH12,"Br-cadherin, CDHB",ENSG00000154162,Cadherin 12,5,21750673-22853622,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA029325,Uncertain,,Approved,Vesicles,,Mixed,Tissue enhanced,,"cerebral cortex: 3.6;cervix, uterine: 4.5;fallopian tube: 3.5",adrenal gland: 2.2,Group enriched,5.0,PC-3: 2.0;SCLC-21H: 3.7;U-2 OS: 1.3
109,CDH18,"CDH14, EY-CADHERIN",ENSG00000145526,Cadherin 18,5,19472951-20575873,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA014416,Uncertain,,,,,Mixed,Tissue enhanced,,adrenal gland: 5.9;cerebral cortex: 19.0,testis: 3.2,Cell line enhanced,,EFO-21: 4.1;U-2 OS: 7.1;U-2197: 5.6
110,CDH4,,ENSG00000179242,Cadherin 4,20,61252426-61940617,Predicted membrane proteins,Evidence at protein level,HPA015613,,,Enhanced,Plasma membrane,,Group enriched,Tissue enhanced,,cerebral cortex: 6.0;spleen: 4.8,seminal vesicle: 1.3,Cell line enhanced,,AF22: 11.0;hTERT-HME1: 11.2;U-2 OS: 20.6;U-251 MG: 29.8
111,CDH7,,ENSG00000081138,Cadherin 7,18,65750252-65890341,Predicted membrane proteins,Evidence at protein level,HPA061419,Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 2.8;prostate: 1.3,testis: 0.7,Cell line enhanced,,AF22: 15.0;Karpas-707: 4.0;RH-30: 7.0;U-87 MG: 3.3
112,CDH9,,ENSG00000113100,Cadherin 9,5,26880600-27121150,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA007167,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 11.4;kidney: 6.5,testis: 4.3,Cell line enhanced,,K-562: 6.6;NTERA-2: 10.2
113,CDKL5,"CFAP247, EIEE2, STK9",ENSG00000008086,Cyclin dependent kinase like 5,X,18425583-18653629,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002847, CAB011577",Supported,,Enhanced,Nucleoplasm,Renal cancer:5.54e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 31.0,testis: 14.4,Mixed,,
114,CECR2,KIAA1740,ENSG00000099954,"CECR2, histone acetyl-lysine reader",22,17359949-17558149,Predicted intracellular proteins,Evidence at protein level,HPA002943,Approved,,Approved,Nucleus<br>Vesicles,,Tissue enriched,Tissue enhanced,,cerebral cortex: 7.8,skeletal muscle: 7.5,Cell line enhanced,,AF22: 15.3;HAP1: 14.9;NTERA-2: 22.8;SCLC-21H: 11.9
115,CELSR2,"ADGRC2, CDHF10, EGFL2, Flamingo1, KIAA0279, MEGF3",ENSG00000143126,Cadherin EGF LAG seven-pass G-type receptor 2,1,109250019-109275750,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA013952,Uncertain,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 45.1,skin: 31.0,Cell line enhanced,,AF22: 49.6;HaCaT: 44.6;MCF7: 45.4
116,CGREF1,CGR11,ENSG00000138028,Cell growth regulator with EF-hand domain 1,2,27098889-27119115,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008241,Uncertain,,,,"Endometrial cancer:3.18e-4 (unfavourable), Liver cancer:7.57e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 44.7,stomach: 11.5,Cell line enhanced,,SK-BR-3: 58.9
117,CHADL,SLRR4B,ENSG00000100399,Chondroadherin like,22,41229510-41240934,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA005696, HPA024654",Uncertain,,,,Lung cancer:1.56e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 28.4,skin: 6.7,Cell line enhanced,,BEWO: 11.4
118,CHI3L1,"GP39, YKL40",ENSG00000133048,Chitinase 3 like 1,1,203178931-203186749,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,appendix: 186.7;cerebral cortex: 267.1;urinary bladder: 179.4,bone marrow: 146.9,Group enriched,7.0,ASC diff: 215.1;ASC TERT1: 484.9;HSkMC: 450.3;THP-1: 704.0;U-138 MG: 292.3;U-87 MG: 289.1
119,CHRM3,,ENSG00000133019,Cholinergic receptor muscarinic 3,1,239386565-239915452,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA024106, HPA048036",Approved,,Supported,Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 15.7,esophagus: 8.4,Cell line enhanced,,RPMI-8226: 11.9;SH-SY5Y: 55.3;U-266/70: 16.6;U-266/84: 11.6
120,CHRM4,,ENSG00000180720,Cholinergic receptor muscarinic 4,11,46385098-46386608,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022444, HPA072083",Uncertain,,Uncertain,Nucleus<br>Golgi apparatus,,Mixed,Tissue enhanced,,cerebral cortex: 8.1;small intestine: 7.8;spleen: 21.4,testis: 6.9,Cell line enhanced,,RH-30: 3.3;SCLC-21H: 11.7;U-2 OS: 3.0
121,CHRM5,,ENSG00000184984,Cholinergic receptor muscarinic 5,15,33968720-34067457,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA013172,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 3.1;testis: 3.4,placenta: 2.3,Group enriched,7.0,BEWO: 4.5;HMC-1: 14.3
122,CHRNA4,"BFNC, EBN, EBN1",ENSG00000101204,Cholinergic receptor nicotinic alpha 4 subunit,20,63343223-63378401,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,CAB034064,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.9;parathyroid gland: 17.4,liver: 3.9,Cell line enhanced,,U-2 OS: 2.6
123,CHST1,"C6ST, KSGal6ST",ENSG00000175264,Carbohydrate sulfotransferase 1,11,45648877-45665622,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:4.64e-7 (unfavourable), Liver cancer:3.95e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 49.0;parathyroid gland: 19.1,thyroid gland: 9.9,Cell line enhanced,,HUVEC TERT2: 11.4;TIME: 10.8;WM-115: 35.6
124,CHST10,HNK-1ST,ENSG00000115526,Carbohydrate sulfotransferase 10,2,100391860-100417656,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA012884, HPA051545",Approved,,Approved,Cytosol,Pancreatic cancer:4.05e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 46.4,endometrium: 19.4,Mixed,,
125,CHST8,GALNAC-4-ST1,ENSG00000124302,Carbohydrate sulfotransferase 8,19,33621955-33773509,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA016004,Supported,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 2.5,breast: 1.4,Group enriched,5.0,RPMI-8226: 16.8;SCLC-21H: 15.9;SH-SY5Y: 24.7
126,CLCN4,"ClC-4, CLC4",ENSG00000073464,Chloride voltage-gated channel 4,X,10156945-10237660,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA031313, HPA063637",Enhanced,,Approved,Vesicles,"Endometrial cancer:2.13e-5 (unfavourable), Pancreatic cancer:9.55e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 49.1;epididymis: 28.1,skeletal muscle: 14.6,Cell line enhanced,,HEL: 21.9;SCLC-21H: 28.6
127,CLDN11,"OSP, OTM",ENSG00000013297,Claudin 11,3,170418865-170860380,Predicted membrane proteins,Evidence at protein level,"CAB009789, HPA013166",Enhanced,,,,Breast cancer:6.31e-4 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 89.0;testis: 183.6,ovary: 61.7,Cell line enhanced,,ASC diff: 254.1;ASC TERT1: 324.5;EFO-21: 266.5;HUVEC TERT2: 345.5;TIME: 539.4
128,CLIP2,"CLIP, CLIP-115, CYLN2, KIAA0291, WBSCR3, WBSCR4, WSCR3, WSCR4",ENSG00000106665,CAP-Gly domain containing linker protein 2,7,74289475-74405943,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA020430, CAB020767",Enhanced,,,,Endometrial cancer:5.35e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 75.8,ovary: 21.0,Mixed,,
129,CLIP3,"CLIPR-59, RSNL1",ENSG00000105270,CAP-Gly domain containing linker protein 3,19,36014660-36033343,Predicted intracellular proteins,Evidence at protein level,,,,,,"Renal cancer:1.56e-10 (unfavourable), Pancreatic cancer:2.80e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 247.6,smooth muscle: 56.2,Cell line enhanced,,ASC TERT1: 58.0;HSkMC: 67.3
130,CLSTN2,"CDHR13, CS2, CSTN2, FLJ39113",ENSG00000158258,Calsyntenin 2,3,139935185-140577397,Predicted membrane proteins,Evidence at protein level,HPA031342,Approved,,Approved,Nucleoplasm<br>Nuclear membrane<br>Cell Junctions,,Tissue enriched,Tissue enhanced,,cerebral cortex: 34.6;ovary: 81.6,adipose tissue: 18.8,Cell line enhanced,,AF22: 5.2;SCLC-21H: 17.0;THP-1: 6.3
131,CLSTN3,"CDHR14, CSTN3, KIAA0726",ENSG00000139182,Calsyntenin 3,12,7129698-7158945,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Pancreatic cancer:1.19e-5 (favourable), Renal cancer:4.49e-5 (unfavourable), Breast cancer:5.08e-4 (favourable), Urothelial cancer:8.07e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 126.6,parathyroid gland: 40.3,Mixed,,
132,CLVS1,"C6orf212L, CRALBPL, MGC34646, RLBP1L1",ENSG00000177182,Clavesin 1,8,61057158-61501645,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 10.3,testis: 3.7,Cell line enhanced,,SCLC-21H: 4.4;SH-SY5Y: 1.7
133,CNIH3,"CNIH-3, FLJ38993",ENSG00000143786,Cornichon family AMPA receptor auxiliary protein 3,1,224434660-224740549,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 14.7,testis: 4.2,Cell line enhanced,,hTEC/SVTERT24-B: 46.6;NTERA-2: 17.2;U-266/70: 18.9;U-87 MG: 53.6
134,CNNM1,ACDP1,ENSG00000119946,Cyclin and CBS domain divalent metal cation transport mediator 1,10,99329099-99394330,Predicted membrane proteins,Evidence at protein level,HPA040408,Approved,,Uncertain,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 10.2;testis: 16.8,ovary: 3.0,Cell line enhanced,,A549: 16.9;BJ hTERT+ SV40 Large T+ RasG12V: 10.6;HAP1: 8.6
135,CNR1,"CANN6, CB-R, CB1, CB1A, CB1K5, CNR",ENSG00000118432,Cannabinoid receptor 1,6,88139864-88166359,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 32.1,adipose tissue: 12.2,Group enriched,7.0,ASC diff: 55.8;HSkMC: 39.1
136,CNRIP1,"C2orf32, CRIP1, CRIP1a, CRIP1b, DKFZP566K1924",ENSG00000119865,Cannabinoid receptor interacting protein 1,2,68284171-68320051,Predicted intracellular proteins,Evidence at protein level,HPA035337,,,Approved,Cytosol,Renal cancer:1.21e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 53.8,adipose tissue: 24.9,Cell line enhanced,,HEL: 139.6
137,CNTFR,,ENSG00000122756,Ciliary neurotrophic factor receptor,9,34551432-34590140,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB025310,Approved,,,,,Tissue enhanced,Tissue enhanced,,adipose tissue: 62.6;cerebral cortex: 53.4,spleen: 27.5,Group enriched,9.0,AF22: 107.8;SH-SY5Y: 55.3
138,CNTN1,"F3, GP135",ENSG00000018236,Contactin 1,12,40692442-41072418,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB025200, HPA070467",Enhanced,,,,Urothelial cancer:3.75e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 225.5,ovary: 65.6,Cell line enhanced,,A549: 218.0;HaCaT: 38.4;SCLC-21H: 85.1;SH-SY5Y: 46.5
139,CNTN3,"BIG-1, PANG",ENSG00000113805,Contactin 3,3,74262568-74521140,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA003341,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 12.4,fallopian tube: 12.0,Cell line enhanced,,BJ: 6.0;fHDF/TERT166: 15.2
140,CNTN5,"hNB-2, NB-2",ENSG00000149972,Contactin 5,11,99020953-100358885,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA039492, HPA041223",Approved,,Supported,Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 2.6;placenta: 3.4;thyroid gland: 3.0,fallopian tube: 1.8,Not detected,,
141,CNTNAP1,"Caspr, CNTNAP, NRXN4, p190",ENSG00000108797,Contactin associated protein 1,17,42682613-42699814,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA011772,Approved,,Approved,Nucleoplasm,Renal cancer:4.16e-14 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 61.8;smooth muscle: 38.9,endometrium: 19.2,Cell line enhanced,,TIME: 59.4;U-138 MG: 80.6
142,CNTNAP5,"caspr5, FLJ31966",ENSG00000155052,Contactin associated protein like 5,2,124025287-124915287,Predicted membrane proteins,Evidence at protein level,"HPA069095, HPA069356",,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.8;gallbladder: 1.6,adrenal gland: 0.7,Cell line enhanced,,AF22: 1.1;SH-SY5Y: 2.8
143,COL26A1,"EMI6, EMID2, Emu2",ENSG00000160963,Collagen type XXVI alpha 1 chain,7,101362820-101559024,Predicted secreted proteins,Evidence at protein level,HPA027059,Approved,,Approved,Vesicles,Liver cancer:2.32e-5 (favourable),Group enriched,Tissue enhanced,,cerebral cortex: 10.2;parathyroid gland: 5.4,prostate: 3.1,Cell line enhanced,,AF22: 29.3;BEWO: 22.8;HAP1: 10.9;NTERA-2: 25.1
144,CORO2B,"ClipinC, KIAA0925",ENSG00000103647,Coronin 2B,15,68578969-68727806,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA017960,Enhanced,,Approved,Plasma membrane<br>Focal adhesion sites,,Group enriched,Tissue enhanced,,cerebral cortex: 73.3;fallopian tube: 36.7,ovary: 17.9,Cell line enhanced,,ASC TERT1: 40.2;HSkMC: 30.2;hTEC/SVTERT24-B: 34.6;U-87 MG: 57.2
145,CPLX2,"CPX-2, DKFZp547D155",ENSG00000145920,Complexin 2,5,175796310-175884020,Predicted intracellular proteins,Evidence at protein level,HPA071191,,,Uncertain,Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 236.4;epididymis: 145.5,adrenal gland: 44.3,Group enriched,19.0,A549: 549.3;Hep G2: 253.5;SCLC-21H: 296.3
146,CPNE4,"COPN4, CPN4",ENSG00000196353,Copine 4,3,131533555-132285410,Predicted intracellular proteins,Evidence at protein level,"HPA032036, HPA078300",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Tissue enriched,Tissue enhanced,,cerebral cortex: 12.1;prostate: 40.8,seminal vesicle: 5.8,Cell line enhanced,,A549: 5.6;AF22: 5.6
147,CPNE5,"COPN5, CPN5, KIAA1599",ENSG00000124772,Copine 5,6,36740775-36840002,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA031369,Uncertain,,Approved,Cytosol,"Head and neck cancer:2.87e-5 (favourable), Renal cancer:6.00e-5 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 119.0,testis: 34.4,Cell line enhanced,,Daudi: 42.5;HUVEC TERT2: 19.9;U-266/70: 15.0;U-266/84: 11.9;U-698: 19.2
148,CPT1C,"CPT1P, CPTIC, FLJ23809",ENSG00000169169,Carnitine palmitoyltransferase 1C,19,49690898-49713731,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA014529, HPA063621",Approved,,Approved,Centrosome,Pancreatic cancer:1.84e-4 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 34.2,adrenal gland: 7.0,Cell line enhanced,,AF22: 39.0;SH-SY5Y: 74.9
149,CRB2,"FLJ16786, FLJ38464",ENSG00000148204,"Crumbs 2, cell polarity complex component",9,123356170-123380324,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA043674,Supported,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 9.4,kidney: 2.0,Cell line enriched,7.0,AF22: 32.2
150,CRH,"CRF, CRH1",ENSG00000147571,Corticotropin releasing hormone,8,66176382-66178725,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA046846, HPA062111",Uncertain,Supported,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 2.1;placenta: 8.0,adipose tissue: 1.2,Not detected,,
151,CRHR1,"CRF-R, CRF1, CRHR",ENSG00000120088,Corticotropin releasing hormone receptor 1,17,45784280-45835828,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,CAB025251,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 4.0,endometrium: 0.8,Cell line enhanced,,RT4: 2.7;SH-SY5Y: 2.2
152,CRLF1,"CISS, CISS1, CLF, CLF-1",ENSG00000006016,Cytokine receptor like factor 1,19,18572220-18607741,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041493, HPA041793",Approved,,,,Renal cancer:3.96e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 17.2;placenta: 16.8,adipose tissue: 10.1,Group enriched,8.0,ASC diff: 706.3;Hep G2: 309.6
153,CRTAC1,"ASPIC1, CEP-68, FLJ10320",ENSG00000095713,Cartilage acidic protein 1,10,97865000-98030828,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008175,Enhanced,,,,"Endometrial cancer:5.01e-6 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Renal cancer:1.85e-4 (favourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 51.0;fallopian tube: 63.6;lung: 76.3;seminal vesicle: 48.1,urinary bladder: 12.8,Cell line enhanced,,HUVEC TERT2: 6.0;SCLC-21H: 5.6;SK-MEL-30: 6.3;TIME: 8.0
154,CSMD1,"KIAA1890, PPP1R24",ENSG00000183117,CUB and Sushi multiple domains 1,8,2935353-4994972,Predicted membrane proteins,Evidence at protein level,HPA074707,,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.2;testis: 4.7,fallopian tube: 1.1,Cell line enhanced,,K-562: 4.4;U-2 OS: 2.3;U-266/70: 1.7;U-266/84: 1.5;U-698: 1.3
155,CSMD2,KIAA1884,ENSG00000121904,CUB and Sushi multiple domains 2,1,33513999-34165842,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008622,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 2.6;gallbladder: 1.8,testis: 1.0,Cell line enhanced,,fHDF/TERT166: 5.3;HEL: 9.4;NTERA-2: 8.1;PC-3: 7.8;U-87 MG: 23.1
156,CSRNP3,"FAM130A2, FLJ32093, PPP1R73, TAIP-2",ENSG00000178662,Cysteine and serine rich nuclear protein 3,2,165469647-165689407,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA017905,Supported,,Approved,Nucleus<br>Nucleoli,,Mixed,Tissue enhanced,,cerebral cortex: 16.1,endometrium: 4.6,Group enriched,5.0,AF22: 9.7;PC-3: 2.2;SCLC-21H: 8.4;SH-SY5Y: 6.2
157,CTD-2207O23.12,,ENSG00000267952,,19,7507052-7519622,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 5.6;skeletal muscle: 4.6,kidney: 2.9,Cell line enhanced,,AF22: 10.9;ASC diff: 8.4;fHDF/TERT166: 10.6;HBF TERT88: 6.7
158,CTD-2410N18.5,,ENSG00000272772,,5,134167170-134226071,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.3,"endometrium,heart muscle,small intestine: 0.6",Mixed,,
159,CTNNA3,"MGC26194, VR22",ENSG00000183230,Catenin alpha 3,10,65912518-67696169,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA061818,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 8.5;heart muscle: 12.4,liver: 4.4,Cell line enhanced,,Daudi: 1.7;NTERA-2: 1.7;RPMI-8226: 1.6;SCLC-21H: 1.8;U-266/70: 5.0
160,CTXN1,FLJ25968,ENSG00000178531,Cortexin 1,19,7924485-7926166,Predicted membrane proteins,Evidence at transcript level,HPA016669,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,,Expressed in all,Tissue enhanced,,cerebral cortex: 100.4,endometrium: 22.7,Cell line enhanced,,AN3-CA: 86.1;NTERA-2: 70.2;SCLC-21H: 63.8;SH-SY5Y: 96.5
161,CUX2,"CDP2, CUTL2, KIAA0293",ENSG00000111249,Cut like homeobox 2,12,111034024-111350554,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 12.2;liver: 9.6;prostate: 18.0,thyroid gland: 6.8,Cell line enhanced,,HBEC3-KT: 4.6;SCLC-21H: 7.5;SH-SY5Y: 14.5
162,CX3CL1,"ABCD-3, C3Xkine, CXC3, CXC3C, fractalkine, neurotactin, NTN, SCYD1",ENSG00000006210,C-X3-C motif chemokine ligand 1,16,57372458-57385048,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB026192, HPA040361",Approved,,Supported,Plasma membrane,"Renal cancer:8.52e-7 (favourable), Cervical cancer:9.46e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 100.1,lung: 69.3,Cell line enhanced,,EFO-21: 28.0;HDLM-2: 78.9;Hep G2: 42.9;RPTEC TERT1: 27.3
163,CX3CR1,"CCRL1, CMKBRL1, CMKDR1, GPR13, V28",ENSG00000168329,C-X3-C motif chemokine receptor 1,3,39263494-39281735,"Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA030311, CAB032478, HPA046587, HPA077743",Approved,,Approved,Nucleus,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 59.2,spleen: 16.6,Cell line enriched,18.0,RPMI-8226: 409.2
164,CXXC4,IDAX,ENSG00000168772,CXXC finger protein 4,4,104468312-104494901,Predicted intracellular proteins,Evidence at protein level,"HPA036600, HPA036925",Uncertain,,Uncertain,Nucleus<br>Golgi apparatus,Pancreatic cancer:2.19e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 8.9,thyroid gland: 4.1,Cell line enhanced,,AF22: 6.9;AN3-CA: 9.0;Karpas-707: 6.4;SCLC-21H: 14.1;U-266/70: 7.4
165,DBNDD1,"FLJ12582, MGC3101",ENSG00000003249,Dysbindin domain containing 1,16,90004865-90020128,Predicted intracellular proteins,Evidence at protein level,HPA043018,Approved,,Approved,Nuclear speckles<br>Cytosol,Renal cancer:2.75e-7 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 24.0,skeletal muscle: 15.6,Cell line enhanced,,MCF7: 109.1
166,DCC,"IGDCC1, NTN1R1",ENSG00000187323,DCC netrin 1 receptor,18,52340172-53535903,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA055376, HPA069552",Supported,,Supported,Golgi apparatus,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 3.7;testis: 13.5,lung: 2.2,Cell line enhanced,,AF22: 36.0;U-266/70: 85.8;U-266/84: 39.7
167,DCX,"DBCN, DC, LISX, SCLH, XLIS",ENSG00000077279,Doublecortin,X,111293779-111412429,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA036121,,Supported,Approved,Cytosol,,Tissue enriched,Tissue enhanced,,cerebral cortex: 10.6,endometrium: 2.4,Group enriched,9.0,SCLC-21H: 65.0;SH-SY5Y: 24.0
168,DGCR6,,ENSG00000183628,DiGeorge syndrome critical region gene 6,22,18906028-18914238,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 11.7,thyroid gland: 4.9,Mixed,,
169,DGKG,DAGK3,ENSG00000058866,Diacylglycerol kinase gamma,3,186105668-186362237,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA036577,Approved,,Approved,Vesicles<br>Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 21.4,placenta: 11.3,Cell line enhanced,,HDLM-2: 22.1;U-87 MG: 13.9
170,DIRAS1,"Di-Ras1, GBTS1, RIG",ENSG00000176490,DIRAS family GTPase 1,19,2714567-2721418,Predicted intracellular proteins,Evidence at protein level,,,,,,Pancreatic cancer:4.78e-4 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 70.9;heart muscle: 42.5,parathyroid gland: 23.9,Cell line enhanced,,HMC-1: 37.7;REH: 44.4
171,DISP2,"C15orf36, DISPB, HsT16908, KIAA1742, LINC00594",ENSG00000140323,Dispatched RND transporter family member 2,15,40358235-40378639,Predicted membrane proteins,Evidence at protein level,HPA059903,Uncertain,,Approved,Nucleoplasm<br>Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 7.4,thyroid gland: 1.8,Group enriched,5.0,HaCaT: 5.9;SCLC-21H: 15.8
172,DKK3,"REIC, RIG",ENSG00000050165,Dickkopf WNT signaling pathway inhibitor 3,11,11963106-12009769,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA011868, CAB024949",Approved,,Approved,Vesicles,Renal cancer:6.31e-5 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 373.5;heart muscle: 805.5,"cervix, uterine: 138.8",Cell line enhanced,,BJ: 355.1;BJ hTERT+: 524.6;fHDF/TERT166: 475.8;TIME: 285.3
173,DLG2,"chapsyn-110, PPP1R58, PSD-93, PSD93",ENSG00000150672,Discs large MAGUK scaffold protein 2,11,83455012-85627922,Predicted intracellular proteins,Evidence at protein level,"HPA021307, HPA023896, CAB072341",Enhanced,,Approved,Vesicles<br>Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 72.8,thyroid gland: 25.8,Cell line enhanced,,BEWO: 7.6;NTERA-2: 5.5;SCLC-21H: 6.4;SH-SY5Y: 8.7;T-47d: 19.2
174,DLX1,,ENSG00000144355,Distal-less homeobox 1,2,172084740-172089677,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA035666, HPA045884",Approved,,Approved,Nucleus<br>Vesicles<br>Cell Junctions,,Tissue enhanced,Tissue enhanced,,adrenal gland: 1.6;cerebral cortex: 5.0,prostate: 0.8,Cell line enhanced,,AN3-CA: 103.9
175,DMRTC1,,ENSG00000269502,DMRT like family C1,X,72872025-72943814,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA046874, HPA046992",Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 2.3,"fallopian tube,thyroid gland: 1.3",Not detected,,
176,DMRTC1B,,ENSG00000184911,DMRT like family C1B,X,72777009-72848802,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA046874, HPA046992",Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 16.6,ovary: 10.3,Not detected,,
177,DNAH10OS,FLJ45278,ENSG00000250091,Dynein axonemal heavy chain 10 opposite strand,12,123926424-123934984,Predicted intracellular proteins,Evidence at transcript level,HPA039786,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 4.0,kidney: 1.6,Mixed,,
178,DNM3,KIAA0820,ENSG00000197959,Dynamin 3,1,171841498-172418466,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA064121,,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,cerebral cortex: 41.1,adrenal gland: 15.6,Cell line enhanced,,HEL: 20.5;RPTEC TERT1: 14.4;U-251 MG: 11.7
179,DOCK4,"FLJ34238, KIAA0716",ENSG00000128512,Dedicator of cytokinesis 4,7,111726110-112206411,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA071516,,,Approved,Nucleoli<br>Golgi apparatus<br>Plasma membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 31.9,lung: 27.7,Cell line enhanced,,hTEC/SVTERT24-B: 42.1;HUVEC TERT2: 67.4;TIME: 57.4
180,DOK5,"C20orf180, dJ805C22.1",ENSG00000101134,Docking protein 5,20,54475597-54651171,Predicted intracellular proteins,Evidence at protein level,"HPA054460, HPA065235",Uncertain,,Approved,Focal adhesion sites,Endometrial cancer:8.99e-7 (unfavourable),Group enriched,Tissue enhanced,,cerebral cortex: 22.0;fallopian tube: 20.0,skeletal muscle: 15.7,Cell line enhanced,,AF22: 32.4;hTEC/SVTERT24-B: 13.7;U-138 MG: 50.6
181,DOK6,"DOK5L, HsT3226, MGC20785",ENSG00000206052,Docking protein 6,18,69401055-69849087,Predicted intracellular proteins,Evidence at protein level,"HPA041099, HPA063534",Approved,,Approved,Focal adhesion sites<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 21.0,placenta: 8.5,Cell line enhanced,,fHDF/TERT166: 8.1;Hep G2: 7.6;RPMI-8226: 7.5;SCLC-21H: 5.6;SH-SY5Y: 11.3
182,DPP6,"DPL1, DPPX",ENSG00000130226,Dipeptidyl peptidase like 6,7,153887097-154894285,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA050509,Enhanced,Supported,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 51.1;endometrium: 27.6,smooth muscle: 15.4,Cell line enriched,9.0,NTERA-2: 5.5
183,DPYSL4,"DRP-4, ULIP4",ENSG00000151640,Dihydropyrimidinase like 4,10,132186900-132205776,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA049066,Approved,,Approved,Vesicles<br>Mitochondria,Urothelial cancer:3.11e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 30.0,heart muscle: 7.5,Cell line enhanced,,AF22: 51.3;AN3-CA: 63.4;SH-SY5Y: 74.6
184,DRAXIN,"C1orf187, Draxin, FLJ34999, Neucrin",ENSG00000162490,Dorsal inhibitory axon guidance protein,1,11691729-11725857,Predicted secreted proteins,Evidence at protein level,HPA014302,Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 1.5,testis: 0.6,Group enriched,5.0,NTERA-2: 28.2;REH: 5.8
185,DRD1,,ENSG00000184845,Dopamine receptor D1,5,175440039-175444208,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA013393,,Supported,,,,Mixed,Tissue enhanced,,cerebral cortex: 8.0,prostate: 1.7,Group enriched,10.0,RT4: 20.9;U-2 OS: 5.4
186,DRD5,"DRD1B, DRD1L2",ENSG00000169676,Dopamine receptor D5,4,9781680-9784009,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA048930,Supported,,,,,Not detected,Tissue enhanced,,appendix: 1.7;cerebral cortex: 2.0;stomach: 3.8,testis: 0.8,Not detected,,
187,DSCAML1,KIAA1132,ENSG00000177103,DS cell adhesion molecule like 1,11,117427773-117817525,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA035230,Uncertain,,,,Renal cancer:8.37e-4 (favourable),Group enriched,Tissue enhanced,,cerebral cortex: 12.1,ovary: 4.4,Cell line enhanced,,EFO-21: 6.2;RPTEC TERT1: 3.7;T-47d: 8.5
188,DTNA,"D18S892E, DRP3, DTN, DTN-1, DTN-2, DTN-3",ENSG00000134769,Dystrobrevin alpha,18,34493290-34891844,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB015196, HPA071177",Enhanced,,Approved,Nucleoplasm<br>Cell Junctions<br>Intermediate filaments,Renal cancer:2.64e-7 (favourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 197.2,heart muscle: 101.8,Cell line enhanced,,NTERA-2: 42.7;SCLC-21H: 70.5;U-87 MG: 59.2
189,DUSP26,"DUSP24, MGC1136",ENSG00000133878,Dual specificity phosphatase 26,8,33591332-33600106,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA018221,Approved,,Supported,Nucleus,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 47.1;skeletal muscle: 138.7,ovary: 39.6,Group enriched,29.0,SCLC-21H: 110.0;SH-SY5Y: 23.6
190,DUSP8,"C11orf81, FLJ42958, HB5, HVH-5",ENSG00000184545,Dual specificity phosphatase 8,11,1554044-1571920,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA020071,Approved,,Approved,Cytosol,Renal cancer:2.75e-6 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 5.1,smooth muscle: 2.3,Cell line enhanced,,MCF7: 1.9;SH-SY5Y: 2.2
191,DYNC1I1,"DNCI1, DNCIC1",ENSG00000158560,Dynein cytoplasmic 1 intermediate chain 1,7,95772506-96110322,Predicted intracellular proteins,Evidence at protein level,HPA061689,Enhanced,,,,Endometrial cancer:3.79e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 83.9,adrenal gland: 16.8,Cell line enhanced,,EFO-21: 13.2;SH-SY5Y: 11.0;WM-115: 9.0
192,EDIL3,DEL1,ENSG00000164176,EGF like repeats and discoidin domains 3,5,83940554-84384793,Predicted secreted proteins,Evidence at protein level,HPA020415,Approved,,,,,Expressed in all,Tissue enhanced,,cerebral cortex: 131.5,epididymis: 54.6,Cell line enhanced,,LHCN-M2: 141.8;TIME: 165.9;U-2 OS: 174.3;U-87 MG: 110.4
193,EFNB3,"EPLG8, LERK-8",ENSG00000108947,Ephrin B3,17,7705202-7711378,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,HPA001623,Approved,,Approved,Nucleoplasm,"Endometrial cancer:5.52e-4 (unfavourable), Pancreatic cancer:8.21e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 48.7,endometrium: 17.4,Cell line enhanced,,AF22: 53.1;AN3-CA: 29.8;SH-SY5Y: 29.8
194,EFR3B,"FLJ37871, KIAA0953",ENSG00000084710,EFR3 homolog B,2,25042130-25159137,Predicted intracellular proteins,Evidence at protein level,HPA038089,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 33.2,skeletal muscle: 6.8,Cell line enhanced,,BEWO: 11.6;SH-SY5Y: 11.3;SK-BR-3: 13.6
195,EHD3,PAST3,ENSG00000013016,EH domain containing 3,2,31234337-31269447,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA049890, HPA049986, HPA066751",Approved,,Approved,Plasma membrane,Renal cancer:1.02e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 64.2,esophagus: 28.8,Cell line enhanced,,BJ: 68.8;BJ hTERT+: 162.4;HEL: 71.6
196,EIF4E1B,FLJ36951,ENSG00000175766,Eukaryotic translation initiation factor 4E family member 1B,5,176630682-176646641,Predicted intracellular proteins,Evidence at transcript level,HPA045045,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.6;epididymis: 1.2,testis: 0.3,Cell line enriched,6.0,T-47d: 3.0
197,ELFN1,PPP1R28,ENSG00000225968,Extracellular leucine rich repeat and fibronectin type III domain containing 1,7,1688119-1747954,Predicted membrane proteins,Evidence at protein level,HPA066382,,,Approved,Nucleoplasm<br>Cell Junctions,Liver cancer:9.68e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 3.5;liver: 3.7,endometrium: 1.7,Cell line enhanced,,REH: 28.4;U-138 MG: 18.3;U-2 OS: 28.4;U-2197: 29.8
198,ELOVL4,"CT118, SCA34, STGD2, STGD3",ENSG00000118402,ELOVL fatty acid elongase 4,6,79914812-79947580,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,Urothelial cancer:6.27e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 24.0;skin: 50.7,parathyroid gland: 15.7,Cell line enhanced,,MOLT-4: 25.9
199,EMX1,,ENSG00000135638,Empty spiracles homeobox 1,2,72916260-72936071,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA006230, HPA006421",Approved,,Approved,Nucleoli,Renal cancer:1.54e-6 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 8.3;kidney: 15.5;parathyroid gland: 5.0,testis: 2.6,Cell line enhanced,,BEWO: 2.2;CACO-2: 3.1;HEK93: 7.5
200,EPHA4,"Hek8, TYRO1",ENSG00000116106,EPH receptor A4,2,221418027-221574202,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB028368,Enhanced,,,,"Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 41.6,testis: 22.2,Cell line enhanced,,AF22: 77.5;CACO-2: 49.0;U-2197: 35.7
201,EPHB1,"EPHT2, Hek6",ENSG00000154928,EPH receptor B1,3,134597801-135260467,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA067740,Enhanced,,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,,Tissue enriched,Tissue enhanced,,cerebral cortex: 23.7;testis: 20.5,thyroid gland: 11.9,Cell line enhanced,,HDLM-2: 59.3;HMC-1: 31.7
202,EPHB6,HEP,ENSG00000106123,EPH receptor B6,7,142855061-142871094,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA035784,,,Approved,Nuclear speckles,"Urothelial cancer:4.68e-5 (favourable), Cervical cancer:1.80e-4 (favourable), Glioma:6.96e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 22.5;skin: 25.0,"cervix, uterine: 7.6",Group enriched,5.0,MOLT-4: 25.8;RT4: 47.4
203,EPHX4,"ABHD7, EPHXRP, FLJ90341",ENSG00000172031,Epoxide hydrolase 4,1,92029982-92063536,Predicted intracellular proteins,Evidence at protein level,HPA035067,Uncertain,,Approved,Vesicles,Pancreatic cancer:2.00e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 14.6,thyroid gland: 3.0,Cell line enhanced,,A-431: 13.4;CAPAN-2: 11.4;EFO-21: 24.3;RPTEC TERT1: 27.3
204,EPOP,"C17orf96, LOC100170841, PRR28",ENSG00000273604,Elongin BC and polycomb repressive complex 2 associated protein,17,38671703-38675421,Predicted intracellular proteins,Evidence at protein level,"HPA055190, HPA056555",Enhanced,,Supported,Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies,,Expressed in all,Tissue enhanced,,cerebral cortex: 5.5;testis: 5.0,parathyroid gland: 2.1,Cell line enhanced,,AN3-CA: 19.3
205,ETV1,ER81,ENSG00000006468,ETS variant 1,7,13891228-13991425,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA077249,,,Approved,Nucleoplasm,,Expressed in all,Tissue enhanced,,cerebral cortex: 106.3,lung: 43.1,Cell line enhanced,,SCLC-21H: 93.4;U-87 MG: 152.1;WM-115: 77.6
206,EXTL1,"EXTL, MGC70794",ENSG00000158008,Exostosin like glycosyltransferase 1,1,26019884-26036464,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA037749,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 11.2,skeletal muscle: 4.3,Cell line enriched,10.0,WM-115: 148.7
207,FA2H,"FAAH, FAXDC1, FLJ25287, SPG35",ENSG00000103089,Fatty acid 2-hydroxylase,16,74712955-74774831,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA056614, HPA077840",Approved,,Uncertain,Nuclear membrane,"Renal cancer:5.01e-6 (favourable), Pancreatic cancer:3.74e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 51.6;stomach: 57.4,gallbladder: 28.6,Cell line enhanced,,A549: 34.7;CAPAN-2: 18.4;HAP1: 50.4;SK-BR-3: 21.5
208,FAM131C,"C1orf117, FLJ36766",ENSG00000185519,Family with sequence similarity 131 member C,1,16057769-16073632,Predicted intracellular proteins,Evidence at protein level,HPA031046,Uncertain,,Approved,Nucleoli<br>Intermediate filaments<br>Cytosol,Renal cancer:9.33e-6 (favourable),Mixed,Tissue enhanced,,adrenal gland: 3.3;cerebral cortex: 4.8;kidney: 3.7,"heart muscle,skin: 1.1",Cell line enhanced,,A549: 7.2;HEK93: 4.6;PC-3: 5.4
209,FAM167A,C8orf13,ENSG00000154319,Family with sequence similarity 167 member A,8,11421463-11474715,Predicted intracellular proteins,Evidence at protein level,"HPA023915, HPA030426",Approved,,Approved,Mitochondria,Endometrial cancer:5.96e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 32.4;thyroid gland: 88.0,lung: 15.8,Cell line enhanced,,Daudi: 41.5;RPMI-8226: 43.0;SH-SY5Y: 48.2
210,FAM169A,"KIAA0888, SLAP75",ENSG00000198780,Family with sequence similarity 169 member A,5,74777574-74866951,Predicted intracellular proteins,Evidence at protein level,HPA041574,Enhanced,,Supported,Nuclear membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 29.2;testis: 25.4,epididymis: 23.2,Cell line enhanced,,BEWO: 35.3
211,FAM171A2,MGC34829,ENSG00000161682,Family with sequence similarity 171 member A2,17,44353215-44363875,Predicted membrane proteins,Evidence at protein level,HPA019770,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 13.3,epididymis: 3.3,Cell line enhanced,,REH: 20.9;SCLC-21H: 18.5
212,FAM181A,C14orf152,ENSG00000140067,Family with sequence similarity 181 member A,14,93918894-93929608,Predicted intracellular proteins,Evidence at protein level,HPA001603,Enhanced,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 3.4;testis: 13.7,fallopian tube: 2.9,Cell line enriched,10.0,AF22: 4.2
213,FAM189A1,"KIAA0574, TMEM228",ENSG00000104059,Family with sequence similarity 189 member A1,15,29120254-29570723,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA009410, HPA010637",Uncertain,,Supported,Nucleus,,Mixed,Tissue enhanced,,cerebral cortex: 2.2;parathyroid gland: 2.0,"colon,testis: 0.8",Cell line enhanced,,EFO-21: 4.4;HDLM-2: 11.1;REH: 2.6
214,FAM196A,"C10orf141, FLJ45557, INSYN2",ENSG00000188916,Family with sequence similarity 196 member A,10,127135426-127196158,Predicted intracellular proteins,Evidence at protein level,"HPA035898, HPA035899",Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 3.2,prostate: 1.3,Group enriched,7.0,SCLC-21H: 3.2;U-87 MG: 5.2
215,FAM196B,C5orf57,ENSG00000204767,Family with sequence similarity 196 member B,5,169864264-169980740,Predicted intracellular proteins,Evidence at transcript level,HPA047227,Uncertain,,,,,Mixed,Tissue enhanced,,breast: 7.6;cerebral cortex: 7.0,ovary: 2.1,Cell line enhanced,,fHDF/TERT166: 30.1;HUVEC TERT2: 20.4;U-138 MG: 61.2
216,FAM19A2,"TAFA-2, TAFA2",ENSG00000198673,"Family with sequence similarity 19 member A2, C-C motif chemokine like",12,61708259-62279150,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 26.3,seminal vesicle: 10.0,Cell line enhanced,,hTCEpi: 4.1;SCLC-21H: 2.5;WM-115: 4.7
217,FAM19A5,TAFA-5,ENSG00000219438,"Family with sequence similarity 19 member A5, C-C motif chemokine like",22,48489460-48850912,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,CAB025629,Approved,,,,,Expressed in all,Tissue enhanced,,cerebral cortex: 49.9,"cervix, uterine: 12.9",Cell line enhanced,,fHDF/TERT166: 15.8;HEK93: 12.4;Hep G2: 21.7;NTERA-2: 17.3;SCLC-21H: 10.2;U-2 OS: 24.8
218,FAM222A,"C12orf34, FLJ14721",ENSG00000139438,Family with sequence similarity 222 member A,12,109714228-109770507,Predicted intracellular proteins,Evidence at protein level,HPA040181,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites<br>Mitochondria,"Cervical cancer:1.82e-5 (favourable), Pancreatic cancer:4.81e-4 (favourable), Stomach cancer:8.59e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 20.0;testis: 16.5,adrenal gland: 9.8,Cell line enriched,5.0,SH-SY5Y: 122.9
219,FAM234B,KIAA1467,ENSG00000084444,Family with sequence similarity 234 member B,12,13044284-13142521,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA010803, HPA010850",Approved,,Approved,Endoplasmic reticulum,,Expressed in all,Tissue enhanced,,cerebral cortex: 32.4,breast: 20.8,Expressed in all,,
220,FAM49A,"DKFZP566A1524, FLJ11080",ENSG00000197872,Family with sequence similarity 49 member A,2,16549459-16666331,Predicted intracellular proteins,Evidence at protein level,"CAB017847, HPA060398",Approved,,Approved,Nucleoplasm,"Renal cancer:1.83e-6 (unfavourable), Urothelial cancer:4.46e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 81.4,thyroid gland: 68.3,Cell line enhanced,,HMC-1: 46.7;HUVEC TERT2: 36.0;RH-30: 92.5
221,FAM69C,C18orf51,ENSG00000187773,Family with sequence similarity 69 member C,18,74434099-74457944,Predicted intracellular proteins,Evidence at protein level,HPA048928,Enhanced,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 28.8;testis: 8.4,skin: 4.9,Cell line enriched,7.0,SK-MEL-30: 4.2
222,FAM81A,MGC26690,ENSG00000157470,Family with sequence similarity 81 member A,15,59372693-59523549,Predicted intracellular proteins,Evidence at protein level,"HPA001847, HPA065797",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 33.3,fallopian tube: 9.9,Cell line enhanced,,Daudi: 47.3
223,FAM86B1,MGC16279,ENSG00000186523,Family with sequence similarity 86 member B1,8,12182096-12194133,Predicted intracellular proteins,Evidence at transcript level,"HPA041610, HPA055718",Uncertain,,Uncertain,Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 4.5,endometrium: 2.6,Mixed,,
224,FAM90A1,FLJ10408,ENSG00000171847,Family with sequence similarity 90 member A1,12,8221260-8227618,Predicted intracellular proteins,Evidence at protein level,,,,,,Endometrial cancer:3.92e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 11.6,ovary: 5.3,Cell line enhanced,,BEWO: 4.7;HDLM-2: 7.1;NTERA-2: 17.6
225,FAT3,"CDHF15, CDHR10, KIAA1989",ENSG00000165323,FAT atypical cadherin 3,11,92352096-92896470,Predicted membrane proteins,Evidence at protein level,HPA026878,Uncertain,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 3.9;seminal vesicle: 2.6,prostate: 1.6,Cell line enhanced,,AF22: 3.6;NTERA-2: 1.2;U-2 OS: 1.1;U-251 MG: 1.8
226,FAXC,"C6orf168, dJ273F20, MGC2817",ENSG00000146267,Failed axon connections homolog,6,99271169-99350062,Predicted intracellular proteins,Evidence at protein level,HPA039106,Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,cerebral cortex: 23.5,seminal vesicle: 14.9,Cell line enhanced,,HAP1: 24.5;SCLC-21H: 40.3;SH-SY5Y: 25.2
227,FBLL1,LOC345630,ENSG00000188573,Fibrillarin-like 1,5,168529116-168530634,Predicted intracellular proteins,Evidence at transcript level,HPA049546,,,Approved,Nucleus<br>Nucleoli fibrillar center,,Mixed,Tissue enhanced,,cerebral cortex: 19.0,testis: 4.3,Group enriched,6.0,SCLC-21H: 24.5;SH-SY5Y: 18.4
228,FBXO2,"Fbg1, Fbs1, FBX2, Nfb42, OCP1",ENSG00000116661,F-box protein 2,1,11648367-11655785,Predicted intracellular proteins,Evidence at protein level,HPA005472,,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:3.45e-6 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 80.5,adrenal gland: 27.7,Cell line enhanced,,CACO-2: 75.6;Hep G2: 131.1;SiHa: 376.0
229,FBXO41,"Fbx41, KIAA1940",ENSG00000163013,F-box protein 41,2,73254682-73284431,Predicted intracellular proteins,Evidence at protein level,"HPA055246, HPA058386",,,Approved,Nucleus<br>Plasma membrane<br>Cytosol,"Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:5.76e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 38.3,parathyroid gland: 11.1,Cell line enhanced,,Daudi: 33.9
230,FGF1,"AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1",ENSG00000113578,Fibroblast growth factor 1,5,142592178-142698070,"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA003265, CAB017519",Enhanced,,,,"Renal cancer:2.59e-5 (favourable), Thyroid cancer:3.45e-5 (favourable)",Tissue enriched,Tissue enhanced,,cerebral cortex: 129.9;kidney: 59.4,heart muscle: 32.8,Cell line enhanced,,BJ: 37.6;BJ hTERT+ SV40 Large T+: 33.4;BJ hTERT+ SV40 Large T+ RasG12V: 43.9;HBF TERT88: 62.3;hTEC/SVTERT24-B: 45.5;U-2 OS: 33.6
231,FGF12,"FGF12B, FHF1",ENSG00000114279,Fibroblast growth factor 12,3,192139395-192767764,"Disease related genes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA071557,,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,adrenal gland: 46.7;cerebral cortex: 52.4;heart muscle: 89.9,spleen: 16.2,Cell line enhanced,,AF22: 14.9;NTERA-2: 10.3;SCLC-21H: 28.2;U-251 MG: 12.2;WM-115: 17.4
232,FGF14,"FHF4, SCA27",ENSG00000102466,Fibroblast growth factor 14,13,101710804-102402457,"Disease related genes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA049828,,,Approved,Nucleoli fibrillar center,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 14.8;cervix, uterine: 22.9;fallopian tube: 17.2",testis: 4.3,Group enriched,7.0,SCLC-21H: 5.4;SH-SY5Y: 20.7;U-87 MG: 4.1
233,FJX1,"FLJ22416, FLJ25593",ENSG00000179431,Four jointed box 1,11,35618419-35620868,Predicted secreted proteins,Evidence at protein level,HPA059220,Uncertain,,Approved,Vesicles,"Renal cancer:9.24e-9 (unfavourable), Urothelial cancer:6.56e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 22.4,endometrium: 8.8,Mixed,,
234,FKBP1B,"FKBP12.6, FKBP1L, FKBP9, OTK4, PPIase",ENSG00000119782,FK506 binding protein 1B,2,24049701-24063681,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA045572, HPA051798",Uncertain,,Approved,Vesicles,,Expressed in all,Tissue enhanced,,cerebral cortex: 24.4,duodenum: 18.6,Cell line enhanced,,Hep G2: 30.2;NTERA-2: 41.7;SH-SY5Y: 31.9;TIME: 30.3
235,FLRT1,"MGC21624, SPG68",ENSG00000126500,Fibronectin leucine rich transmembrane protein 1,11,64103188-64119173,Predicted membrane proteins,Evidence at protein level,HPA054589,Uncertain,,,,,Mixed,Tissue enhanced,,adrenal gland: 5.9;cerebral cortex: 12.5,"cervix, uterine: 4.0",Cell line enhanced,,SCLC-21H: 6.4;SH-SY5Y: 14.3;THP-1: 7.6
236,FMNL2,"FHOD2, KIAA1902",ENSG00000157827,Formin like 2,2,152335237-152649834,Predicted intracellular proteins,Evidence at protein level,HPA005464,Enhanced,,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Liver cancer:9.04e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 137.8,placenta: 82.9,Cell line enhanced,,BEWO: 184.8
237,FREM3,,ENSG00000183090,FRAS1 related extracellular matrix 3,4,143577302-143700675,Predicted secreted proteins,Evidence at protein level,HPA041641,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.6,lung: 0.6,Not detected,,
238,FRMD5,MGC14161,ENSG00000171877,FERM domain containing 5,15,43870761-44195252,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA011746, HPA013961",,,Uncertain,Golgi apparatus<br>Centrosome,Pancreatic cancer:5.89e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 20.4;heart muscle: 29.4,adrenal gland: 7.2,Cell line enhanced,,WM-115: 59.3
239,FRMPD2,"MGC35285, PDZD5C, PDZK5C",ENSG00000170324,FERM and PDZ domain containing 2,10,48153088-48274870,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.6;fallopian tube: 4.6,thyroid gland: 0.8,Cell line enhanced,,BEWO: 2.3;SCLC-21H: 1.2
240,FRMPD3,"KIAA1817, RP5-1070B1.1",ENSG00000147234,FERM and PDZ domain containing 3,X,107522450-107605251,Predicted intracellular proteins,Evidence at transcript level,HPA003164,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.9;ovary: 6.7;thyroid gland: 5.5,seminal vesicle: 1.9,Cell line enhanced,,Daudi: 4.2;SCLC-21H: 2.1;WM-115: 2.1
241,FRRS1L,"C9orf4, CG-6",ENSG00000260230,Ferric chelate reductase 1 like,9,109130293-109167291,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA071086,Enhanced,,,,,Mixed,Tissue enhanced,,cerebral cortex: 47.7,ovary: 14.2,Cell line enhanced,,AF22: 1.6;SH-SY5Y: 4.3
242,FSCN1,"FLJ38511, p55, SNL",ENSG00000075618,Fascin actin-bundling protein 1,7,5592823-5606655,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000121, HPA005723, CAB035991, HPA050654",Enhanced,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:8.15e-7 (unfavourable), Lung cancer:2.28e-4 (unfavourable), Head and neck cancer:5.76e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 85.5,spleen: 54.6,Cell line enhanced,,BEWO: 579.4
243,FSD1L,"CCDC10, CSDUFD1, FSD1CL, FSD1NL",ENSG00000106701,Fibronectin type III and SPRY domain containing 1 like,9,105447796-105552433,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA035138,Approved,,Approved,Plasma membrane<br>Actin filaments,,Mixed,Tissue enhanced,,cerebral cortex: 17.8,testis: 13.5,Mixed,,
244,FSTL4,KIAA1061,ENSG00000053108,Follistatin like 4,5,133196455-133612564,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA045920,Uncertain,,Approved,Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 9.5,urinary bladder: 7.3,Cell line enhanced,,SCLC-21H: 66.8
245,GABBR1,"GPRC3A, hGB1a",ENSG00000204681,Gamma-aminobutyric acid type B receptor subunit 1,6,29555629-29633976,"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA050483, HPA058459",Uncertain,,Approved,Centrosome,"Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 20.8,spleen: 13.1,Cell line enhanced,,U-2 OS: 6.7
246,GABRB3,,ENSG00000166206,Gamma-aminobutyric acid type A receptor beta3 subunit,15,26543546-26939539,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 78.3,gallbladder: 21.5,Cell line enhanced,,A549: 61.5;HAP1: 28.7;NTERA-2: 48.0;SCLC-21H: 51.8
247,GABRQ,THETA,ENSG00000268089,Gamma-aminobutyric acid type A receptor theta subunit,X,152638183-152657534,"FDA approved drug targets, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 6.6;cervix, uterine: 12.9",adrenal gland: 3.0,Group enriched,7.0,HeLa: 8.2;SiHa: 12.7;U-87 MG: 37.4
248,GAL3ST1,CST,ENSG00000128242,Galactose-3-O-sulfotransferase 1,22,30554635-30574587,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA001220,Approved,,Approved,Vesicles,Renal cancer:1.79e-4 (unfavourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 18.0;duodenum: 23.2;small intestine: 27.0,kidney: 10.1,Cell line enhanced,,A549: 25.1;EFO-21: 13.7
249,GAL3ST3,GAL3ST2,ENSG00000175229,Galactose-3-O-sulfotransferase 3,11,66041952-66049180,Predicted secreted proteins,Evidence at protein level,,,,,,Endometrial cancer:6.53e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 4.3;endometrium: 4.3;smooth muscle: 4.8;thyroid gland: 8.2,seminal vesicle: 2.5,Group enriched,5.0,NTERA-2: 8.8;SH-SY5Y: 7.6
250,GALNT15,"GALNT7, GALNTL2, pp-GalNAc-T15",ENSG00000131386,Polypeptide N-acetylgalactosaminyltransferase 15,3,16174649-16231992,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA017076,Uncertain,,Approved,Golgi apparatus<br>Cytosol,,Tissue enriched,Tissue enhanced,,adipose tissue: 36.3;cerebral cortex: 41.2;placenta: 43.0,breast: 18.3,Group enriched,11.0,ASC diff: 91.0;ASC TERT1: 90.9;HSkMC: 72.4;U-2197: 22.3
251,GALNT9,GALNAC-T9,ENSG00000182870,Polypeptide N-acetylgalactosaminyltransferase 9,12,132196372-132329349,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA075016,,,Approved,Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 29.4,thyroid gland: 6.3,Cell line enriched,6.0,U-87 MG: 30.6
252,GALNTL6,"GalNAc-T6L, GALNT17",ENSG00000174473,Polypeptide N-acetylgalactosaminyltransferase-like 6,4,171812254-173041559,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA031019,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 5.4;testis: 4.5,spleen: 1.9,Not detected,,
253,GALR1,"GALNR, GALNR1",ENSG00000166573,Galanin receptor 1,18,77250549-77277896,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,adrenal gland: 2.1;cerebral cortex: 1.7,"prostate,seminal vesicle,testis: 0.4",Not detected,,
254,GAS7,"KIAA0394, MGC1348",ENSG00000007237,Growth arrest specific 7,17,9910609-10198551,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA004838, HPA064678",Enhanced,,Approved,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,Urothelial cancer:6.89e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 154.7,"cervix, uterine: 47.6",Cell line enriched,11.0,WM-115: 526.3
255,GATS,"DKFZp686B07267, STAG3OS",ENSG00000239521,"GATS, stromal antigen 3 opposite strand",7,100200653-100272218,Predicted intracellular proteins,Evidence at transcript level,HPA043176,Uncertain,,,,Cervical cancer:7.56e-7 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 3.3;skeletal muscle: 2.2,bone marrow: 0.7,Cell line enhanced,,A549: 1.4
256,GATSL2,GATSL1,ENSG00000274070,GATS protein like 2,7,74964818-75024798,Predicted intracellular proteins,Evidence at protein level,HPA057229,Uncertain,,,,,Expressed in all,Tissue enhanced,,cerebral cortex: 14.9,skeletal muscle: 13.8,Cell line enhanced,,A549: 24.5
257,GDA,,ENSG00000119125,Guanine deaminase,9,72114595-72257193,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019352, HPA024099, HPA030387",Enhanced,,Approved,Nucleus,Renal cancer:2.66e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 102.2;duodenum: 95.2;small intestine: 104.1,kidney: 43.6,Cell line enhanced,,A-431: 31.0;EFO-21: 125.3;HeLa: 32.0;hTCEpi: 45.2
258,GDAP1,"CMT2K, CMT4, CMT4A",ENSG00000104381,Ganglioside induced differentiation associated protein 1,8,74321130-74488872,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA014266, HPA024334",Enhanced,,Supported,Mitochondria<br>Cytosol,"Endometrial cancer:1.82e-4 (unfavourable), Lung cancer:2.68e-4 (favourable), Thyroid cancer:4.54e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 76.7,parathyroid gland: 18.3,Cell line enhanced,,SH-SY5Y: 49.8
259,GDPD1,"FLJ37451, GDE4",ENSG00000153982,Glycerophosphodiester phosphodiesterase domain containing 1,17,59220467-59275967,Predicted membrane proteins,Evidence at protein level,,,,,,Lung cancer:2.98e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 27.9,testis: 20.0,Cell line enhanced,,HEL: 27.1;SCLC-21H: 21.6
260,GJC2,"CX46.6, CX47, GJA12, SPG44",ENSG00000198835,Gap junction protein gamma 2,1,228149852-228159826,"Disease related genes, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 11.5,fallopian tube: 3.7,Cell line enhanced,,EFO-21: 5.1;SCLC-21H: 3.4
261,GJD4,"CX40.1, FLJ90023",ENSG00000177291,Gap junction protein delta 4,10,35605410-35608935,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA038266,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.7,skin: 1.0,Cell line enhanced,,RH-30: 1.6
262,GLDN,"CLOM, COLM, colmedin, CRG-L2, UNC-112",ENSG00000186417,Gliomedin,15,51341629-51408013,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA059441,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 23.9,adipose tissue: 12.9,Cell line enhanced,,HHSteC: 2.3;U-266/70: 2.5;U-266/84: 2.0
263,GLP1R,,ENSG00000112164,Glucagon like peptide 1 receptor,6,39048798-39087743,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 1.9;heart muscle: 1.8,pancreas: 1.5,Cell line enhanced,,NTERA-2: 1.3;SCLC-21H: 3.7
264,GLRB,,ENSG00000109738,Glycine receptor beta,4,157076057-157172090,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA052363,Approved,,,,Renal cancer:4.89e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 62.0;parathyroid gland: 63.1,"cervix, uterine: 14.1",Mixed,,
265,GLT1D1,FLJ31978,ENSG00000151948,Glycosyltransferase 1 domain containing 1,12,128853427-128984968,Predicted intracellular proteins,Evidence at protein level,"HPA039051, HPA039052",,,Enhanced,Cytosol,,Group enriched,Tissue enhanced,,cerebral cortex: 22.4;testis: 28.2,bone marrow: 18.6,Group enriched,7.0,MOLT-4: 10.5;NTERA-2: 18.0;SCLC-21H: 9.9
266,GNAZ,,ENSG00000128266,G protein subunit alpha z,22,23070361-23125037,Predicted intracellular proteins,Evidence at protein level,HPA003011,Enhanced,,Approved,Vesicles,Endometrial cancer:4.85e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 49.7,seminal vesicle: 23.0,Cell line enhanced,,SCLC-21H: 44.4;SH-SY5Y: 24.7
267,GNG13,"G(gamma)13, h2-35",ENSG00000127588,G protein subunit gamma 13,16,798041-800733,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA046272,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 2.5;duodenum: 1.4;small intestine: 1.4,colon: 0.7,Cell line enhanced,,CACO-2: 8.6;HEK93: 8.3;MCF7: 10.0
268,GNG4,,ENSG00000168243,G protein subunit gamma 4,1,235547687-235650754,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 25.3;ovary: 18.4;prostate: 17.5,endometrium: 8.4,Cell line enhanced,,NTERA-2: 75.6;SCLC-21H: 93.5;SH-SY5Y: 118.5
269,GPC5,,ENSG00000179399,Glypican 5,13,91398607-92873682,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA040152, HPA044081",Enhanced,,Approved,Nucleus<br>Cytosol,Glioma:5.67e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 15.8;kidney: 8.1;testis: 11.5,lung: 4.9,Group enriched,9.0,CACO-2: 41.2;HeLa: 18.9
270,GPR12,"GPCR21, PPP1R84",ENSG00000132975,G protein-coupled receptor 12,13,26755200-26760785,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA050972,Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 7.9,breast: 1.7,Cell line enriched,8.0,SCLC-21H: 16.7
271,GPR150,PGR11,ENSG00000178015,G protein-coupled receptor 150,5,95620078-95622142,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA026635,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 1.3;parathyroid gland: 2.0,pancreas: 1.0,Cell line enhanced,,ASC diff: 1.0;SiHa: 1.3;TIME: 2.2
272,GPR173,SREB3,ENSG00000184194,G protein-coupled receptor 173,X,53049091-53080615,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA003905,,,Approved,Plasma membrane<br>Cytosol,"Endometrial cancer:2.88e-6 (unfavourable), Pancreatic cancer:2.33e-5 (favourable), Renal cancer:2.47e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 19.1,ovary: 8.9,Cell line enhanced,,HAP1: 10.2
273,GPR19,,ENSG00000183150,G protein-coupled receptor 19,12,12660891-12696207,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA013955,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 8.4;testis: 7.8,appendix: 2.7,Cell line enhanced,,HDLM-2: 37.0;NTERA-2: 39.8
274,GPR21,,ENSG00000188394,G protein-coupled receptor 21,9,123034527-123035696,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA041651,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 2.1,endometrium: 0.9,Cell line enriched,6.0,HBEC3-KT: 2.2
275,GPR3,ACCA,ENSG00000181773,G protein-coupled receptor 3,1,27392644-27395814,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,CAB006254,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 5.2,thyroid gland: 1.3,Cell line enhanced,,U-2197: 21.6
276,GPR37,"EDNRBL, hET(B)R-LP, PAELR",ENSG00000170775,G protein-coupled receptor 37,7,124745997-124765627,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA042903, HPA068009",Approved,,Approved,Nuclear membrane<br>Cytosol,"Lung cancer:6.00e-5 (unfavourable), Ovarian cancer:7.26e-4 (favourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 78.7;testis: 27.6,placenta: 12.8,Cell line enhanced,,AF22: 12.8;fHDF/TERT166: 24.0;TIME: 17.5
277,GPR45,"PSP24, PSP24A",ENSG00000135973,G protein-coupled receptor 45,2,105241743-105243049,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA055940,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.8,testis: 0.4,Group enriched,14.0,BEWO: 1.3;U-2 OS: 4.5
278,GPR61,BALGR,ENSG00000156097,G protein-coupled receptor 61,1,109539872-109548406,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA007326, HPA026088",Approved,,,,,Not detected,Tissue enhanced,,adrenal gland: 1.0;cerebral cortex: 3.4;thyroid gland: 1.2,testis: 0.5,Not detected,,
279,GPR75,WI-31133,ENSG00000119737,G protein-coupled receptor 75,2,53852913-53859989,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 17.8,parathyroid gland: 6.5,Mixed,,
280,GPR75-ASB3,,ENSG00000270898,GPR75-ASB3 readthrough,2,53670293-53860160,Predicted intracellular proteins,Evidence at transcript level,HPA003940,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.0,spleen: 0.3,Cell line enhanced,,K-562: 1.3
281,GPR85,SREB2,ENSG00000164604,G protein-coupled receptor 85,7,113078331-113087778,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 16.7,skeletal muscle: 11.4,Cell line enriched,6.0,HEL: 99.3
282,GPRC5B,RAIG-2,ENSG00000167191,G protein-coupled receptor class C group 5 member B,16,19856691-19886167,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA015247,Enhanced,,Supported,Nucleus<br>Nucleoli<br>Vesicles,"Colorectal cancer:9.27e-5 (unfavourable), Renal cancer:6.30e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 308.3,testis: 66.2,Cell line enhanced,,EFO-21: 84.6;HHSteC: 50.7
283,GRIA3,"GluA3, GLUR3, GLURC, MRX94",ENSG00000125675,Glutamate ionotropic receptor AMPA type subunit 3,X,123184153-123490915,"Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA058659,Uncertain,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 56.6,adrenal gland: 11.3,Cell line enhanced,,BJ: 20.3;BJ hTERT+: 28.1;fHDF/TERT166: 35.8;U-2197: 14.1
284,GRID1,"GluD1, KIAA1220",ENSG00000182771,Glutamate ionotropic receptor delta type subunit 1,10,85599555-86366493,Predicted membrane proteins,Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 7.7,thyroid gland: 3.4,Cell line enhanced,,Daudi: 1.8;HEL: 2.3;SH-SY5Y: 1.0
285,GRIK1,"GluK1, GLUR5",ENSG00000171189,Glutamate ionotropic receptor kainate type subunit 1,21,29536933-29940033,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA014623,Uncertain,,,,Glioma:9.12e-4 (unfavourable),Group enriched,Tissue enhanced,,adrenal gland: 16.3;cerebral cortex: 9.0,prostate: 4.0,Not detected,,
286,GRIK2,"GluK2, GLUR6, MRT6",ENSG00000164418,Glutamate ionotropic receptor kainate type subunit 2,6,101398788-102070083,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA014395, HPA014623, CAB022463",Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 22.5,thyroid gland: 6.3,Cell line enhanced,,BJ: 14.3;BJ hTERT+: 22.6;fHDF/TERT166: 16.5;WM-115: 25.2
287,GRIK4,"GluK4, GRIK, KA1",ENSG00000149403,Glutamate ionotropic receptor kainate type subunit 4,11,120511700-120988904,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA074453,Enhanced,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 11.3,"ovary,thyroid gland: 3.5",Group enriched,5.0,HDLM-2: 5.7;HEL: 16.7;T-47d: 4.4
288,GRIK5,"GluK5, GRIK2, KA2",ENSG00000105737,Glutamate ionotropic receptor kainate type subunit 5,19,41998321-42069498,Predicted membrane proteins,Evidence at protein level,HPA074001,,,Supported,Nucleus<br>Plasma membrane,"Pancreatic cancer:7.23e-4 (favourable), Renal cancer:9.32e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 30.8;parathyroid gland: 22.1,testis: 18.8,Cell line enhanced,,HEL: 12.3;NTERA-2: 13.1;REH: 34.1;SCLC-21H: 12.1;SH-SY5Y: 24.1
289,GRIN2A,"GluN2A, NMDAR2A",ENSG00000183454,Glutamate ionotropic receptor NMDA type subunit 2A,16,9753404-10182754,"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,CAB022725,Enhanced,,,,,Mixed,Tissue enhanced,,cerebral cortex: 25.8,testis: 6.1,Cell line enhanced,,fHDF/TERT166: 3.3;U-138 MG: 4.4
290,GRIN2C,"GluN2C, NMDAR2C",ENSG00000161509,Glutamate ionotropic receptor NMDA type subunit 2C,17,74842023-74861504,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.5;thyroid gland: 14.1,heart muscle: 6.1,Cell line enhanced,,BEWO: 6.1;SCLC-21H: 3.3
291,GRIN2D,"EB11, GluN2D, NMDAR2D, NR2D",ENSG00000105464,Glutamate ionotropic receptor NMDA type subunit 2D,19,48394875-48444931,"Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 2.3,placenta: 1.3,Cell line enhanced,,A549: 16.7;HMC-1: 27.0
292,GRM4,"GPRC1D, mGlu4, MGLUR4",ENSG00000124493,Glutamate metabotropic receptor 4,6,34018645-34155622,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB022096,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 2.9,testis: 0.7,Group enriched,11.0,BEWO: 7.2;SCLC-21H: 35.0
293,GRM7,"GLUR7, GPRC1G, mGlu7, MGLUR7, PPP1R87",ENSG00000196277,Glutamate metabotropic receptor 7,3,6770001-7741533,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA015964,,,Uncertain,Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 10.1;parathyroid gland: 7.2,smooth muscle: 3.4,Cell line enriched,12.0,SH-SY5Y: 5.0
294,GRM8,"GLUR8, GPRC1H, mGlu8, MGLUR8",ENSG00000179603,Glutamate metabotropic receptor 8,7,126438598-127253294,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA051481,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 4.1,testis: 3.0,Group enriched,6.0,HAP1: 3.1;HEK93: 1.4;NTERA-2: 3.9;RH-30: 2.2;SCLC-21H: 4.1;SH-SY5Y: 2.0;U-2 OS: 1.3
295,GSG1L,"KTSR5831, MGC18079, PRO19651",ENSG00000169181,GSG1 like,16,27787535-28063509,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA014479,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 11.7;heart muscle: 7.3,fallopian tube: 2.7,Group enriched,7.0,HMC-1: 7.3;THP-1: 2.1
296,HAGHL,MGC2605,ENSG00000103253,Hydroxyacylglutathione hydrolase-like,16,726936-735525,Predicted intracellular proteins,Evidence at transcript level,HPA074402,Approved,,,,Renal cancer:1.18e-5 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 9.1,spleen: 4.4,Cell line enhanced,,RPMI-8226: 44.3;U-266/70: 49.9
297,HAP1,"HAP2, hHLP1, HIP5, HLP",ENSG00000173805,Huntingtin associated protein 1,17,41717742-41734644,Predicted intracellular proteins,Evidence at protein level,HPA023394,Uncertain,,,,Pancreatic cancer:4.26e-4 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 11.5;stomach: 12.8,thyroid gland: 6.4,Cell line enriched,8.0,REH: 87.3
298,HECW1,"KIAA0322, NEDL1",ENSG00000002746,"HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1",7,43112599-43566001,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007203, HPA007593, HPA007609",Approved,,Supported,Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 10.9;kidney: 8.2,testis: 3.4,Cell line enhanced,,A549: 3.9;U-266/70: 9.1
299,HES5,bHLHb38,ENSG00000197921,Hes family bHLH transcription factor 5,1,2528745-2530245,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA065458, HPA076164",Enhanced,,Approved,Nucleoplasm<br>Nuclear speckles<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 1.8,skin: 0.9,Cell line enhanced,,HaCaT: 1.1
300,HES6,bHLHb41,ENSG00000144485,Hes family bHLH transcription factor 6,2,238238267-238240662,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA061763,,,Approved,Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol,"Lung cancer:9.18e-5 (favourable), Liver cancer:2.79e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 76.8,fallopian tube: 22.3,Cell line enhanced,,NB-4: 122.5;SCLC-21H: 144.1;SK-MEL-30: 141.7
301,HEY1,"bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1",ENSG00000164683,Hes related family bHLH transcription factor with YRPW motif 1,8,79764010-79767863,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA055599, HPA063472",Uncertain,,Approved,Nucleoplasm<br>Nuclear membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 96.4,placenta: 28.8,Cell line enhanced,,HEK93: 120.1;SK-MEL-30: 70.9
302,HHIPL1,KIAA1822,ENSG00000182218,HHIP like 1,14,99645110-99680569,Predicted secreted proteins,Evidence at transcript level,HPA052767,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 6.6,smooth muscle: 2.6,Cell line enhanced,,EFO-21: 2.9;fHDF/TERT166: 4.3;SiHa: 3.9;THP-1: 2.6
303,HMGCLL1,"bA418P12.1, DKFZP434G1411",ENSG00000146151,3-hydroxymethyl-3-methylglutaryl-CoA lyase like 1,6,55434369-55579214,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 14.5;placenta: 9.0,prostate: 5.2,Cell line enriched,11.0,SCLC-21H: 7.1
304,HMX1,"H6, NKX5-3",ENSG00000215612,H6 family homeobox 1,4,8846076-8871817,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 1.1,testis: 0.9,Cell line enhanced,,AN3-CA: 9.5;EFO-21: 5.6;HEK93: 10.2;SH-SY5Y: 4.4
305,HOMER1,"HOMER-1B, SYN47, Ves-1",ENSG00000152413,Homer scaffolding protein 1,5,79372636-79514217,Predicted intracellular proteins,Evidence at protein level,"CAB004437, HPA036521, HPA036522",Enhanced,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 48.9,thyroid gland: 25.2,Mixed,,
306,HS6ST3,,ENSG00000185352,Heparan sulfate 6-O-sulfotransferase 3,13,96090839-96839562,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA078257,,,Approved,Nucleoplasm<br>Nuclear membrane<br>Actin filaments,Renal cancer:6.12e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 27.7,urinary bladder: 6.0,Group enriched,8.0,HAP1: 2.9;RT4: 13.7
307,HSD11B1L,"SCDR10, SDR26C2",ENSG00000167733,Hydroxysteroid 11-beta dehydrogenase 1 like,19,5680604-5688523,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA049078,,,Approved,Vesicles,Head and neck cancer:4.38e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 25.6,fallopian tube: 7.9,Cell line enhanced,,SH-SY5Y: 20.1
308,HSPA12A,"FLJ13874, KIAA0417",ENSG00000165868,Heat shock protein family A (Hsp70) member 12A,10,116671192-116849741,Predicted intracellular proteins,Evidence at protein level,"HPA011273, HPA073244",Approved,,Approved,Golgi apparatus<br>Cytosol,Renal cancer:3.61e-7 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 65.0,adrenal gland: 26.7,Cell line enhanced,,RPTEC TERT1: 46.5
309,HTR3B,5-HT3B,ENSG00000149305,5-hydroxytryptamine receptor 3B,11,113904677-113946565,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA039559,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 2.7,testis: 1.1,Not detected,,
310,IBSP,"BSP, BSP-II, SP-II",ENSG00000029559,Integrin binding sialoprotein,4,87799581-87812435,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 1.6;cervix, uterine: 1.3","gallbladder,placenta: 0.3",Cell line enriched,6.0,U-138 MG: 7.3
311,IGSF11,"BT-IgSF, CT119, Igsf13, MGC35227, VSIG3",ENSG00000144847,Immunoglobulin superfamily member 11,3,118900557-119146068,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA046377,Uncertain,,Approved,Nucleus<br>Cell Junctions<br>Cytosol,,Group enriched,Tissue enhanced,,cerebral cortex: 31.0;testis: 64.9,ovary: 20.1,Cell line enhanced,,A549: 7.2;SK-MEL-30: 26.9;U-266/70: 8.9;U-266/84: 10.2
312,IGSF21,"MGC15730, RP11-121A23.1",ENSG00000117154,Immunoglobin superfamily member 21,1,18107746-18378483,Predicted secreted proteins,Evidence at protein level,HPA044535,Approved,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 28.9;spleen: 13.2,adrenal gland: 5.9,Cell line enriched,6.0,SCLC-21H: 21.2
313,IL9,"HP40, IL-9, P40",ENSG00000145839,Interleukin 9,5,135892246-135895827,"Cancer-related genes, Predicted secreted proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.7,skin: 0.5,Cell line enriched,235.0,HDLM-2: 41.4
314,ILDR2,C1orf32,ENSG00000143195,Immunoglobulin like domain containing receptor 2,1,166895711-166975482,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012545,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 11.3;testis: 17.4,kidney: 3.1,Cell line enhanced,,AF22: 7.8;U-2 OS: 10.6;U-251 MG: 4.6
315,IMPG1,"GP147, IPM150, SPACR",ENSG00000112706,Interphotoreceptor matrix proteoglycan 1,6,75921115-76072678,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA027142, HPA030332, HPA030333",Enhanced,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.5;skin: 1.6,"duodenum,small intestine: 0.9",Cell line enhanced,,HaCaT: 1.0
316,INSM2,"IA-6, Mlt1",ENSG00000168348,INSM transcriptional repressor 2,14,35534042-35537054,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA044885, HPA051925",Uncertain,,Approved,Nucleoplasm,,Not detected,Tissue enhanced,,cerebral cortex: 1.3,testis: 0.7,Cell line enriched,121.0,SH-SY5Y: 115.7
317,IQCJ-SCHIP1,,ENSG00000283154,IQCJ-SCHIP1 readthrough,3,158962235-159897366,Predicted intracellular proteins,Evidence at protein level,"HPA003243, HPA003445",Approved,,Approved,Cytosol,,,Tissue enhanced,,cerebral cortex: 99.0,smooth muscle: 36.8,Mixed,,
318,IQSEC3,"KIAA1110, MGC30156",ENSG00000120645,IQ motif and Sec7 domain 3,12,66765-178460,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 16.1,fallopian tube: 5.4,Cell line enhanced,,HEL: 6.3;U-266/70: 6.9;U-266/84: 1.6
319,ITPKA,"IP3-3KA, IP3KA",ENSG00000137825,Inositol-trisphosphate 3-kinase A,15,41493393-41503551,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040454,Enhanced,Approved,Approved,Vesicles,"Renal cancer:3.76e-9 (unfavourable), Glioma:5.08e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 25.7;duodenum: 17.7;small intestine: 19.8,stomach: 8.9,Cell line enhanced,,Hep G2: 22.6
320,JAKMIP3,"bA140A10.5, C10orf14, C10orf39, FLJ37857, KIAA4091, NECC2",ENSG00000188385,Janus kinase and microtubule interacting protein 3,10,132104671-132184809,Predicted membrane proteins,Evidence at protein level,HPA022872,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 5.8,prostate: 2.2,Cell line enhanced,,A549: 2.2;U-266/84: 4.1
321,JPH4,"JPHL1, KIAA1831",ENSG00000092051,Junctophilin 4,14,23568035-23578800,Predicted membrane proteins,Evidence at transcript level,CAB013492,,,Uncertain,Nucleoplasm<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 107.1;seminal vesicle: 51.9,endometrium: 28.1,Group enriched,7.0,SCLC-21H: 16.8;SH-SY5Y: 37.5;U-2 OS: 27.7
322,KALRN,"ARHGEF24, DUET, duo, HAPIP, Hs.8004, Kalirin, TRAD",ENSG00000160145,"Kalirin, RhoGEF kinase",3,124080023-124726325,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA011913, CAB026456",Approved,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 51.3,spleen: 11.8,Cell line enhanced,,CACO-2: 47.6;HEL: 31.9;SH-SY5Y: 16.9
323,KBTBD11,"KIAA0711, KLHDC7C",ENSG00000176595,Kelch repeat and BTB domain containing 11,8,1973878-2006936,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051159,Uncertain,,Approved,Intermediate filaments,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 21.7,kidney: 8.8,Cell line enhanced,,HDLM-2: 12.9;SCLC-21H: 13.6;THP-1: 13.0;U-937: 21.4
324,KCNA4,"HK1, HPCN2, KCNA4L, Kv1.4",ENSG00000182255,Potassium voltage-gated channel subfamily A member 4,11,30009741-30017023,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"CAB001977, HPA016422",Approved,,,,,Not detected,Tissue enhanced,,adrenal gland: 7.9;cerebral cortex: 4.3,heart muscle: 1.4,Not detected,,
325,KCNAB2,"AKR6A5, HKvbeta2.1, HKvbeta2.2, KCNA2B",ENSG00000069424,Potassium voltage-gated channel subfamily A regulatory beta subunit 2,1,5991466-6101193,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB001975,Enhanced,,,,Renal cancer:3.50e-5 (unfavourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 145.9,bone marrow: 74.8,Cell line enhanced,,HL-60: 277.8;U-937: 287.1
326,KCNB1,Kv2.1,ENSG00000158445,Potassium voltage-gated channel subfamily B member 1,20,49293394-49484297,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"CAB001979, HPA042434",Enhanced,,,,,Mixed,Tissue enhanced,,adipose tissue: 10.9;cerebral cortex: 21.6,"fallopian tube,smooth muscle: 7.4",Cell line enhanced,,CACO-2: 1.8;U-2 OS: 1.8
327,KCNB2,Kv2.2,ENSG00000182674,Potassium voltage-gated channel subfamily B member 2,8,72537391-72938349,"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA065970,,,Approved,Nucleoli<br>Plasma membrane<br>Midbody,,Not detected,Tissue enhanced,,cerebral cortex: 3.2;spleen: 3.3,"fallopian tube,testis: 0.7",Cell line enhanced,,HaCaT: 1.3;HDLM-2: 1.4;HEK93: 3.2;SCLC-21H: 3.4
328,KCND2,"KIAA1044, Kv4.2, RK5",ENSG00000184408,Potassium voltage-gated channel subfamily D member 2,7,120273668-120750331,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA029068,Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 20.7,gallbladder: 6.8,Cell line enhanced,,ASC TERT1: 3.5;SCLC-21H: 15.6
329,KCNE5,KCNE1L,ENSG00000176076,Potassium voltage-gated channel subfamily E regulatory subunit 5,X,109623700-109625172,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA042316,Uncertain,,Uncertain,Cytosol,,Group enriched,Tissue enhanced,,cerebral cortex: 2.1,adipose tissue: 1.1,Cell line enhanced,,hTEC/SVTERT24-B: 2.0
330,KCNG3,Kv6.3,ENSG00000171126,Potassium voltage-gated channel modifier subfamily G member 3,2,42442017-42494097,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA041625,,,Approved,Cytoplasmic bodies,,Mixed,Tissue enhanced,,adrenal gland: 1.2;cerebral cortex: 1.3;testis: 1.1,"colon,endometrium: 0.4",Cell line enhanced,,HAP1: 4.9;HMC-1: 14.2;NTERA-2: 10.3
331,KCNH4,"elk1, Kv12.3",ENSG00000089558,Potassium voltage-gated channel subfamily H member 4,17,42156891-42181278,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.8,appendix: 0.7,Cell line enhanced,,HDLM-2: 4.2;K-562: 3.8;RPMI-8226: 5.6;RT4: 2.3;U-266/70: 3.1
332,KCNH5,"eag2, H-EAG2, Kv10.2",ENSG00000140015,Potassium voltage-gated channel subfamily H member 5,14,62699454-63102037,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA030487,Uncertain,,Uncertain,Microtubules<br>Mitotic spindle,,Not detected,Tissue enhanced,,adrenal gland: 1.4;cerebral cortex: 3.6,testis: 0.7,Cell line enhanced,,BEWO: 1.5;HeLa: 5.0;RT4: 7.9
333,KCNH8,"elk3, Kv12.1",ENSG00000183960,Potassium voltage-gated channel subfamily H member 8,3,19148454-19535646,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA016586,,,Supported,Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 4.8,adrenal gland: 2.3,Cell line enhanced,,HAP1: 1.0;SH-SY5Y: 4.4
334,KCNIP1,KCHIP1,ENSG00000182132,Potassium voltage-gated channel interacting protein 1,5,170353487-170736632,Predicted intracellular proteins,Evidence at protein level,HPA022864,Uncertain,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 40.4;epididymis: 26.3,seminal vesicle: 7.9,Cell line enriched,17.0,RPTEC TERT1: 43.9
335,KCNIP3,"CSEN, DREAM, KCHIP3",ENSG00000115041,Potassium voltage-gated channel interacting protein 3,2,95297304-95386083,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA069797,Approved,,,,Endometrial cancer:1.58e-5 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 40.6;parathyroid gland: 44.0,thyroid gland: 28.0,Cell line enhanced,,BJ hTERT+: 14.6;RPTEC TERT1: 26.5;U-138 MG: 16.1
336,KCNIP4,"CALP, KCHIP4, MGC44947",ENSG00000185774,Potassium voltage-gated channel interacting protein 4,4,20728616-21948799,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA022862,,Supported,,,,Mixed,Tissue enhanced,,cerebral cortex: 57.3,"cervix, uterine: 18.9",Cell line enhanced,,RPTEC TERT1: 4.6;SCLC-21H: 5.6
337,KCNJ3,"GIRK1, KGA, Kir3.1",ENSG00000162989,Potassium voltage-gated channel subfamily J member 3,2,154698299-154858352,"Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA024231,Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 25.4;parathyroid gland: 39.8,seminal vesicle: 14.1,Cell line enhanced,,BJ: 1.2
338,KCNK10,"K2p10.1, PPP1R97, TREK-2, TREK2",ENSG00000100433,Potassium two pore domain channel subfamily K member 10,14,88180103-88326907,Predicted membrane proteins,Evidence at protein level,HPA030462,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 5.6;duodenum: 5.1,"small intestine,stomach: 2.7",Cell line enhanced,,AF22: 1.0;REH: 1.6;SCLC-21H: 3.7
339,KCNN3,"hSK3, KCa2.3, SKCA3",ENSG00000143603,Potassium calcium-activated channel subfamily N member 3,1,154697455-154870280,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA017990, HPA057127",Uncertain,,Approved,Nucleoplasm,Renal cancer:1.97e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 25.4,fallopian tube: 9.4,Cell line enhanced,,Daudi: 28.1;HMC-1: 23.0;Karpas-707: 46.9;U-266/70: 47.5
340,KCNQ5,Kv7.5,ENSG00000185760,Potassium voltage-gated channel subfamily Q member 5,6,72621792-73198851,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA016655,Enhanced,,Approved,Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 22.3,thyroid gland: 7.9,Cell line enhanced,,BJ: 29.6
341,KCNS1,Kv9.1,ENSG00000124134,Potassium voltage-gated channel modifier subfamily S member 1,20,45092310-45101112,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,Ovarian cancer:6.45e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.3;gallbladder: 3.8;seminal vesicle: 4.2,testis: 1.7,Cell line enhanced,,HBF TERT88: 1.3;HHSteC: 1.8;THP-1: 1.2;U-87 MG: 3.0
342,KCNS2,Kv9.2,ENSG00000156486,Potassium voltage-gated channel modifier subfamily S member 2,8,98427022-98432848,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA051417,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 7.2,placenta: 2.2,Group enriched,9.0,HSkMC: 1.5;SCLC-21H: 7.5
343,KCTD17,FLJ12242,ENSG00000100379,Potassium channel tetramerization domain containing 17,22,37051736-37063390,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA018459,Uncertain,,,,"Renal cancer:5.13e-12 (unfavourable), Liver cancer:3.59e-5 (unfavourable), Pancreatic cancer:4.22e-5 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 55.9,testis: 35.3,Mixed,,
344,KCTD2,KIAA0176,ENSG00000180901,Potassium channel tetramerization domain containing 2,17,75032575-75065889,Predicted intracellular proteins,Evidence at protein level,,,,,,"Pancreatic cancer:1.25e-5 (favourable), Liver cancer:1.83e-4 (unfavourable)",Expressed in all,Tissue enhanced,,adipose tissue: 3.4;cerebral cortex: 7.3,kidney: 2.0,Cell line enhanced,,HEK93: 10.4
345,KCTD8,,ENSG00000183783,Potassium channel tetramerization domain containing 8,4,44173909-44448807,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA031562,Enhanced,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 11.5;thyroid gland: 5.2,testis: 2.4,Cell line enhanced,,HAP1: 2.2;NTERA-2: 1.5;SCLC-21H: 6.8;U-2 OS: 1.8
346,KHDC1,"bA257K9.4, C6orf147, C6orf148, Em:AC019205.8, MGC10818, NDG1",ENSG00000135314,KH homology domain containing 1,6,73241314-73310365,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA029032,,,Approved,Mitochondria<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 9.9,testis: 6.8,Mixed,,
347,KHDRBS2,"MGC26664, SLM-1, SLM1",ENSG00000112232,"KH RNA binding domain containing, signal transduction associated 2",6,61679960-62286227,Predicted intracellular proteins,Evidence at protein level,"HPA000500, HPA029392",Supported,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.6;lung: 5.6;thyroid gland: 11.0,spleen: 1.8,Cell line enhanced,,AF22: 7.2;NTERA-2: 1.9;THP-1: 1.0
348,KIAA0408,,ENSG00000189367,KIAA0408,6,127440343-127459391,Predicted intracellular proteins,Evidence at protein level,"HPA044035, HPA053341",Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 43.8,lung: 30.8,Cell line enhanced,,AF22: 21.1;SCLC-21H: 62.8;SH-SY5Y: 28.1
349,KIAA1211L,"C2orf55, MGC42367",ENSG00000196872,KIAA1211 like,2,98793846-98936259,Predicted intracellular proteins,Evidence at protein level,"HPA051082, HPA061678",Uncertain,,Approved,Microtubules<br>Cytokinetic bridge<br>Centrosome,"Renal cancer:1.13e-5 (favourable), Thyroid cancer:1.33e-5 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 36.7;epididymis: 38.2,fallopian tube: 36.1,Cell line enhanced,,BEWO: 39.4;HDLM-2: 56.9
350,KIAA1644,,ENSG00000138944,KIAA1644,22,44243667-44312851,Predicted membrane proteins,Evidence at transcript level,HPA051178,Uncertain,,Approved,Vesicles<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 27.6;endometrium: 42.8;smooth muscle: 44.6,"cervix, uterine: 19.2",Cell line enhanced,,SiHa: 38.9;U-2197: 76.1;U-87 MG: 46.0;WM-115: 27.3
351,KIAA2022,"KIDLIA, MRX98, XPN",ENSG00000050030,KIAA2022,X,74732849-74925485,"Disease related genes, Predicted intracellular proteins",Evidence at transcript level,HPA000407,Uncertain,,Uncertain,Nucleoplasm<br>Midbody,,Mixed,Tissue enhanced,,cerebral cortex: 5.4;parathyroid gland: 5.3,prostate: 1.9,Group enriched,6.0,HAP1: 5.0;Karpas-707: 5.9;SiHa: 6.2
352,KIF21A,"FEOM1, FLJ20052",ENSG00000139116,Kinesin family member 21A,12,39293228-39443390,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB022079, HPA058432",Enhanced,,Supported,Plasma membrane<br>Cytosol,Renal cancer:8.07e-8 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 75.0,fallopian tube: 54.6,Cell line enhanced,,SH-SY5Y: 199.8
353,KIF21B,"DKFZP434J212, KIAA0449",ENSG00000116852,Kinesin family member 21B,1,200969390-201023700,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027249, HPA027274",Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 28.8,bone marrow: 22.9,Cell line enhanced,,HMC-1: 37.2;Karpas-707: 36.3;U-266/70: 69.6;U-266/84: 31.7
354,KIF3A,"FLA10, KLP-20",ENSG00000131437,Kinesin family member 3A,5,132692628-132737638,Predicted intracellular proteins,Evidence at protein level,CAB037085,Approved,,Approved,Nucleoplasm<br>Intermediate filaments<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 82.8,testis: 43.9,Expressed in all,,
355,KIF5C,,ENSG00000168280,Kinesin family member 5C,2,148875250-149026759,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035210, HPA062272",Enhanced,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 205.3,prostate: 44.3,Cell line enhanced,,AF22: 38.5;NTERA-2: 39.3;SCLC-21H: 236.2;SH-SY5Y: 49.2
356,KLHL1,"FLJ30047, KIAA1490, MRP2",ENSG00000150361,Kelch like family member 1,13,69700594-70108493,Predicted intracellular proteins,Evidence at transcript level,HPA021196,Uncertain,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 1.9,prostate: 0.5,Cell line enriched,8.0,HeLa: 1.6
357,KLHL2,MAV,ENSG00000109466,Kelch like family member 2,4,165207618-165323156,Predicted intracellular proteins,Evidence at protein level,HPA051637,,,Uncertain,Nucleoplasm<br>Vesicles,Renal cancer:3.77e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 77.5,thyroid gland: 22.0,Mixed,,
358,KLHL25,"ENC-2, ENC2, FLJ12587",ENSG00000183655,Kelch like family member 25,15,85759323-85795030,Predicted intracellular proteins,Evidence at protein level,HPA023450,Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 15.8,testis: 9.9,Mixed,,
359,KLHL35,FLJ33790,ENSG00000149243,Kelch like family member 35,11,75422394-75430629,Predicted intracellular proteins,Evidence at protein level,"HPA039232, HPA039864",Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Centrosome,Cervical cancer:4.63e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 3.6;testis: 6.2,"cervix, uterine: 1.1",Cell line enhanced,,CACO-2: 13.0;HMC-1: 8.9;PC-3: 8.3;SiHa: 19.5
360,KLRC3,NKG2-E,ENSG00000205810,Killer cell lectin like receptor C3,12,10412312-10420595,Predicted membrane proteins,Evidence at transcript level,"HPA039910, HPA062570",Approved,,Uncertain,Vesicles,,Tissue enriched,Tissue enhanced,,cerebral cortex: 9.2;spleen: 6.2,lymph node: 2.3,Cell line enhanced,,HEL: 1.1;HeLa: 4.5;U-698: 1.3
361,KNDC1,"bB439H18.3, C10orf23, FLJ25027, KIAA1768, RASGEF2",ENSG00000171798,Kinase non-catalytic C-lobe domain containing 1,10,133160447-133226412,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA039624,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 19.4;fallopian tube: 10.4,adrenal gland: 6.4,Cell line enhanced,,AN3-CA: 1.5;EFO-21: 1.1;NTERA-2: 1.4;RPMI-8226: 1.4
362,KRT222,"KA21, KRT222P, MGC45562",ENSG00000213424,Keratin 222,17,40654665-40665181,Predicted intracellular proteins,Evidence at protein level,"HPA043708, HPA054586, HPA069774",Uncertain,,Approved,Vesicles<br>Lipid droplets,,Mixed,Tissue enhanced,,cerebral cortex: 10.0;epididymis: 6.0,gallbladder: 2.7,Cell line enriched,6.0,RPTEC TERT1: 8.8
363,KRTAP5-2,"KRTAP5-8, KRTAP5.2",ENSG00000205867,Keratin associated protein 5-2,11,1597177-1598294,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 3.6,gallbladder: 0.9,Cell line enhanced,,MCF7: 1.9;SCLC-21H: 3.3;SH-SY5Y: 1.3
364,KSR2,FLJ25965,ENSG00000171435,Kinase suppressor of ras 2,12,117453012-117968983,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA035536,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 4.1,adrenal gland: 1.2,Group enriched,6.0,HUVEC TERT2: 3.8;SCLC-21H: 3.8;TIME: 5.6
365,L1CAM,"CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1",ENSG00000198910,L1 cell adhesion molecule,X,153861514-153909223,"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB010896,Enhanced,,Approved,Nucleoplasm<br>Plasma membrane,"Endometrial cancer:8.51e-10 (unfavourable), Lung cancer:2.36e-6 (unfavourable), Renal cancer:1.17e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,adrenal gland: 36.0;cerebral cortex: 66.9,seminal vesicle: 12.8,Cell line enhanced,,BJ hTERT+: 303.8;BJ hTERT+ SV40 Large T+ RasG12V: 195.5;HeLa: 182.1
366,LAMP5,"BAD-LAMP, C20orf103, dJ1119D9.3, UNC-46",ENSG00000125869,Lysosomal associated membrane protein family member 5,20,9514358-9530524,Predicted membrane proteins,Evidence at protein level,"HPA004802, HPA070765",Uncertain,,Approved,Mitotic spindle<br>Microtubule organizing center<br>Cytosol,Renal cancer:6.46e-6 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 44.9;ovary: 24.6,fallopian tube: 14.9,Group enriched,9.0,Karpas-707: 298.2;SH-SY5Y: 80.2;THP-1: 100.4
367,LANCL2,"GPR69B, TASP",ENSG00000132434,LanC like 2,7,55365448-55433742,Predicted intracellular proteins,Evidence at protein level,"HPA019711, HPA029535",Uncertain,,Supported,Nucleus<br>Cytosol,"Renal cancer:1.03e-6 (favourable), Ovarian cancer:1.89e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 41.2,parathyroid gland: 16.5,Cell line enriched,6.0,A-431: 130.0
368,LARP6,"acheron, FLJ11196",ENSG00000166173,La ribonucleoprotein domain family member 6,15,70829130-70854159,Predicted intracellular proteins,Evidence at protein level,"HPA020338, HPA049029",Approved,,Approved,Microtubules<br>Cytokinetic bridge,Renal cancer:9.90e-5 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 84.7,thyroid gland: 40.7,Cell line enhanced,,U-2197: 216.0
369,LHFPL1,,ENSG00000182508,Lipoma HMGIC fusion partner-like 1,X,112630648-112680054,Predicted membrane proteins,Evidence at transcript level,HPA003029,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 1.8,seminal vesicle: 1.3,Cell line enhanced,,SK-MEL-30: 1.9
370,LHX5,,ENSG00000089116,LIM homeobox 5,12,113462034-113472280,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA053908,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 1.4,stomach: 0.3,Cell line enhanced,,HMC-1: 1.0
371,LINC01314,,ENSG00000259417,Long intergenic non-protein coding RNA 1314,15,80195484-80252213,Predicted membrane proteins,Evidence at transcript level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 5.7;epididymis: 6.6,liver: 4.8,Group enriched,7.0,SK-MEL-30: 1.2;WM-115: 4.7
372,LINGO3,"LERN2, LRRN6B",ENSG00000220008,Leucine rich repeat and Ig domain containing 3,19,2289784-2292024,Predicted membrane proteins,Evidence at protein level,"HPA043781, HPA055932, HPA059558",Uncertain,,Approved,Mitochondria,,Tissue enhanced,Tissue enhanced,,appendix: 1.6;cerebral cortex: 1.6;spleen: 3.7,lymph node: 1.2,Group enriched,6.0,HMC-1: 15.2;RPMI-8226: 3.0
373,LL0XNC01-16G2.1,,ENSG00000225110,,X,153317681-153321822,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 4.0,adrenal gland: 0.9,Not detected,,
374,LLGL1,"DLG4, HUGL, HUGL-1, Lgl1, LLGL, Mgl1",ENSG00000131899,"LLGL1, scribble cell polarity complex component",17,18225587-18244875,Predicted intracellular proteins,Evidence at protein level,"HPA022924, HPA023569",Enhanced,,,,Liver cancer:2.72e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 21.1,endometrium: 7.0,Expressed in all,,
375,LMO3,"DAT1, RBTNL2, Rhom-3",ENSG00000048540,LIM domain only 3,12,16548373-16610594,Predicted intracellular proteins,Evidence at protein level,,,,,,Endometrial cancer:1.10e-7 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 190.9,thyroid gland: 67.7,Group enriched,6.0,ASC diff: 157.0;LHCN-M2: 88.8
376,LRFN1,"KIAA1484, SALM2",ENSG00000128011,Leucine rich repeat and fibronectin type III domain containing 1,19,39306568-39315336,Predicted membrane proteins,Evidence at protein level,,,,,,"Endometrial cancer:3.31e-5 (unfavourable), Ovarian cancer:3.13e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 5.5,spleen: 2.2,Cell line enhanced,,CACO-2: 14.4;HEK93: 19.2
377,LRP1B,"LRP-DIT, LRPDIT",ENSG00000168702,LDL receptor related protein 1B,2,140231423-142131701,"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA069094, HPA074788",Approved,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 16.4;thyroid gland: 9.6,epididymis: 2.7,Cell line enhanced,,ASC diff: 1.0;HEK93: 1.5;U-138 MG: 1.8
378,LRP4,"CLSS, LRP-4, MEGF7, SOST2",ENSG00000134569,LDL receptor related protein 4,11,46856868-46918642,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA011934, HPA012300",Approved,,Uncertain,Nucleus<br>Nucleoli<br>Mitochondria,,Expressed in all,Tissue enhanced,,cerebral cortex: 35.4;skin: 37.9,parathyroid gland: 13.1,Cell line enhanced,,AF22: 21.2
379,LRRC4,NAG14,ENSG00000128594,Leucine rich repeat containing 4,7,128027071-128032107,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA051100,,,Approved,Golgi apparatus,"Renal cancer:6.98e-4 (favourable), Endometrial cancer:8.19e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 52.8,parathyroid gland: 13.1,Group enriched,9.0,AF22: 16.3;NTERA-2: 36.7;REH: 32.0;SCLC-21H: 22.0;SH-SY5Y: 12.3
380,LRRC4B,"DKFZp761A179, HSM, LRIG4",ENSG00000131409,Leucine rich repeat containing 4B,19,50516892-50568045,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA058986,Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 61.4,"cervix, uterine: 12.9",Cell line enhanced,,HMC-1: 29.7;SH-SY5Y: 31.3;U-2 OS: 28.7
381,LRRC55,FLJ45686,ENSG00000183908,Leucine rich repeat containing 55,11,57181747-57191717,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA014053,Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 6.6,lymph node: 2.4,Group enriched,33.0,AF22: 19.1;NTERA-2: 4.6
382,LRRC7,"densin-180, KIAA1365",ENSG00000033122,Leucine rich repeat containing 7,1,69568398-70151945,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 14.4,"testis,thyroid gland: 4.2",Cell line enhanced,,HaCaT: 13.5;HEL: 41.5;SCLC-21H: 6.0
383,LRRC8B,"KIAA0231, TA-LRRP",ENSG00000197147,Leucine rich repeat containing 8 family member B,1,89524836-89597864,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA017950,Uncertain,,Approved,Nuclear speckles,"Colorectal cancer:7.15e-4 (favourable), Endometrial cancer:9.99e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 37.6,testis: 28.8,Mixed,,
384,LRRN1,FIGLER3,ENSG00000175928,Leucine rich repeat neuronal 1,3,3799437-3847703,Predicted membrane proteins,Evidence at protein level,HPA011071,Enhanced,,,,,Mixed,Tissue enhanced,,cerebral cortex: 44.3,parathyroid gland: 18.3,Cell line enhanced,,AF22: 159.4;CAPAN-2: 50.8;HAP1: 50.2;NTERA-2: 96.1
385,LRRN2,"FIGLER7, GAC1, LRANK1, LRRN5",ENSG00000170382,Leucine rich repeat neuronal 2,1,204617170-204685733,Predicted membrane proteins,Evidence at transcript level,HPA029124,Uncertain,,Approved,Endoplasmic reticulum,Endometrial cancer:2.59e-7 (unfavourable),Group enriched,Tissue enhanced,,cerebral cortex: 23.4;parathyroid gland: 21.2,fallopian tube: 11.5,Cell line enhanced,,HEL: 8.3;NTERA-2: 17.9;RPMI-8226: 20.1;T-47d: 9.4
386,LRRN3,"FIGLER5, FLJ11129, NLRR3",ENSG00000173114,Leucine rich repeat neuronal 3,7,111091006-111125454,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,"HPA043820, HPA046792",Uncertain,,Approved,Nucleus<br>Cytosol,,Group enriched,Tissue enhanced,,adrenal gland: 30.8;cerebral cortex: 31.2;testis: 29.1;thyroid gland: 33.6,lung: 11.6,Cell line enhanced,,AF22: 24.9;BJ hTERT+: 25.6;SH-SY5Y: 47.7;T-47d: 23.4
387,LRRTM1,FLJ32082,ENSG00000162951,Leucine rich repeat transmembrane neuronal 1,2,80288351-80304749,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA062660,Approved,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 13.3;salivary gland: 4.9,thyroid gland: 2.2,Cell line enhanced,,SH-SY5Y: 1.4
388,LSAMP,"IGLON3, LAMP",ENSG00000185565,Limbic system-associated membrane protein,3,115802363-117139389,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA054051, HPA076122",,,Approved,Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 102.7,prostate: 43.6,Group enriched,6.0,AF22: 11.1;SH-SY5Y: 24.0;WM-115: 55.4
389,LY6G5C,"C6orf20, G5c, NG33",ENSG00000204428,Lymphocyte antigen 6 family member G5C,6,31676684-31684040,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA038690,Approved,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:1.07e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 1.5,testis: 0.9,Not detected,,
390,LYNX1,SLURP2,ENSG00000180155,Ly6/neurotoxin 1,8,142771197-142777810,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,Renal cancer:2.82e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 94.6,parathyroid gland: 58.6,Cell line enhanced,,BJ: 6.9;fHDF/TERT166: 7.9;HHSteC: 6.9;T-47d: 6.7
391,LZTS3,"KIAA0552, ProSAPiP1",ENSG00000088899,Leucine zipper tumor suppressor family member 3,20,3162617-3173592,Predicted intracellular proteins,Evidence at protein level,"HPA031008, HPA031009",Approved,,Approved,Vesicles,"Renal cancer:5.92e-8 (favourable), Endometrial cancer:7.26e-4 (unfavourable), Lung cancer:7.98e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 58.6,parathyroid gland: 20.3,Cell line enhanced,,SCLC-21H: 21.3
392,MAGED4B,,ENSG00000187243,MAGE family member D4B,X,52061827-52069248,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA003554,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 35.1,endometrium: 13.8,Cell line enhanced,,AF22: 48.8;NTERA-2: 40.6
393,MAGEE1,"DAMAGE, KIAA1587",ENSG00000198934,MAGE family member E1,X,76427724-76431353,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003047,Approved,,Approved,Cytokinetic bridge<br>Cytosol,"Renal cancer:6.86e-6 (favourable), Pancreatic cancer:3.95e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 29.8,parathyroid gland: 14.3,Mixed,,
394,MAGEL2,"NDNL1, nM15",ENSG00000254585,MAGE family member L2,15,23643544-23647841,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 3.3,"cervix, uterine: 2.9",Group enriched,6.0,AF22: 3.2;NTERA-2: 1.9;U-2 OS: 1.0
395,MAGI2,"ACVRIP1, AIP1, ARIP1, KIAA0705, MAGI-2",ENSG00000187391,"Membrane associated guanylate kinase, WW and PDZ domain containing 2",7,78017057-79453574,Predicted intracellular proteins,Evidence at protein level,HPA013650,Approved,,,,Renal cancer:1.08e-4 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 46.2;parathyroid gland: 38.6,prostate: 14.0,Group enriched,5.0,AF22: 19.3;Karpas-707: 58.7
396,MANEAL,FLJ31434,ENSG00000185090,Mannosidase endo-alpha like,1,37793802-37801137,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA063423,,,Approved,Golgi apparatus,"Liver cancer:3.32e-4 (unfavourable), Head and neck cancer:5.28e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 27.2,adrenal gland: 9.5,Cell line enhanced,,SCLC-21H: 167.3
397,MAP3K10,"MEKK10, MLK2, MST",ENSG00000130758,Mitogen-activated protein kinase kinase kinase 10,19,40191744-40215575,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007039,Approved,,Approved,Nucleus<br>Actin filaments<br>Cytosol,"Urothelial cancer:2.13e-4 (favourable), Head and neck cancer:8.69e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 31.1,testis: 7.1,Mixed,,
398,MAP6,"FLJ41346, KIAA1878, MAP6-N, STOP",ENSG00000171533,Microtubule associated protein 6,11,75586918-75669120,Predicted intracellular proteins,Evidence at protein level,"CAB015442, CAB022600, HPA039061, HPA039062",Enhanced,,Uncertain,Plasma membrane,"Pancreatic cancer:3.41e-4 (favourable), Prostate cancer:9.15e-4 (favourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 68.1;fallopian tube: 65.5,parathyroid gland: 52.6,Group enriched,6.0,AF22: 37.3;CACO-2: 31.4;HDLM-2: 19.9;SCLC-21H: 73.4;SH-SY5Y: 33.6
399,MAP7D2,FLJ14503,ENSG00000184368,MAP7 domain containing 2,X,20006713-20116917,Predicted intracellular proteins,Evidence at protein level,"HPA051508, HPA059537",Enhanced,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:7.27e-5 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 49.2;epididymis: 45.6,testis: 18.3,Cell line enhanced,,A549: 12.0;CACO-2: 16.0;HEK93: 23.8;HeLa: 15.1;SCLC-21H: 34.5;SiHa: 13.5
400,MAPK10,"JNK3, p493F12, p54bSAPK, PRKM10",ENSG00000109339,Mitogen-activated protein kinase 10,4,86010395-86594131,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,CAB022625,Approved,,,,"Renal cancer:3.11e-4 (favourable), Urothelial cancer:5.57e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 113.0,seminal vesicle: 38.6,Cell line enriched,16.0,AF22: 181.7
401,MAPK4,"Erk3-related, Erk4, PRKM4",ENSG00000141639,Mitogen-activated protein kinase 4,18,50560078-50731824,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,adrenal gland: 29.7;cerebral cortex: 33.4;parathyroid gland: 60.1,seminal vesicle: 13.9,Cell line enhanced,,SCLC-21H: 13.6;SH-SY5Y: 3.0
402,MAPRE3,"EB3, RP3",ENSG00000084764,Microtubule associated protein RP/EB family member 3,2,26970612-27027196,Predicted intracellular proteins,Evidence at protein level,HPA009263,Uncertain,,Supported,Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 177.3,testis: 70.2,Mixed,,
403,MAS1,,ENSG00000130368,"MAS1 proto-oncogene, G protein-coupled receptor",6,159906690-159916530,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.8,"cervix, uterine: 0.7",Cell line enriched,9.0,HMC-1: 6.7
404,MATK,"CHK, CTK, DKFZp434N1212, HHYLTK, HYL, HYLTK, Lsk, MGC1708, MGC2101",ENSG00000007264,Megakaryocyte-associated tyrosine kinase,19,3777970-3802129,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004847,Approved,,,,Breast cancer:5.27e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 22.0,spleen: 19.8,Cell line enhanced,,HL-60: 85.8;K-562: 43.3;NB-4: 47.4;SCLC-21H: 36.7
405,MCHR1,"GPR24, MCH1R, SLC1",ENSG00000128285,Melanin concentrating hormone receptor 1,22,40678750-40682814,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,Renal cancer:1.49e-6 (unfavourable),Group enriched,Tissue enhanced,,cerebral cortex: 8.6,ovary: 2.1,Cell line enhanced,,NTERA-2: 1.2;RH-30: 1.6;T-47d: 1.3;U-87 MG: 1.5
406,MED12L,"KIAA1635, TNRC11L, TRALP, TRALPUSH",ENSG00000144893,Mediator complex subunit 12 like,3,151085697-151437072,Predicted intracellular proteins,Evidence at protein level,HPA036807,Uncertain,,Approved,Nucleoli,,Mixed,Tissue enhanced,,cerebral cortex: 26.6,testis: 8.5,Cell line enhanced,,BEWO: 17.8;HEL: 18.7
407,METRN,"C16orf23, MGC2601",ENSG00000103260,"Meteorin, glial cell differentiation regulator",16,715115-719655,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA051164,Approved,,Approved,Nucleoplasm<br>Nuclear membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 64.7,fallopian tube: 38.3,Expressed in all,,
408,MGAT3,GNT-III,ENSG00000128268,"Mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase",22,39457344-39492194,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA017598,Approved,,,,Renal cancer:5.04e-8 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 38.6,small intestine: 32.5,Cell line enhanced,,BEWO: 65.1;HMC-1: 51.2;U-266/70: 57.7
409,MICU3,"DKFZp313A0139, EFHA2",ENSG00000155970,Mitochondrial calcium uptake family member 3,8,17027238-17122644,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA024048, HPA024771, HPA024779",Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 34.8,parathyroid gland: 14.2,Cell line enhanced,,HBF TERT88: 12.3
410,MKRN3,"D15S9, MGC88288, RNF63, ZFP127, ZNF127",ENSG00000179455,Makorin ring finger protein 3,15,23565678-23630075,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA029494,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Glioma:9.23e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 5.9;placenta: 4.1;testis: 3.6,epididymis: 1.1,Cell line enhanced,,K-562: 22.8
411,MMP16,"C8orf57, DKFZp761D112, MT3-MMP",ENSG00000156103,Matrix metallopeptidase 16,8,88032009-88328025,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA023693,Uncertain,,Approved,Vesicles<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.6,gallbladder: 4.2,Cell line enhanced,,AN3-CA: 27.2;SH-SY5Y: 17.2;WM-115: 28.4
412,MMP17,MT4-MMP,ENSG00000198598,Matrix metallopeptidase 17,12,131828393-131851783,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 24.0,skin: 8.2,Group enriched,5.0,REH: 53.0;SK-MEL-30: 109.1;WM-115: 201.0
413,MMP24,MT5-MMP,ENSG00000125966,Matrix metallopeptidase 24,20,35226654-35277000,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at transcript level,HPA049280,,,Approved,Nucleoli<br>Plasma membrane,Renal cancer:8.17e-11 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 10.6,lung: 7.0,Cell line enhanced,,A549: 32.8;CACO-2: 46.1;RPTEC TERT1: 18.5;U-2 OS: 18.9
414,MPP2,"DKFZp761D0712, DLG2",ENSG00000108852,Membrane palmitoylated protein 2,17,43875357-43909711,Predicted intracellular proteins,Evidence at protein level,HPA026486,Approved,,Approved,Mitochondria<br>Cytosol,Endometrial cancer:1.87e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 37.9;epididymis: 33.0;parathyroid gland: 43.8,testis: 24.0,Mixed,,
415,MRAP2,"bA51G5.2, C6orf117",ENSG00000135324,Melanocortin 2 receptor accessory protein 2,6,84033756-84090881,"Disease related genes, Predicted membrane proteins",Evidence at protein level,,,,,,Endometrial cancer:1.66e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 21.0,fallopian tube: 13.4,Group enriched,5.0,K-562: 81.0;SCLC-21H: 35.1
416,MRO,"B29, C18orf3, FLJ30140",ENSG00000134042,Maestro,18,50795120-50825402,Predicted intracellular proteins,Evidence at transcript level,HPA022011,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 27.5;kidney: 25.5;testis: 54.7,thyroid gland: 10.4,Cell line enhanced,,ASC diff: 1.9;ASC TERT1: 6.0
417,MSANTD3-TMEFF1,C9orf30-TMEFF1,ENSG00000251349,MSANTD3-TMEFF1 readthrough,9,100442271-100577636,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 48.0,testis: 10.2,Cell line enhanced,,AF22: 98.5;NTERA-2: 50.5;SCLC-21H: 63.0
418,MSI1,,ENSG00000135097,Musashi RNA binding protein 1,12,120341330-120369180,Predicted intracellular proteins,Evidence at protein level,HPA064401,,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Pancreatic cancer:5.99e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 17.5;testis: 14.6,skeletal muscle: 7.2,Cell line enhanced,,AF22: 118.2;HAP1: 57.0;NTERA-2: 62.4;SCLC-21H: 104.1;SH-SY5Y: 45.6
419,MTMR7,,ENSG00000003987,Myotubularin related protein 7,8,17298030-17413528,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 22.9;parathyroid gland: 15.2,thyroid gland: 5.5,Cell line enhanced,,SCLC-21H: 12.4;SH-SY5Y: 6.5
420,MYH15,KIAA1000,ENSG00000144821,Myosin heavy chain 15,3,108380369-108529322,Predicted intracellular proteins,Evidence at protein level,HPA034871,Uncertain,,Approved,Nucleoplasm<br>Centrosome<br>Mitochondria,,Not detected,Tissue enhanced,,cerebral cortex: 1.9,testis: 0.8,Cell line enhanced,,Karpas-707: 1.7;PC-3: 4.7;SH-SY5Y: 1.9;U-87 MG: 1.9
421,MYO16,"KIAA0865, Myo16b, MYR8, NYAP3, PPP1R107",ENSG00000041515,Myosin XVI,13,108596152-109208007,Predicted intracellular proteins,Evidence at protein level,"HPA040110, HPA058769, HPA071948",Uncertain,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 2.1,testis: 1.0,Cell line enhanced,,SH-SY5Y: 2.4;U-2197: 1.2
422,MYRF,"C11orf9, MRF, Ndt80, pqn-47",ENSG00000124920,Myelin regulatory factor,11,61752642-61788518,"Plasma proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,HPA018310,,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:2.01e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 67.4;stomach: 62.1,gallbladder: 38.3,Cell line enhanced,,A549: 36.8;CACO-2: 56.7;CAPAN-2: 34.1;EFO-21: 48.7
423,MYRIP,"DKFZp586F1018, exophilin-8, MyRIP, SLAC2-C, SLAC2C",ENSG00000170011,Myosin VIIA and Rab interacting protein,3,39808914-40260321,Predicted intracellular proteins,Evidence at protein level,HPA006433,,,Approved,Nucleus<br>Nucleoli<br>Golgi apparatus,Renal cancer:3.96e-8 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 20.6,spleen: 9.9,Cell line enhanced,,HAP1: 4.2;HUVEC TERT2: 13.0;SCLC-21H: 3.8;SH-SY5Y: 10.0
424,NALCN,"bA430M15.1, CanIon, VGCNL1",ENSG00000102452,"Sodium leak channel, non-selective",13,101053776-101416492,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA031889, HPA031890, HPA031958",Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 28.1,adrenal gland: 6.0,Cell line enhanced,,HaCaT: 12.6;HHSteC: 12.3;TIME: 15.4;U-87 MG: 11.1
425,NAP1L3,"MB20, MGC26312, NPL3",ENSG00000186310,Nucleosome assembly protein 1 like 3,X,93670930-93673568,Predicted intracellular proteins,Evidence at protein level,HPA026075,,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 131.3,testis: 31.1,Cell line enhanced,,AF22: 13.4;HAP1: 13.7;NTERA-2: 24.0;U-2197: 15.0
426,NAP1L5,DRLM,ENSG00000177432,Nucleosome assembly protein 1 like 5,4,88695915-88698235,Predicted intracellular proteins,Evidence at protein level,HPA058227,Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 91.1,adrenal gland: 29.5,Cell line enhanced,,SH-SY5Y: 42.7
427,NAV3,"KIAA0938, POMFIL1",ENSG00000067798,Neuron navigator 3,12,77324641-78213008,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA032111, HPA032112, CAB037063",Uncertain,,Approved,Nuclear membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 27.2;ovary: 24.6,spleen: 12.3,Cell line enhanced,,hTEC/SVTERT24-B: 46.2;WM-115: 38.6
428,NBEA,"BCL8B, FLJ10197, KIAA1544, LYST2",ENSG00000172915,Neurobeachin,13,34942287-35673022,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039730, HPA040385",Enhanced,,Supported,Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol,Renal cancer:7.86e-8 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 30.3,seminal vesicle: 12.2,Cell line enriched,5.0,SH-SY5Y: 83.5
429,NCAM1,"CD56, NCAM",ENSG00000149294,Neural cell adhesion molecule 1,11,112961247-113278436,"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000142, CAB018071, HPA039835",Enhanced,,Enhanced,Plasma membrane<br>Cytosol,"Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,cerebral cortex: 334.9,heart muscle: 87.5,Cell line enhanced,,RH-30: 128.0;SCLC-21H: 126.2;U-138 MG: 71.8;WM-115: 77.9
430,NCAM2,"MGC51008, NCAM21",ENSG00000154654,Neural cell adhesion molecule 2,21,20998315-21543329,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA030900, HPA030901",Supported,,Supported,Nuclear bodies<br>Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 68.8,adrenal gland: 15.8,Cell line enhanced,,T-47d: 86.4;WM-115: 22.5
431,NCS1,"FREQ, NCS-1",ENSG00000107130,Neuronal calcium sensor 1,9,130172578-130237304,Predicted intracellular proteins,Evidence at protein level,"CAB018587, HPA019713",Enhanced,Supported,Enhanced,Plasma membrane,"Liver cancer:1.11e-4 (unfavourable), Breast cancer:5.40e-4 (unfavourable), Thyroid cancer:8.25e-4 (unfavourable), Endometrial cancer:8.69e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 178.1,seminal vesicle: 92.3,Mixed,,
432,NDRG4,"KIAA1180, SMAP-8",ENSG00000103034,NDRG family member 4,16,58462846-58513628,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015313, HPA017587",Enhanced,,Uncertain,Nucleus<br>Cytosol,,Tissue enriched,Tissue enhanced,,adrenal gland: 146.6;cerebral cortex: 420.0;heart muscle: 150.6,testis: 72.0,Cell line enhanced,,EFO-21: 30.7;SCLC-21H: 58.1
433,NDST3,HSST3,ENSG00000164100,N-deacetylase and N-sulfotransferase 3,4,118033618-118258648,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA056189,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 3.0;spleen: 2.8,"cervix, uterine: 0.7",Cell line enriched,16.0,MOLT-4: 13.3
434,NDST4,,ENSG00000138653,N-deacetylase and N-sulfotransferase 4,4,114827763-115113876,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA011129,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.4;ovary: 1.8,spleen: 1.0,Cell line enhanced,,AF22: 2.8;CACO-2: 2.4;RH-30: 14.2;T-47d: 3.1
435,NECAB2,EFCBP2,ENSG00000103154,N-terminal EF-hand calcium binding protein 2,16,83968632-84002776,Predicted intracellular proteins,Evidence at protein level,"HPA013998, HPA014144, CAB068211",Enhanced,Supported,Approved,Vesicles,Renal cancer:1.58e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 46.8,kidney: 10.6,Cell line enhanced,,AF22: 10.4;SCLC-21H: 47.1;U-87 MG: 13.8
436,NECAP1,DKFZP566B183,ENSG00000089818,NECAP endocytosis associated 1,12,8076939-8097859,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA053980, HPA063300",Uncertain,,Approved,Vesicles<br>Cytosol,,Expressed in all,Tissue enhanced,,cerebral cortex: 117.8,parathyroid gland: 34.8,Expressed in all,,
437,NEFM,"NEF3, NF-M, NFM",ENSG00000104722,Neurofilament medium,8,24913012-24919098,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB010900, CAB012976, HPA022845, HPA023138",Enhanced,,Enhanced,Intermediate filaments,,Mixed,Tissue enhanced,,cerebral cortex: 171.7;seminal vesicle: 42.2,adrenal gland: 28.2,Cell line enriched,22.0,HEK93: 3411.6
438,NEGR1,"IGLON4, KILON, MGC46680, Ntra",ENSG00000172260,Neuronal growth regulator 1,1,71395940-72282734,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA011894,Uncertain,,Approved,Vesicles<br>Actin filaments<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 54.3,gallbladder: 16.9,Mixed,,
439,NELL1,"FLJ45906, IDH3GL",ENSG00000165973,Neural EGFL like 1,11,20669551-21575681,Predicted secreted proteins,Evidence at protein level,HPA051535,Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 22.9;kidney: 18.8,prostate: 8.8,Cell line enhanced,,HAP1: 4.3;SH-SY5Y: 2.0;U-2 OS: 1.1;WM-115: 1.2
440,NELL2,NRP2,ENSG00000184613,Neural EGFL like 2,12,44508275-44921848,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA035714, HPA035715",Uncertain,,Approved,Vesicles,Pancreatic cancer:5.56e-4 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 204.1;fallopian tube: 96.7,prostate: 46.5,Cell line enhanced,,AF22: 102.5;NTERA-2: 41.0;SCLC-21H: 88.2
441,NEUROD1,"BETA2, BHF-1, bHLHa3, MODY6, NEUROD",ENSG00000162992,Neuronal differentiation 1,2,181673088-181680876,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA003278, CAB022450",Approved,,,,Glioma:6.83e-5 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.9;duodenum: 6.0;small intestine: 4.4;stomach: 4.9,pancreas: 1.8,Cell line enriched,79.0,SCLC-21H: 331.4
442,NFASC,"FLJ46866, KIAA0756, NF, NRCAML",ENSG00000163531,Neurofascin,1,204828651-205022822,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA008832,Enhanced,,,,"Renal cancer:2.93e-5 (unfavourable), Pancreatic cancer:3.21e-5 (favourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 55.7,seminal vesicle: 22.4,Cell line enhanced,,BJ: 23.3;fHDF/TERT166: 39.1;SCLC-21H: 26.9;U-138 MG: 62.0;U-87 MG: 30.5
443,NGEF,ARHGEF27,ENSG00000066248,Neuronal guanine nucleotide exchange factor,2,232878686-233013272,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008160,Approved,,Uncertain,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,adrenal gland: 66.5;cerebral cortex: 151.4,duodenum: 42.8,Cell line enhanced,,A-431: 46.9;HDLM-2: 42.0;PC-3: 52.8;T-47d: 30.2
444,NIPA1,"MGC35570, SPG6",ENSG00000170113,Non imprinted in Prader-Willi/Angelman syndrome 1,15,22773063-22829791,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA023269,Uncertain,,,,,Expressed in all,Tissue enhanced,,cerebral cortex: 38.2,parathyroid gland: 16.8,Mixed,,
445,NKX2-2,"NKX2.2, NKX2B",ENSG00000125820,NK2 homeobox 2,20,21511010-21514026,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003468,Approved,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 9.9;stomach: 2.6,duodenum: 2.4,Cell line enhanced,,HAP1: 4.3;T-47d: 4.6;U-138 MG: 17.1;U-2 OS: 3.7;WM-115: 7.0
446,NLGN1,KIAA1070,ENSG00000169760,Neuroligin 1,3,173396284-174286644,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA006572, HPA006680",Approved,,Uncertain,Nuclear bodies<br>Plasma membrane,,Group enriched,Tissue enhanced,,cerebral cortex: 25.4,testis: 12.5,Cell line enhanced,,fHDF/TERT166: 20.1;HUVEC TERT2: 20.7;RH-30: 25.4;WM-115: 26.7
447,NLGN2,KIAA1366,ENSG00000169992,Neuroligin 2,17,7404874-7419860,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA055321, HPA069278",Enhanced,,Approved,Mitochondria,Renal cancer:3.44e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 40.7,endometrium: 21.8,Cell line enhanced,,AF22: 43.3
448,NLGN3,"ASPGX1, AUTSX1, HNL3, KIAA1480",ENSG00000196338,Neuroligin 3,X,71144831-71171201,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA003183, HPA004066",Enhanced,,Supported,Golgi apparatus<br>Cell Junctions,,Tissue enriched,Tissue enhanced,,cerebral cortex: 62.2,seminal vesicle: 17.3,Cell line enhanced,,AF22: 6.8;NTERA-2: 5.0;SH-SY5Y: 2.9
449,NLGN4X,"HLNX, KIAA1260, NLGN, NLGN4",ENSG00000146938,"Neuroligin 4, X-linked",X,5840637-6228863,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA001651,Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 20.1,ovary: 12.9,Group enriched,5.0,AF22: 51.1;NTERA-2: 42.7
450,NMB,"MGC17211, MGC2277, MGC3936",ENSG00000197696,Neuromedin B,15,84655129-84658563,Predicted secreted proteins,Evidence at protein level,CAB019302,Approved,,Approved,Nucleus<br>Vesicles<br>Plasma membrane,"Renal cancer:2.25e-4 (unfavourable), Glioma:5.07e-4 (favourable)",Expressed in all,Tissue enhanced,,adipose tissue: 46.2;cerebral cortex: 47.2,thyroid gland: 14.8,Cell line enhanced,,A-431: 46.7
451,NOVA1,,ENSG00000139910,NOVA alternative splicing regulator 1,14,26443093-26597754,Predicted intracellular proteins,Evidence at protein level,HPA004155,Uncertain,,Supported,Nucleus<br>Nucleoli,,Tissue enriched,Tissue enhanced,,cerebral cortex: 62.2,breast: 31.8,Cell line enhanced,,AF22: 40.2;HAP1: 20.8
452,NOVA2,"ANOVA, NOVA3",ENSG00000104967,NOVA alternative splicing regulator 2,19,45933734-45973546,Predicted intracellular proteins,Evidence at protein level,HPA045607,Enhanced,,Approved,Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus,Renal cancer:3.04e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 24.3,adipose tissue: 6.0,Cell line enhanced,,AF22: 10.0;HDLM-2: 10.4;HUVEC TERT2: 14.6;TIME: 21.5
453,NPAS3,"bHLHe12, MOP6, PASD6",ENSG00000151322,Neuronal PAS domain protein 3,14,32934933-33804176,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA002892,Enhanced,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 24.9,"cervix, uterine: 10.1",Group enriched,8.0,AF22: 9.3;U-266/70: 17.8;U-266/84: 5.0
454,NPAS4,"bHLHe79, Le-PAS, NXF, PASD10",ENSG00000174576,Neuronal PAS domain protein 4,11,66421004-66426707,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA039255,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 4.1;endometrium: 1.9,smooth muscle: 1.6,Not detected,,
455,NPTX2,,ENSG00000106236,Neuronal pentraxin 2,7,98617297-98629868,Predicted secreted proteins,Evidence at protein level,"CAB020801, HPA049799, HPA058320",Supported,,Approved,Golgi apparatus<br>Actin filaments<br>Centrosome,"Renal cancer:5.46e-9 (unfavourable), Endometrial cancer:5.46e-5 (unfavourable)",Expressed in all,Tissue enhanced,,adrenal gland: 33.5;cerebral cortex: 80.3;testis: 44.3,"cervix, uterine: 12.1",Cell line enriched,8.0,LHCN-M2: 600.5
456,NPY2R,,ENSG00000185149,Neuropeptide Y receptor Y2,4,155208629-155217078,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,breast: 1.0;cerebral cortex: 1.7;testis: 1.0,rectum: 0.6,Cell line enriched,6.0,SH-SY5Y: 8.0
457,NRCAM,"Bravo, KIAA0343",ENSG00000091129,Neuronal cell adhesion molecule,7,108147623-108456717,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012606,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 180.4,adrenal gland: 49.5,Cell line enhanced,,A549: 90.2;AF22: 93.7;EFO-21: 165.3;HMC-1: 165.2;SH-SY5Y: 122.8
458,NRG3,,ENSG00000185737,Neuregulin 3,10,81875314-82987179,"Cancer-related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA075789,,,Approved,Vesicles,,Group enriched,Tissue enhanced,,cerebral cortex: 30.3,fallopian tube: 7.3,Cell line enhanced,,HEK93: 1.4;SK-MEL-30: 2.6;U-2 OS: 2.9
459,NRIP3,C11orf14,ENSG00000175352,Nuclear receptor interacting protein 3,11,8980576-9004049,Predicted intracellular proteins,Evidence at protein level,"HPA040573, HPA058827",Uncertain,,Approved,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 36.5;testis: 55.5,adrenal gland: 13.3,Cell line enhanced,,HMC-1: 44.7;SiHa: 35.9;U-87 MG: 46.3
460,NRN1,NRN,ENSG00000124785,Neuritin 1,6,5997999-6007605,Predicted membrane proteins,Evidence at protein level,,,,,,Renal cancer:4.79e-5 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 152.5,adipose tissue: 61.5,Cell line enhanced,,fHDF/TERT166: 111.6;REH: 174.8
461,NRSN2,"C20orf98, dJ1103G7.6",ENSG00000125841,Neurensin 2,20,346782-359660,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA015967,Approved,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Pancreatic cancer:1.61e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 126.1,parathyroid gland: 69.0,Mixed,,
462,NRXN3,"C14orf60, KIAA0743",ENSG00000021645,Neurexin 3,14,78170373-79868290,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA002727,Approved,,,,Renal cancer:1.83e-7 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 43.0;smooth muscle: 28.9,seminal vesicle: 15.3,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 8.7;RT4: 19.0
463,NTM,"HNT, IGLON2, NTRI",ENSG00000182667,Neurotrimin,11,131370478-132336822,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB024875,Enhanced,,,,Renal cancer:1.10e-8 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 116.0,lung: 39.1,Cell line enhanced,,LHCN-M2: 102.1;U-2 OS: 86.6;WM-115: 164.5
464,NTNG1,"KIAA0976, Lmnt1",ENSG00000162631,Netrin G1,1,107140007-107483458,Predicted secreted proteins,Evidence at protein level,HPA065954,,,Supported,Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 8.6,seminal vesicle: 6.7,Cell line enhanced,,ASC TERT1: 34.3;fHDF/TERT166: 19.6;RPTEC TERT1: 20.8;U-138 MG: 22.6;U-87 MG: 25.0
465,NTRK2,TRKB,ENSG00000148053,Neurotrophic receptor tyrosine kinase 2,9,84668551-85027070,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA007637, CAB010346",Enhanced,,Approved,Cytosol,,Group enriched,Tissue enhanced,,cerebral cortex: 439.6;thyroid gland: 215.7,breast: 82.1,Group enriched,5.0,AF22: 9.4;HaCaT: 3.1;RPTEC TERT1: 8.1;SH-SY5Y: 12.9;WM-115: 2.8
466,NTRK3,TRKC,ENSG00000140538,Neurotrophic receptor tyrosine kinase 3,15,87859751-88256768,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009233, HPA027484, HPA048065",Enhanced,,Supported,Nuclear membrane<br>Nucleoli,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 39.6,testis: 15.2,Cell line enriched,8.0,U-138 MG: 99.2
467,NUAK1,"ARK5, KIAA0537, NuaK1",ENSG00000074590,NUAK family kinase 1,12,106063340-106140033,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA057143,,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Microtubules,"Stomach cancer:4.27e-4 (unfavourable), Endometrial cancer:9.83e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 47.0;parathyroid gland: 42.5,skin: 21.0,Cell line enhanced,,AF22: 50.0;EFO-21: 47.3;RH-30: 70.1
468,NUDT11,"DIPP3b, FLJ10628, hDIPP3beta",ENSG00000196368,Nudix hydrolase 11,X,51490011-51496596,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047027, HPA057684",Approved,,Approved,Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 40.1;testis: 67.7,"prostate,seminal vesicle: 14.7",Cell line enhanced,,HAP1: 71.2;NTERA-2: 42.7
469,NWD2,KIAA1239,ENSG00000174145,NACHT and WD repeat domain containing 2,4,37244220-37449465,Predicted intracellular proteins,Evidence at protein level,HPA046911,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 6.2;thyroid gland: 1.4,adipose tissue: 0.8,Not detected,,
470,NXPH3,NPH3,ENSG00000182575,Neurexophilin 3,17,49575858-49583827,Predicted secreted proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 15.6,seminal vesicle: 9.6,Cell line enhanced,,BEWO: 14.1;BJ: 4.0
471,NXPH4,NPH4,ENSG00000182379,Neurexophilin 4,12,57216795-57226449,Predicted secreted proteins,Evidence at transcript level,,,,,,"Renal cancer:7.68e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable), Endometrial cancer:6.21e-4 (unfavourable), Glioma:8.20e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 8.3;prostate: 7.1;skin: 12.2,placenta: 3.8,Cell line enhanced,,AN3-CA: 71.1;RH-30: 60.3
472,NYAP1,"C7orf51, FLJ37538, KIAA1486L",ENSG00000166924,Neuronal tyrosine phosphorylated phosphoinositide-3-kinase adaptor 1,7,100483927-100494799,Predicted intracellular proteins,Evidence at protein level,HPA022251,Uncertain,,Supported,Golgi apparatus<br>Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 25.1;testis: 7.7,adrenal gland: 3.3,Cell line enhanced,,HUVEC TERT2: 3.2;SH-SY5Y: 9.9
473,OLFM2,"NOE2, OlfC",ENSG00000105088,Olfactomedin 2,19,9853718-9936552,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA049961, HPA057771",Uncertain,,Approved,Nucleoplasm,"Renal cancer:2.21e-4 (unfavourable), Colorectal cancer:3.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 124.0;skin: 111.2,adipose tissue: 36.8,Cell line enhanced,,AN3-CA: 23.7;SH-SY5Y: 25.7;U-2 OS: 30.2;WM-115: 25.2
474,OPN4,"melanopsin, MOP",ENSG00000122375,Opsin 4,10,86654557-86666848,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA039147,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 2.2;parathyroid gland: 1.4,skeletal muscle: 0.9,Not detected,,
475,OPRD1,,ENSG00000116329,Opioid receptor delta 1,1,28812142-28871267,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA070831,Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 2.6,adrenal gland: 0.8,Group enriched,12.0,RH-30: 15.8;SCLC-21H: 7.6;SH-SY5Y: 6.9;WM-115: 21.7
476,OPRL1,"KOR-3, NOCIR, NOPr, OOR, ORL1",ENSG00000125510,Opioid related nociceptin receptor 1,20,64080173-64100643,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 12.3,testis: 4.7,Cell line enhanced,,REH: 4.4;SCLC-21H: 9.4;U-937: 7.1
477,OR2L13,OR2L14,ENSG00000196071,Olfactory receptor family 2 subfamily L member 13,1,248098649-248100922,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 4.0,prostate: 1.0,Not detected,,
478,OSBPL6,ORP6,ENSG00000079156,Oxysterol binding protein like 6,2,178194481-178402891,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA032131,Enhanced,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 15.5,skin: 9.2,Cell line enhanced,,HEL: 43.7
479,OSTN,,ENSG00000188729,Osteocrin,3,191199241-191265615,Predicted secreted proteins,Evidence at protein level,"CAB024997, CAB025649, HPA030878",Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 4.4,"cervix, uterine,epididymis: 2.0",Cell line enriched,30.0,U-2197: 36.4
480,OTUD7A,"C15orf16, CEZANNE2, OTUD7",ENSG00000169918,OTU deubiquitinase 7A,15,31475398-31870789,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044554,Uncertain,,Approved,Nucleoli<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 13.5,testis: 5.1,Cell line enhanced,,SCLC-21H: 6.3;SH-SY5Y: 2.7
481,OTX1,,ENSG00000115507,Orthodenticle homeobox 1,2,63050057-63057836,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB012341, HPA052122",Approved,,Uncertain,Nuclear speckles<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 1.7;skin: 6.1,prostate: 1.0,Cell line enriched,6.0,THP-1: 35.9
482,P2RX6,"MGC129625, P2RXL1, P2X6, P2XM",ENSG00000099957,Purinergic receptor P2X 6,22,21009808-21028830,Predicted membrane proteins,Evidence at protein level,"HPA028776, HPA028777",Approved,,Approved,Nucleoli<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 3.4;skeletal muscle: 3.0,spleen: 2.3,Cell line enhanced,,LHCN-M2: 5.6;RH-30: 4.0;U-87 MG: 11.5
483,PADI2,"KIAA0994, PDI2",ENSG00000117115,Peptidyl arginine deiminase 2,1,17066761-17119435,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047735,Enhanced,,,,,Mixed,Tissue enhanced,,cerebral cortex: 85.0;colon: 89.8;rectum: 99.9;skeletal muscle: 108.6,breast: 48.8,Group enriched,5.0,A549: 10.4;RPTEC TERT1: 25.1;SK-BR-3: 38.1;T-47d: 13.1
484,PAK3,"bPAK, hPAK3, MRX30, MRX47",ENSG00000077264,P21 (RAC1) activated kinase 3,X,110944285-111227361,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA044791, HPA060219",Approved,,Approved,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 34.3,thyroid gland: 10.4,Cell line enhanced,,EFO-21: 10.2;HAP1: 10.2;HDLM-2: 11.9;NTERA-2: 9.6;SCLC-21H: 14.7;U-251 MG: 11.1
485,PALM,KIAA0270,ENSG00000099864,Paralemmin,19,708939-748329,Predicted intracellular proteins,Evidence at protein level,"HPA041713, HPA049578",Approved,,Enhanced,Nucleus<br>Plasma membrane,"Renal cancer:5.44e-4 (favourable), Pancreatic cancer:9.81e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 84.8,adipose tissue: 53.1,Cell line enhanced,,AN3-CA: 28.0;EFO-21: 25.9;REH: 46.8;SH-SY5Y: 33.4
486,PALM2,,ENSG00000243444,Paralemmin 2,9,109640788-109946703,Predicted intracellular proteins,Evidence at protein level,HPA074153,,,Approved,Plasma membrane,,Not detected,Tissue enhanced,,cerebral cortex: 9.8,liver: 3.6,Cell line enhanced,,RH-30: 19.4
487,PANX2,"hPANX2, PX2",ENSG00000073150,Pannexin 2,22,50170731-50180294,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA004624, HPA039117",Enhanced,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 8.7,seminal vesicle: 2.1,Cell line enhanced,,HDLM-2: 15.5;Hep G2: 13.2;SCLC-21H: 11.5
488,PAQR4,FLJ30002,ENSG00000162073,Progestin and adipoQ receptor family member 4,16,2969245-2973489,Predicted membrane proteins,Evidence at protein level,HPA068394,,,Approved,Vesicles,"Renal cancer:3.01e-6 (unfavourable), Stomach cancer:1.70e-4 (favourable), Liver cancer:6.86e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 54.0;parathyroid gland: 65.2,"prostate,skin: 19.2",Mixed,,
489,PCDH11X,"PCDH-X, PCDH11, PCDHX, PPP1R119",ENSG00000102290,Protocadherin 11 X-linked,X,91779261-92623230,Predicted membrane proteins,Evidence at transcript level,HPA000432,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 4.6;ovary: 8.9;parathyroid gland: 4.9,"cervix, uterine: 1.5",Cell line enhanced,,AF22: 1.4;AN3-CA: 2.1
490,PCDH15,"CDHR15, DFNB23, USH1F",ENSG00000150275,Protocadherin related 15,10,53802771-55627942,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA074437,,Supported,,,,Tissue enriched,Tissue enhanced,,adrenal gland: 25.0;cerebral cortex: 12.2,kidney: 8.1,Cell line enhanced,,U-2 OS: 1.1;U-266/70: 2.5
491,PCDH17,"PCDH68, PCH68",ENSG00000118946,Protocadherin 17,13,57631810-57729311,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA026817,Uncertain,,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Renal cancer:3.31e-5 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 25.8;spleen: 33.8,lung: 18.3,Cell line enhanced,,AF22: 13.8;HEK93: 8.1;U-87 MG: 5.1
492,PCDH19,"EFMR, EIEE9, KIAA1313",ENSG00000165194,Protocadherin 19,X,100291644-100410273,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA027533,Approved,,Approved,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 11.3,"cervix, uterine: 2.6",Cell line enriched,7.0,AF22: 17.7
493,PCDH20,"FLJ22218, PCDH13",ENSG00000280165,Protocadherin 20,13,61409685-61415522,Predicted membrane proteins,Evidence at protein level,HPA062669,,,Approved,Vesicles<br>Cytokinetic bridge,,Not detected,Tissue enhanced,,cerebral cortex: 14.5;smooth muscle: 13.0,lung: 5.0,Cell line enriched,12.0,RPTEC TERT1: 39.0
494,PCDHA1,,ENSG00000204970,Protocadherin alpha 1,5,140786136-141012347,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035969,Enhanced,,Approved,Plasma membrane,,Not detected,Tissue enhanced,,cerebral cortex: 2.8;testis: 1.4,adrenal gland: 0.4,Cell line enriched,6.0,T-47d: 8.6
495,PCDHA10,"CNR8, CNRN8, CNRS8, CRNR8, PCDH-ALPHA10",ENSG00000250120,Protocadherin alpha 10,5,140855883-141012344,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 17.5,thyroid gland: 4.3,Cell line enriched,10.0,EFO-21: 16.6
496,PCDHA11,"CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11",ENSG00000249158,Protocadherin alpha 11,5,140868183-141012344,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA077160,,,Approved,Vesicles<br>Cell Junctions<br>Cytoplasmic bodies,,Not detected,Tissue enhanced,,cerebral cortex: 7.6;parathyroid gland: 3.8,testis: 1.8,Cell line enhanced,,AN3-CA: 14.0;EFO-21: 7.3;T-47d: 5.0
497,PCDHA4,"CNR1, CNRN1, CRNR1, PCDH-ALPHA4",ENSG00000204967,Protocadherin alpha 4,5,140806929-141012344,Predicted membrane proteins,Evidence at protein level,"HPA043180, HPA073478",Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 4.4,gallbladder: 2.5,Cell line enhanced,,A549: 5.9;AF22: 6.1;EFO-21: 5.0;T-47d: 5.1
498,PCDHA6,"CNR2, CNRS2, CRNR2, PCDH-ALPHA6",ENSG00000081842,Protocadherin alpha 6,5,140827958-141012344,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA059326, HPA078110",Enhanced,,Approved,Vesicles,,Not detected,Tissue enhanced,,cerebral cortex: 4.8,parathyroid gland: 1.9,Cell line enhanced,,AF22: 2.0;EFO-21: 8.1;U-2 OS: 3.7;WM-115: 5.1
499,PCDHA7,"CNR4, CNRS4, CRNR4",ENSG00000204963,Protocadherin alpha 7,5,140834248-141012344,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.6;testis: 1.0,"endometrium,gallbladder,smooth muscle: 0.3",Cell line enhanced,,NTERA-2: 1.0;WM-115: 1.0
500,PCDHB10,,ENSG00000120324,Protocadherin beta 10,5,141192353-141195642,Predicted membrane proteins,Evidence at protein level,HPA013445,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 8.3,endometrium: 5.1,Cell line enhanced,,EFO-21: 13.2
501,PCDHB2,PCDH-BETA2,ENSG00000112852,Protocadherin beta 2,5,141094578-141098703,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA007548,Enhanced,,Approved,Nucleoplasm,"Urothelial cancer:4.84e-4 (unfavourable), Renal cancer:6.99e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 7.7,testis: 7.5,Cell line enhanced,,AF22: 23.3;AN3-CA: 47.2;EFO-21: 26.8
502,PCDHB9,"PCDH-BETA9, PCDH3H",ENSG00000177839,Protocadherin beta 9,5,141187127-141191541,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA013445,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 7.9,"epididymis,ovary: 2.5",Cell line enhanced,,ASC diff: 7.0;SH-SY5Y: 15.3
503,PCDHGA1,PCDH-GAMMA-A1,ENSG00000204956,"Protocadherin gamma subfamily A, 1",5,141330571-141512981,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580, HPA036547",Uncertain,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 3.2,testis: 1.3,Cell line enhanced,,LHCN-M2: 3.7;T-47d: 6.9
504,PCDHGA3,PCDH-GAMMA-A3,ENSG00000254245,"Protocadherin gamma subfamily A, 3",5,141343829-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 6.5,ovary: 3.1,Group enriched,7.0,AF22: 7.0;BJ: 2.0;EFO-21: 5.4
505,PCDHGA7,PCDH-GAMMA-A7,ENSG00000253537,"Protocadherin gamma subfamily A, 7",5,141382739-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 7.4,thyroid gland: 3.3,Cell line enhanced,,BJ hTERT+: 17.1;SH-SY5Y: 19.7
506,PCDHGA9,PCDH-GAMMA-A9,ENSG00000261934,"Protocadherin gamma subfamily A, 9",5,141402932-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.6,endometrium: 4.1,Cell line enhanced,,EFO-21: 3.4;TIME: 3.7;U-87 MG: 5.0
507,PCDHGB6,PCDH-GAMMA-B6,ENSG00000253305,"Protocadherin gamma subfamily B, 6",5,141408021-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 20.8,parathyroid gland: 11.9,Cell line enhanced,,AF22: 15.8;EFO-21: 5.1
508,PCDHGC3,"PC-43, PC43, PCDH-GAMMA-C3, PCDH2",ENSG00000240184,"Protocadherin gamma subfamily C, 3",5,141475947-141512979,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008755, HPA010580, HPA077289",Approved,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,"Urothelial cancer:6.00e-4 (unfavourable), Ovarian cancer:6.19e-4 (unfavourable), Renal cancer:8.18e-4 (unfavourable)",Group enriched,Tissue enhanced,,cerebral cortex: 376.0,"cervix, uterine: 93.8",Cell line enhanced,,U-138 MG: 264.5;WM-115: 404.1
509,PCLO,"ACZ, DKFZp779G1236, KIAA0559",ENSG00000186472,Piccolo presynaptic cytomatrix protein,7,82754013-83162930,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015858, HPA029579, CAB079012",Approved,Approved,Approved,Nuclear speckles<br>Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 17.4,parathyroid gland: 9.8,Group enriched,36.0,REH: 239.6;U-2 OS: 298.6
510,PCP4L1,IQM1,ENSG00000248485,Purkinje cell protein 4 like 1,1,161258727-161285450,Predicted intracellular proteins,Evidence at protein level,HPA052833,Enhanced,Supported,Approved,Nucleoplasm<br>Mitochondria,Lung cancer:8.10e-5 (favourable),Group enriched,Tissue enhanced,,cerebral cortex: 45.2;urinary bladder: 39.5,seminal vesicle: 22.7,Cell line enhanced,,RT4: 10.8;T-47d: 8.2
511,PCSK1,"NEC1, PC1, PC3, SPC3",ENSG00000175426,Proprotein convertase subtilisin/kexin type 1,5,96390415-96434143,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048564,Approved,,,,Glioma:1.31e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 33.6,adrenal gland: 8.3,Group enriched,6.0,SCLC-21H: 26.6;U-138 MG: 18.8;U-87 MG: 15.5
512,PCSK1N,"BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII",ENSG00000102109,Proprotein convertase subtilisin/kexin type 1 inhibitor,X,48831094-48835633,Predicted secreted proteins,Evidence at protein level,"HPA003925, HPA064734",Enhanced,,Approved,Vesicles,"Endometrial cancer:1.15e-4 (unfavourable), Renal cancer:1.36e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 93.6;kidney: 65.7,adrenal gland: 28.5,Cell line enhanced,,HEK93: 52.2;PC-3: 133.3;SCLC-21H: 66.4;SH-SY5Y: 55.2;SiHa: 53.6;U-266/84: 49.2
513,PCSK2,"NEC2, PC2, SPC2",ENSG00000125851,Proprotein convertase subtilisin/kexin type 2,20,17226107-17484578,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049627,Enhanced,,Approved,Vesicles,,Group enriched,Tissue enhanced,,adrenal gland: 37.5;cerebral cortex: 31.7,skin: 16.5,Group enriched,6.0,AF22: 59.2;SCLC-21H: 18.5
514,PCYT1B,"CCT-beta, CTB",ENSG00000102230,"Phosphate cytidylyltransferase 1, choline, beta",X,24558087-24672677,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006367,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 21.9;testis: 17.4,"fallopian tube,smooth muscle: 4.7",Cell line enhanced,,AF22: 11.6;CACO-2: 21.4;HEL: 28.7;NTERA-2: 13.3;SCLC-21H: 10.7
515,PDE1B,PDES1B,ENSG00000123360,Phosphodiesterase 1B,12,54549350-54579239,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA018492,Approved,,,,Renal cancer:4.77e-6 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 18.4,parathyroid gland: 11.9,Cell line enhanced,,HDLM-2: 10.6;HL-60: 5.1;HMC-1: 10.2;NB-4: 5.1;THP-1: 5.1;U-937: 5.0
516,PDE2A,,ENSG00000186642,Phosphodiesterase 2A,11,72576141-72674591,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB009752, HPA031192",Enhanced,,Supported,Cytosol,Liver cancer:1.76e-6 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 141.8;spleen: 184.3,adipose tissue: 62.1,Cell line enriched,6.0,HeLa: 340.7
517,PDXP,"CIN, dJ37E16.5, FLJ32703",ENSG00000241360,Pyridoxal phosphatase,22,37658727-37666934,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000531,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 135.9,testis: 30.5,Mixed,,
518,PGBD5,"DKFZp761A0620, FLJ11413",ENSG00000177614,PiggyBac transposable element derived 5,1,230314482-230426371,Predicted intracellular proteins,Evidence at protein level,HPA065010,,,Approved,Nucleoplasm,Glioma:1.20e-4 (unfavourable),Mixed,Tissue enhanced,,"cerebral cortex: 40.1;cervix, uterine: 29.1",adrenal gland: 12.6,Cell line enhanced,,Daudi: 21.9;NTERA-2: 30.2;RH-30: 15.9;SCLC-21H: 48.7
519,PHACTR1,"dJ257A7.2, KIAA1733, RPEL1",ENSG00000112137,Phosphatase and actin regulator 1,6,12716805-13290484,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA029755, HPA029756, HPA029757",Enhanced,,Uncertain,Plasma membrane,Renal cancer:5.48e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 26.6,bone marrow: 15.6,Cell line enhanced,,HMC-1: 33.9;U-266/70: 72.3;U-266/84: 46.3
520,PHF21B,"BHC80L, FLJ34161, PHF4",ENSG00000056487,PHD finger protein 21B,22,44881162-45009999,Predicted intracellular proteins,Evidence at protein level,HPA053834,Uncertain,,Uncertain,Nucleus<br>Nucleoli fibrillar center,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 6.7;cervix, uterine: 5.5;testis: 6.4",endometrium: 5.4,Cell line enhanced,,AF22: 11.1;AN3-CA: 9.4;SCLC-21H: 10.3;SH-SY5Y: 41.0;U-2 OS: 9.1
521,PHYHIP,"DYRK1AP3, KIAA0273, PAHX-AP",ENSG00000168490,Phytanoyl-CoA 2-hydroxylase interacting protein,8,22219704-22232341,Predicted intracellular proteins,Evidence at protein level,"HPA068030, HPA069318",Approved,,Enhanced,Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 182.7;skin: 58.2,adrenal gland: 28.8,Cell line enhanced,,RPMI-8226: 6.4;SH-SY5Y: 3.6
522,PHYHIPL,"Em:AC025038.1, KIAA1796",ENSG00000165443,Phytanoyl-CoA 2-hydroxylase interacting protein like,10,59176590-59247774,Predicted intracellular proteins,Evidence at protein level,HPA038746,Uncertain,,Approved,Cytosol,Renal cancer:1.60e-7 (favourable),Group enriched,Tissue enhanced,,cerebral cortex: 89.4,adrenal gland: 22.4,Cell line enhanced,,Hep G2: 22.4;SCLC-21H: 6.7;SH-SY5Y: 20.0;SK-BR-3: 6.0
523,PIANP,"C12orf53, DKFZp547D2210, PANP",ENSG00000139200,PILR alpha associated neural protein,12,6693792-6700800,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA010631,Enhanced,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 64.3,endometrium: 13.4,Cell line enhanced,,NTERA-2: 20.8;SH-SY5Y: 20.6;U-2 OS: 11.2
524,PIRT,,ENSG00000233670,Phosphoinositide interacting regulator of transient receptor potential channels,17,10822475-10838445,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA042337,Uncertain,,Uncertain,Plasma membrane<br>Cytosol,,Tissue enriched,Tissue enhanced,,adrenal gland: 3.1;cerebral cortex: 2.6;rectum: 2.7,colon: 2.1,Not detected,,
525,PLCB1,"KIAA0581, PLC-I, PLC154",ENSG00000182621,Phospholipase C beta 1,20,8077251-8968360,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004275, CAB005334, HPA034743, HPA057910",Enhanced,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 68.3;parathyroid gland: 121.3,placenta: 28.2,Cell line enhanced,,Hep G2: 46.8
526,PLCXD2,FLJ31579,ENSG00000240891,Phosphatidylinositol specific phospholipase C X domain containing 2,3,111674676-111846447,Predicted intracellular proteins,Evidence at protein level,HPA055947,Uncertain,,Approved,Nucleoplasm,"Renal cancer:1.23e-7 (favourable), Urothelial cancer:2.99e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 6.4,lymph node: 3.3,Mixed,,
527,PLEKHH1,KIAA1200,ENSG00000054690,"Pleckstrin homology, MyTH4 and FERM domain containing H1",14,67533301-67589612,Predicted intracellular proteins,Evidence at protein level,"HPA047707, HPA051964",Uncertain,,Approved,Centrosome,"Renal cancer:4.03e-7 (favourable), Endometrial cancer:8.03e-5 (favourable), Urothelial cancer:2.26e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 43.3;thyroid gland: 51.2,prostate: 16.7,Cell line enhanced,,AN3-CA: 9.4;BEWO: 9.4;SK-MEL-30: 9.8;T-47d: 9.1
528,PLPP4,"DPPL2, PPAPDC1, PPAPDC1A",ENSG00000203805,Phospholipid phosphatase 4,10,120456954-120589855,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045188,Approved,,Approved,Nucleus<br>Nucleoli,,Mixed,Tissue enhanced,,cerebral cortex: 17.1;gallbladder: 10.4;testis: 12.7,kidney: 7.8,Cell line enhanced,,BJ: 30.3;U-251 MG: 92.6
529,PLPPR3,"FLJ11535, LPPR3, PRG-2, PRG2",ENSG00000129951,Phospholipid phosphatase related 3,19,812488-821977,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA052293, HPA057034",Uncertain,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,,Tissue enhanced,Tissue enhanced,,bone marrow: 6.1;cerebral cortex: 9.6;fallopian tube: 8.9,testis: 2.1,Cell line enhanced,,NB-4: 38.6;THP-1: 86.0
530,PLXNB3,"PLEXB3, PLEXR, PLXN6",ENSG00000198753,Plexin B3,X,153764196-153779346,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA048046,Enhanced,,,,Breast cancer:6.13e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 67.3,adrenal gland: 19.7,Cell line enhanced,,WM-115: 69.8
531,PNCK,"CaMK1b, MGC45419",ENSG00000130822,Pregnancy up-regulated nonubiquitous CaM kinase,X,153669730-153689010,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007458,Approved,,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:1.04e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 40.5;seminal vesicle: 52.3,smooth muscle: 22.4,Cell line enriched,7.0,AN3-CA: 29.8
532,PNMA6A,"MGC15827, PNMA6C",ENSG00000235961,Paraneoplastic Ma antigen family member 6A,X,153072482-153075018,Predicted intracellular proteins,Evidence at protein level,"HPA045007, HPA052115",Uncertain,,Uncertain,Nucleoli<br>Mitochondria,Renal cancer:1.93e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 22.9,epididymis: 7.3,Cell line enhanced,,HHSteC: 6.4;U-2 OS: 15.5
533,PNMAL1,"FLJ10781, KIAA1183L",ENSG00000182013,Paraneoplastic Ma antigen family like 1,19,46466491-46471563,Predicted intracellular proteins,Evidence at protein level,HPA012956,Approved,,Approved,Nucleoplasm<br>Nuclear bodies<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 133.9,testis: 42.5,Cell line enhanced,,HAP1: 33.8;K-562: 32.4;LHCN-M2: 29.9;SH-SY5Y: 33.2
534,PNOC,"N/OFQ, NOP, PPNOC",ENSG00000168081,Prepronociceptin,8,28316986-28343355,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA044507, HPA056724",Enhanced,,,,Endometrial cancer:2.94e-6 (unfavourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 44.2;fallopian tube: 26.3;lymph node: 28.9,tonsil: 21.4,Group enriched,6.0,Daudi: 27.2;Karpas-707: 20.9;RPMI-8226: 7.7;U-698: 15.7
535,PNPLA5,"dJ388M5.4, GS2L",ENSG00000100341,Patatin like phospholipase domain containing 5,22,43879678-43892013,Predicted intracellular proteins,Evidence at transcript level,"HPA050409, HPA054211",Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 1.1;epididymis: 2.1,skin: 0.7,Cell line enhanced,,NTERA-2: 1.4;RPMI-8226: 1.9;SCLC-21H: 1.0
536,PODXL2,"endoglycan, PODLX2",ENSG00000114631,Podocalyxin like 2,3,127629181-127672809,Predicted membrane proteins,Evidence at protein level,"CAB024934, HPA042265",Approved,,Approved,Golgi apparatus<br>Vesicles,,Expressed in all,Tissue enhanced,,cerebral cortex: 77.1,testis: 35.9,Cell line enhanced,,SCLC-21H: 195.4
537,POU6F2,RPF-1,ENSG00000106536,POU class 6 homeobox 2,7,38977998-39493095,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 3.1;placenta: 1.8,"gallbladder,testis: 1.2",Cell line enhanced,,EFO-21: 3.0;NTERA-2: 3.1;T-47d: 5.3;U-266/70: 4.7;U-266/84: 5.5
538,PPFIA4,,ENSG00000143847,PTPRF interacting protein alpha 4,1,203026498-203078740,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA053419, HPA054132",Enhanced,,,,Renal cancer:1.73e-8 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 24.8;heart muscle: 14.5,skeletal muscle: 6.5,Cell line enhanced,,RH-30: 13.1;U-87 MG: 12.1
539,PPP1R16B,"ANKRD4, KIAA0823, TIMAP",ENSG00000101445,Protein phosphatase 1 regulatory subunit 16B,20,38805705-38923024,Predicted intracellular proteins,Evidence at protein level,HPA049571,,,Supported,Nuclear speckles<br>Plasma membrane,"Head and neck cancer:7.87e-5 (favourable), Cervical cancer:2.11e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 50.9,lymph node: 44.2,Cell line enhanced,,Daudi: 40.9;HMC-1: 52.2;HUVEC TERT2: 29.7;U-266/70: 73.8;U-266/84: 29.1
540,PPP1R3F,Hb2E,ENSG00000049769,Protein phosphatase 1 regulatory subunit 3F,X,49269843-49301461,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000244, HPA000918",Approved,,Approved,Nucleoplasm,Pancreatic cancer:1.85e-6 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 26.8,epididymis: 14.6,Mixed,,
541,PPP2R2B,"PR52B, PR55-BETA, SCA12",ENSG00000156475,Protein phosphatase 2 regulatory subunit Bbeta,5,146581146-147084784,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA038118, HPA042122, HPA042770",Approved,,Approved,Cytosol,,Tissue enriched,Tissue enhanced,,cerebral cortex: 135.2,testis: 33.9,Cell line enhanced,,HaCaT: 19.5;HDLM-2: 97.5;RT4: 19.0
542,PPP2R2C,"IMYPNO, MGC33570, PR52, PR55G",ENSG00000074211,Protein phosphatase 2 regulatory subunit Bgamma,4,6320578-6563600,Predicted intracellular proteins,Evidence at protein level,"HPA042122, HPA042770",Approved,,,,Lung cancer:4.94e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 164.4,endometrium: 53.2,Cell line enhanced,,A-431: 30.5;A549: 45.5;MCF7: 32.3;PC-3: 43.7;SCLC-21H: 53.0
543,PPP4R4,"CFAP14, KIAA1622, PP4R4",ENSG00000119698,Protein phosphatase 4 regulatory subunit 4,14,94146128-94279735,Predicted intracellular proteins,Evidence at protein level,"HPA041866, HPA050321",Approved,,Supported,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 14.0;testis: 11.1,ovary: 5.4,Cell line enhanced,,RH-30: 17.0;T-47d: 17.6
544,PRKCB,"PKCB, PRKCB1, PRKCB2",ENSG00000166501,Protein kinase C beta,16,23836001-24220611,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB003843, HPA048321, HPA054203",Approved,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 125.4,spleen: 64.5,Cell line enhanced,,HEL: 145.7;HMC-1: 137.9;K-562: 211.8
545,PRKCE,,ENSG00000171132,Protein kinase C epsilon,2,45651345-46187990,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB001948, HPA044496, HPA054252",Enhanced,,Approved,Vesicles,"Renal cancer:2.63e-7 (favourable), Endometrial cancer:2.42e-4 (unfavourable), Lung cancer:9.62e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 48.3,parathyroid gland: 20.5,Mixed,,
546,PRKCZ,PKC2,ENSG00000067606,Protein kinase C zeta,1,2050470-2185395,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA021851,Enhanced,,Approved,Plasma membrane<br>Cytosol,Renal cancer:1.64e-9 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 99.7,placenta: 62.3,Cell line enhanced,,BEWO: 45.1
547,PROKR2,"dJ680N4.3, GPR73b, GPR73L1, GPRg2, KAL3, PKR2",ENSG00000101292,Prokineticin receptor 2,20,5302040-5314369,"Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA047281,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 3.0,bone marrow: 0.8,Cell line enhanced,,NTERA-2: 1.1;SH-SY5Y: 2.2
548,PRR7,MGC10772,ENSG00000131188,"Proline rich 7, synaptic",5,177446445-177456286,Predicted intracellular proteins,Evidence at transcript level,HPA046636,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Liver cancer:1.50e-4 (unfavourable), Renal cancer:1.98e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 8.1,bone marrow: 3.7,Mixed,,
549,PRRG3,TMG3,ENSG00000130032,Proline rich and Gla domain 3,X,151695124-151705924,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA060566,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 8.9,"cervix, uterine: 7.5",Cell line enhanced,,NTERA-2: 1.0
550,PRRT2,"DKFZp547J199, DSPB3, DYT10, EKD1, FICCA, FLJ25513, ICCA, IFITMD1, PKC",ENSG00000167371,Proline rich transmembrane protein 2,16,29811382-29815892,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA014447, HPA019203",Enhanced,,Supported,Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 98.1,ovary: 54.6,Cell line enhanced,,AF22: 26.4;REH: 19.4;U-138 MG: 18.0
551,PRRT3,FLJ33674,ENSG00000163704,Proline rich transmembrane protein 3,3,9945542-9952394,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA035127, HPA035128",Uncertain,,Approved,Nucleus<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 19.4;parathyroid gland: 27.8,fallopian tube: 12.2,Cell line enhanced,,MCF7: 17.7;SK-BR-3: 25.1
552,PSAT1,PSA,ENSG00000135069,Phosphoserine aminotransferase 1,9,78297143-78330093,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB014882, CAB040567, HPA042924",Enhanced,,Enhanced,Cytosol,"Renal cancer:6.00e-7 (unfavourable), Endometrial cancer:5.62e-5 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 186.0,liver: 138.7,Cell line enhanced,,hTCEpi: 853.3
553,PSD,"EFA6, EFA6A, KIAA2011, PSD1, TYL",ENSG00000059915,Pleckstrin and Sec7 domain containing,10,102402617-102421539,Predicted intracellular proteins,Evidence at protein level,HPA059237,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 112.7,endometrium: 40.4,Cell line enhanced,,HSkMC: 5.6;SCLC-21H: 8.7;SH-SY5Y: 6.8
554,PSD3,"DKFZp761K1423, EFA6D, EFA6R, HCA67, KIAA0942",ENSG00000156011,Pleckstrin and Sec7 domain containing 3,8,18527301-19084730,Predicted intracellular proteins,Evidence at protein level,HPA002455,Enhanced,,Approved,Nucleus<br>Vesicles,"Endometrial cancer:5.76e-5 (unfavourable), Colorectal cancer:7.55e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 83.3,testis: 29.6,Cell line enhanced,,U-87 MG: 48.5
555,PSRC1,DDA3,ENSG00000134222,Proline and serine rich coiled-coil 1,1,109279556-109283186,Predicted intracellular proteins,Evidence at protein level,"HPA049315, HPA056561",Approved,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.36e-9 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 36.6,testis: 14.0,Expressed in all,,
556,PTCHD1,FLJ30296,ENSG00000165186,Patched domain containing 1,X,23334016-23404372,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA046110,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 4.6;seminal vesicle: 5.1,endometrium: 2.6,Cell line enhanced,,HEK93: 1.5;RT4: 1.3;WM-115: 5.3
557,PTPRD,"HPTP, PTPD",ENSG00000153707,"Protein tyrosine phosphatase, receptor type D",9,8314246-10612723,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054829,Uncertain,,Approved,Vesicles,Renal cancer:7.45e-6 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 32.7;parathyroid gland: 47.0,ovary: 11.7,Cell line enhanced,,AF22: 27.3;RH-30: 9.9
558,PTPRN2,"IA-2beta, ICAAR, KIAA0387, phogrin",ENSG00000155093,"Protein tyrosine phosphatase, receptor type N2",7,157539056-158587788,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA006900, HPA026656",Approved,,Supported,Vesicles,"Glioma:7.72e-5 (unfavourable), Renal cancer:8.68e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 82.3,stomach: 38.9,Cell line enhanced,,AF22: 28.0;HDLM-2: 38.8;NB-4: 27.1;SCLC-21H: 26.6;SH-SY5Y: 24.3;U-87 MG: 27.1
559,PTPRR,"EC-PTP, PCPTP1, PTP-SL, PTPBR7, PTPRQ",ENSG00000153233,"Protein tyrosine phosphatase, receptor type R",12,70638073-70920843,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB011461, HPA011851, HPA071067",Uncertain,,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,Urothelial cancer:1.40e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 20.8,endometrium: 9.0,Group enriched,11.0,HDLM-2: 18.5;RT4: 29.7;SH-SY5Y: 6.2
560,PURG,"PURG-A, PURG-B",ENSG00000172733,Purine rich element binding protein G,8,30995802-31033715,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA047746,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.6;testis: 4.8,endometrium: 2.6,Cell line enhanced,,AF22: 6.0;NTERA-2: 4.8;SH-SY5Y: 6.0
561,RAB11FIP4,"FLJ00131, KIAA1821, MGC11316, RAB11-FIP4",ENSG00000131242,RAB11 family interacting protein 4,17,31391624-31538217,Predicted intracellular proteins,Evidence at protein level,HPA021595,Approved,,,,"Renal cancer:7.74e-8 (favourable), Stomach cancer:1.22e-4 (favourable), Colorectal cancer:2.70e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 67.9,testis: 42.4,Cell line enhanced,,BEWO: 62.0;HMC-1: 36.4
562,RAB26,,ENSG00000167964,"RAB26, member RAS oncogene family",16,2140803-2154165,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA075624,,,Uncertain,Vesicles<br>Plasma membrane<br>Centrosome,Cervical cancer:8.20e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 21.1,liver: 11.4,Cell line enhanced,,A549: 18.3;HeLa: 14.7;SCLC-21H: 32.1;SK-BR-3: 18.7
563,RAB33A,RabS10,ENSG00000134594,"RAB33A, member RAS oncogene family",X,130171649-130184870,Predicted intracellular proteins,Evidence at protein level,HPA059737,Uncertain,,Approved,Vesicles,,Group enriched,Tissue enhanced,,cerebral cortex: 31.9,lymph node: 9.1,Cell line enhanced,,HMC-1: 70.4;Karpas-707: 65.9;U-266/70: 50.9
564,RAB39A,RAB39,ENSG00000179331,"RAB39A, member RAS oncogene family",11,107928503-107963482,Predicted intracellular proteins,Evidence at protein level,HPA042505,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 7.0,spleen: 4.3,Cell line enhanced,,RPMI-8226: 11.4;SCLC-21H: 33.8;SH-SY5Y: 18.8
565,RAB39B,MRX72,ENSG00000155961,"RAB39B, member RAS oncogene family",X,155258241-155264589,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001114, HPA042505",Approved,,,,Breast cancer:8.95e-4 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 19.4,epididymis: 7.5,Cell line enhanced,,Daudi: 19.2;Karpas-707: 24.8;SCLC-21H: 15.4;U-266/70: 26.3;U-266/84: 17.9
566,RAB3B,,ENSG00000169213,"RAB3B, member RAS oncogene family",1,51907956-51990764,Predicted intracellular proteins,Evidence at protein level,"HPA003159, CAB023293",Enhanced,,Approved,Cell Junctions,,Group enriched,Tissue enhanced,,cerebral cortex: 8.2;prostate: 17.8,adrenal gland: 4.0,Cell line enhanced,,BJ: 105.7;TIME: 79.3
567,RAB40B,"RAR, SEC4L",ENSG00000141542,"RAB40B, member RAS oncogene family",17,82654973-82698728,Predicted intracellular proteins,Evidence at transcript level,,,,,,"Renal cancer:2.95e-6 (favourable), Lung cancer:9.77e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 56.8,epididymis: 18.0,Mixed,,
568,RAB41,,ENSG00000147127,"RAB41, member RAS oncogene family",X,70282093-70285002,Predicted intracellular proteins,Evidence at protein level,HPA001510,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.0;testis: 7.0,skin: 1.6,Cell line enhanced,,U-2197: 3.5;U-87 MG: 4.5
569,RALYL,HNRPCL3,ENSG00000184672,RALY RNA binding protein-like,8,84182787-84921844,Predicted intracellular proteins,Evidence at protein level,"HPA055868, HPA059112",Enhanced,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,adrenal gland: 26.1;cerebral cortex: 49.2;kidney: 19.7,gallbladder: 8.1,Cell line enhanced,,AF22: 4.0
570,RANBP3L,FLJ25422,ENSG00000164188,RAN binding protein 3 like,5,36248434-36302114,Predicted intracellular proteins,Evidence at protein level,"HPA037471, HPA037472, HPA061526",Approved,,Uncertain,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 31.0;kidney: 28.7;prostate: 23.0,breast: 10.0,Cell line enhanced,,ASC diff: 8.5;HSkMC: 1.8;T-47d: 2.0
571,RAP1GAP,"KIAA0474, RAP1GA1, RAP1GAP1, RAP1GAPII",ENSG00000076864,RAP1 GTPase activating protein,1,21596215-21669363,Predicted intracellular proteins,Evidence at protein level,"HPA001922, CAB003851",Enhanced,Supported,Approved,Cytosol,"Renal cancer:1.12e-6 (favourable), Liver cancer:5.85e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 122.1;thyroid gland: 232.8,adrenal gland: 93.2,Cell line enhanced,,A549: 41.8;K-562: 26.3;SCLC-21H: 61.3
572,RAPGEF4,"cAMP-GEFII, CGEF2",ENSG00000091428,Rap guanine nucleotide exchange factor 4,2,172735274-173052893,Predicted intracellular proteins,Evidence at protein level,"CAB004388, HPA028968",Approved,,Approved,Focal adhesion sites,Pancreatic cancer:1.32e-4 (favourable),Mixed,Tissue enhanced,,adrenal gland: 53.3;cerebral cortex: 119.2,liver: 18.3,Cell line enhanced,,Karpas-707: 15.5;SCLC-21H: 9.8;U-266/70: 8.4;U-266/84: 16.0
573,RASGEF1A,"CG4853, FLJ37817",ENSG00000198915,RasGEF domain family member 1A,10,43194535-43266919,Predicted intracellular proteins,Evidence at protein level,HPA035593,Enhanced,,Approved,Golgi apparatus,"Renal cancer:4.11e-7 (unfavourable), Breast cancer:1.86e-5 (favourable), Endometrial cancer:4.28e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 22.7,parathyroid gland: 12.8,Cell line enhanced,,K-562: 15.4;SCLC-21H: 18.4;T-47d: 14.7
574,RASGRF2,"GRF2, Ras-GRF2",ENSG00000113319,Ras protein specific guanine nucleotide releasing factor 2,5,80960672-81230156,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA018679,Uncertain,,Supported,Endoplasmic reticulum,,Mixed,Tissue enhanced,,cerebral cortex: 25.5,ovary: 22.8,Cell line enhanced,,BEWO: 37.2;CACO-2: 19.9;Hep G2: 21.9;HHSteC: 17.6
575,RASGRP1,"CalDAG-GEFII, RASGRP",ENSG00000172575,RAS guanyl releasing protein 1,15,38488103-38565575,"Disease related genes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA039389,,,Supported,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 28.4;lymph node: 25.0,tonsil: 15.2,Cell line enhanced,,HDLM-2: 50.5;MOLT-4: 41.7
576,RASSF2,"CENP-34, KIAA0168",ENSG00000101265,Ras association domain family member 2,20,4780023-4823645,Predicted intracellular proteins,Evidence at protein level,HPA051200,Uncertain,,Supported,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:7.82e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 148.5,lymph node: 68.8,Cell line enhanced,,HL-60: 59.0;NB-4: 60.4;U-937: 91.0
577,RBFOX3,"FOX-3, HRNBP3, NeuN",ENSG00000167281,"RNA binding protein, fox-1 homolog 3",17,79089345-79516148,Predicted intracellular proteins,Evidence at protein level,"HPA030790, CAB078782",Enhanced,Approved,Supported,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 62.3;seminal vesicle: 33.2,prostate: 24.1,Group enriched,7.0,A549: 14.1;NTERA-2: 13.9;SCLC-21H: 26.0;U-2 OS: 10.8
578,RCOR2,,ENSG00000167771,REST corepressor 2,11,63911221-63916844,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA021638,Uncertain,,Approved,Nucleus<br>Vesicles<br>Midbody,,Mixed,Tissue enhanced,,cerebral cortex: 13.2,testis: 3.7,Cell line enhanced,,AF22: 39.9;NTERA-2: 52.3;SCLC-21H: 95.8;SH-SY5Y: 57.5
579,REEP2,"C5orf19, SGC32445, SPG72, Yip2d",ENSG00000132563,Receptor accessory protein 2,5,138439017-138446969,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA031813,Enhanced,,,,"Breast cancer:7.83e-5 (favourable), Glioma:3.43e-4 (unfavourable), Melanoma:9.31e-4 (favourable)",Tissue enriched,Tissue enhanced,,cerebral cortex: 90.1,smooth muscle: 18.0,Cell line enhanced,,AN3-CA: 89.1;SCLC-21H: 46.8;SH-SY5Y: 47.6
580,RELL2,"C5orf16, FLJ90583",ENSG00000164620,RELT like 2,5,141636950-141641077,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA077928,,,Uncertain,Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 13.2;parathyroid gland: 23.3,testis: 4.3,Mixed,,
581,RESP18,,ENSG00000182698,Regulated endocrine specific protein 18,2,219327409-219333177,Predicted intracellular proteins,Evidence at transcript level,HPA045849,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 2.1,testis: 0.7,Not detected,,
582,RFTN2,"C2orf11, FLJ30574, Raftlin-2",ENSG00000162944,Raftlin family member 2,2,197568224-197676045,Predicted intracellular proteins,Evidence at protein level,HPA035232,Approved,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 31.4,ovary: 8.7,Cell line enhanced,,AF22: 17.0;ASC diff: 8.0;WM-115: 7.5
583,RGMA,"RGM, RGMa",ENSG00000182175,Repulsive guidance molecule family member a,15,93035273-93089204,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB012343, HPA039880, HPA044222",Approved,,Supported,Nucleoplasm<br>Cytosol,Lung cancer:2.78e-4 (favourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 116.6;smooth muscle: 84.8,skeletal muscle: 42.6,Cell line enhanced,,AF22: 49.7;NTERA-2: 22.5
584,RGS11,,ENSG00000076344,Regulator of G-protein signaling 11,16,268301-275980,Predicted intracellular proteins,Evidence at protein level,"HPA041692, HPA043039",Uncertain,,,,Pancreatic cancer:1.24e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 20.3,adipose tissue: 8.1,Cell line enhanced,,HHSteC: 2.6;SCLC-21H: 3.6;SH-SY5Y: 2.5;T-47d: 2.4
585,RGS20,"RGSZ1, ZGAP1",ENSG00000147509,Regulator of G-protein signaling 20,8,53851808-53959303,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA070193,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 10.1,thyroid gland: 2.1,Cell line enhanced,,SK-MEL-30: 23.4;U-87 MG: 28.2
586,RGS6,,ENSG00000182732,Regulator of G-protein signaling 6,14,71932439-72566529,Predicted intracellular proteins,Evidence at protein level,HPA003067,Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 17.5;testis: 18.7,thyroid gland: 8.8,Group enriched,8.0,HEL: 10.1;Karpas-707: 24.7
587,RGS7BP,R7BP,ENSG00000186479,Regulator of G-protein signaling 7 binding protein,5,64506257-64612312,Predicted intracellular proteins,Evidence at protein level,HPA039600,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 38.9,fallopian tube: 13.2,Cell line enhanced,,HUVEC TERT2: 9.7;NTERA-2: 2.0;SCLC-21H: 1.5
588,RHBDL1,"RHBDL, RRP",ENSG00000103269,Rhomboid like 1,16,675666-678268,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA030359, HPA030360, HPA046593",Uncertain,,Approved,Nucleoplasm,Breast cancer:8.12e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 8.0,adrenal gland: 3.3,Mixed,,
589,RHBDL3,"RHBDL4, VRHO",ENSG00000141314,Rhomboid like 3,17,32266176-32324661,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA059607,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 20.7,adrenal gland: 5.5,Cell line enhanced,,A549: 4.0;AF22: 4.3;HDLM-2: 5.7;NTERA-2: 6.4;U-2 OS: 4.6
590,RHPN1,"KIAA1929, ODF5, RHPN",ENSG00000158106,Rhophilin Rho GTPase binding protein 1,8,143368887-143384220,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA024288, HPA024671",Approved,,Approved,Nucleoplasm,,Expressed in all,Tissue enhanced,,cerebral cortex: 7.1,parathyroid gland: 4.8,Cell line enhanced,,MCF7: 21.9;MOLT-4: 21.1;T-47d: 42.5
591,RIMKLA,"FAM80A, MGC47816, NAAGS-II, RP11-157D18.1",ENSG00000177181,Ribosomal modification protein rimK like family member A,1,42380795-42422578,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027826,Uncertain,,Uncertain,Nucleoli fibrillar center,Lung cancer:1.43e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 10.2,"parathyroid gland,rectum: 3.8",Cell line enhanced,,AN3-CA: 6.7;SCLC-21H: 12.8
592,RIMS1,"CORD7, KIAA0340, RAB3IP2, RIM, RIM1",ENSG00000079841,Regulating synaptic membrane exocytosis 1,6,71886703-72403143,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 30.2,testis: 7.5,Cell line enhanced,,EFO-21: 8.3;LHCN-M2: 8.3;RPTEC TERT1: 11.5;SH-SY5Y: 11.4
593,RIMS2,"KIAA0751, OBOE, RAB3IP3, RIM2",ENSG00000176406,Regulating synaptic membrane exocytosis 2,8,103500748-104256094,Predicted intracellular proteins,Evidence at protein level,"HPA046538, HPA066498, CAB079049",Enhanced,Supported,Approved,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,adrenal gland: 67.7;cerebral cortex: 45.0,"cervix, uterine: 11.5",Cell line enhanced,,Daudi: 10.2;RT4: 8.0;SCLC-21H: 28.6
594,RIMS4,"C20orf190, dJ781B1.3",ENSG00000101098,Regulating synaptic membrane exocytosis 4,20,44751808-44810338,Predicted intracellular proteins,Evidence at protein level,HPA060928,Approved,,Approved,Nucleoplasm,,Group enriched,Tissue enhanced,,cerebral cortex: 27.3;testis: 20.3,fallopian tube: 13.3,Cell line enhanced,,HAP1: 20.7;SCLC-21H: 48.2;SH-SY5Y: 22.3;SiHa: 15.5
595,RND1,"ARHS, Rho6, RHOS",ENSG00000172602,Rho family GTPase 1,12,48857145-48865898,Predicted intracellular proteins,Evidence at protein level,HPA077800,,,Supported,Vesicles<br>Plasma membrane<br>Actin filaments,,Mixed,Tissue enhanced,,cerebral cortex: 39.8;liver: 31.1,gallbladder: 23.6,Cell line enriched,6.0,SK-BR-3: 51.2
596,RND2,"ARHN, Rho7, RhoN",ENSG00000108830,Rho family GTPase 2,17,43025241-43032036,Predicted intracellular proteins,Evidence at protein level,HPA077757,Approved,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 37.0;testis: 30.7,thyroid gland: 11.0,Cell line enhanced,,AF22: 11.9;AN3-CA: 14.4;HAP1: 12.5;NTERA-2: 17.2;SH-SY5Y: 11.0
597,RNF103-CHMP3,RNF103-VPS24,ENSG00000249884,RNF103-CHMP3 readthrough,2,86505668-86721122,Predicted intracellular proteins,Evidence at protein level,"HPA015673, HPA073383",Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 4.2,"bone marrow,heart muscle: 2.7",Mixed,,
598,RNF112,"BFP, ZNF179",ENSG00000128482,Ring finger protein 112,17,19411125-19417276,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA015970,Approved,,Approved,Nuclear speckles,,Tissue enriched,Tissue enhanced,,cerebral cortex: 33.0,prostate: 11.0,Cell line enhanced,,SCLC-21H: 7.1;SH-SY5Y: 11.1;U-87 MG: 33.6
599,RNF157,KIAA1917,ENSG00000141576,Ring finger protein 157,17,76142453-76240373,Predicted intracellular proteins,Evidence at protein level,"HPA021854, HPA021991, HPA023922",Uncertain,,Approved,Golgi apparatus<br>Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 60.6;testis: 57.3,skeletal muscle: 24.9,Cell line enhanced,,HDLM-2: 92.0;U-266/70: 38.2
600,RNF165,"ARKL2, RNF111L2",ENSG00000141622,Ring finger protein 165,18,46326809-46463140,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041615, HPA047798",Uncertain,,Approved,Nucleus<br>Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 9.3;parathyroid gland: 9.8,thyroid gland: 7.0,Cell line enhanced,,AF22: 13.9;SCLC-21H: 17.1;SH-SY5Y: 17.5
601,RNF175,FLJ34190,ENSG00000145428,Ring finger protein 175,4,153710125-153760235,Predicted membrane proteins,Evidence at protein level,HPA035837,Uncertain,,,,Glioma:4.15e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 13.2,seminal vesicle: 4.1,Cell line enhanced,,AF22: 6.9;REH: 5.6;SH-SY5Y: 6.3;THP-1: 10.0;U-87 MG: 3.4
602,RNF182,MGC33993,ENSG00000180537,Ring finger protein 182,6,13924446-13980302,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012309,Approved,,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,Endometrial cancer:4.66e-5 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 14.6,testis: 6.9,Cell line enhanced,,HeLa: 57.3;RPTEC TERT1: 51.0
603,RNF208,DKFZP761H1710,ENSG00000212864,Ring finger protein 208,9,137220247-137221581,Predicted intracellular proteins,Evidence at protein level,"HPA021256, HPA021429",Uncertain,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:1.12e-8 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 25.1,adrenal gland: 7.4,Cell line enhanced,,MCF7: 42.5;REH: 40.9
604,RNFT2,"FLJ14627, TMEM118",ENSG00000135119,"Ring finger protein, transmembrane 2",12,116738178-116853631,Predicted membrane proteins,Evidence at protein level,HPA064161,Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 15.3,testis: 6.0,Mixed,,
605,ROBO2,KIAA1568,ENSG00000185008,Roundabout guidance receptor 2,3,75906695-77649964,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA013371,Approved,,Approved,Nucleus<br>Microtubule organizing center,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 33.8,lung: 15.1,Cell line enhanced,,BJ hTERT+: 24.2;HEL: 75.2
606,ROM1,"ROM, TSPAN23",ENSG00000149489,Retinal outer segment membrane protein 1,11,62611722-62615120,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA028910,Supported,,Approved,Plasma membrane<br>Cytosol,"Renal cancer:2.85e-6 (unfavourable), Lung cancer:2.20e-4 (favourable)",Tissue enriched,Tissue enhanced,,cerebral cortex: 25.4,ovary: 13.3,Mixed,,
607,RORB,"NR1F2, ROR-BETA, RZRB",ENSG00000198963,RAR related orphan receptor B,9,74497365-74693177,"Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA008393,Uncertain,,Approved,Nucleus,,Group enriched,Tissue enhanced,,"cerebral cortex: 12.6;cervix, uterine: 14.1",prostate: 7.4,Cell line enhanced,,HHSteC: 18.9;HSkMC: 9.0;MOLT-4: 5.5;SH-SY5Y: 14.3
608,RP11-192H23.4,,ENSG00000258472,,17,28455752-28614197,Predicted intracellular proteins,Evidence at protein level,HPA046590,Uncertain,,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 2.2,lung: 1.2,Cell line enhanced,,A549: 2.3;PC-3: 1.1
609,RP11-231C18.3,,ENSG00000282278,,4,53377839-54295272,Predicted intracellular proteins,Evidence at protein level,HPA058202,,,,,,,Tissue enhanced,,appendix: 1.2;cerebral cortex: 3.3,"ovary,smooth muscle: 0.7",Cell line enhanced,,BJ hTERT+: 2.8;fHDF/TERT166: 6.4;HDLM-2: 2.1;NTERA-2: 1.8;U-2197: 1.7
610,RP11-449K6.5,,ENSG00000283765,,3,183815568-183884889,Predicted membrane proteins,Evidence at protein level,HPA019545,Uncertain,,Approved,Mitochondria,,,Tissue enhanced,,cerebral cortex: 3.4;testis: 2.1,"adrenal gland,esophagus,skeletal muscle: 0.6",Cell line enhanced,,T-47d: 7.0
611,RP11-540D14.8,,ENSG00000251246,,1,155063748-155086807,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.2,testis: 0.7,Cell line enhanced,,RPMI-8226: 2.2;U-266/70: 2.0
612,RP11-73M18.2,,ENSG00000256500,,14,103562962-103685924,Predicted intracellular proteins,Evidence at protein level,"HPA044617, HPA052450",Uncertain,,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 21.5;testis: 21.6,skeletal muscle: 9.0,Expressed in all,,
613,RP4-576H24.4,,ENSG00000260861,,20,1540144-1620009,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,appendix: 3.3;cerebral cortex: 4.5,testis: 2.5,Cell line enhanced,,HL-60: 2.6;HMC-1: 5.9;NB-4: 1.4;THP-1: 1.8;U-937: 1.5
614,RP5-850E9.3,,ENSG00000270299,,20,646626-675800,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 2.7;testis: 1.7,endometrium: 1.5,Cell line enhanced,,Hep G2: 9.9;SK-BR-3: 6.5
615,RPE65,"BCO3, LCA2, rd12, RP20",ENSG00000116745,"RPE65, retinoid isomerohydrolase",1,68428822-68449959,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 2.7;prostate: 3.0;seminal vesicle: 6.2,endometrium: 1.0,Group enriched,27.0,A-431: 3.0;PC-3: 5.3;U-2 OS: 1.4
616,RPRM,"FLJ90327, REPRIMO",ENSG00000177519,"Reprimo, TP53 dependent G2 arrest mediator candidate",2,153477338-153478808,Predicted membrane proteins,Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 21.2;endometrium: 21.8,smooth muscle: 17.4,Group enriched,6.0,HEK93: 22.9;MCF7: 21.9;NTERA-2: 19.8;SCLC-21H: 8.5;SH-SY5Y: 8.7
617,RPS6KL1,MGC11287,ENSG00000198208,Ribosomal protein S6 kinase like 1,14,74903954-74923396,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,"HPA027451, HPA027794",Approved,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,cerebral cortex: 31.4,testis: 14.7,Cell line enhanced,,SCLC-21H: 41.7
618,RSPO2,MGC35555,ENSG00000147655,R-spondin 2,8,107899316-108083648,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA024764, CAB025900, HPA053068",Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 20.2;placenta: 25.7,prostate: 15.8,Cell line enhanced,,HEK93: 1.7;HEL: 1.6;NTERA-2: 1.0;U-138 MG: 1.8;U-266/70: 4.2
619,RTN4R,NOGOR,ENSG00000040608,Reticulon 4 receptor,22,20241415-20283246,Predicted membrane proteins,Evidence at protein level,CAB012443,,,Supported,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,Head and neck cancer:7.73e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 23.8,spleen: 5.0,Cell line enhanced,,NB-4: 24.1;REH: 48.8;SCLC-21H: 36.8
620,RTN4RL1,"DKFZp547J144, NgR3, NGRH2",ENSG00000185924,Reticulon 4 receptor like 1,17,1934677-2025345,Predicted secreted proteins,Evidence at protein level,HPA044428,Uncertain,,,,Renal cancer:7.69e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 12.5,skin: 6.2,Cell line enhanced,,fHDF/TERT166: 8.4;HaCaT: 9.4;hTCEpi: 7.2;T-47d: 12.5
621,RTP1,"MGC35450, Z3CXXC1",ENSG00000175077,Receptor transporter protein 1,3,187197486-187201465,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.3,testis: 0.7,Cell line enriched,24.0,T-47d: 2.4
622,RXFP1,"LGR7, RXFPR1",ENSG00000171509,Relaxin/insulin like family peptide receptor 1,4,158315311-158653372,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA027067,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 21.6;endometrium: 10.1,adrenal gland: 5.7,Group enriched,6.0,EFO-21: 26.8;HEL: 8.8;RPTEC TERT1: 10.0
623,S1PR5,"Edg-8, EDG8",ENSG00000180739,Sphingosine-1-phosphate receptor 5,19,10512742-10517931,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029683,Enhanced,,,,Renal cancer:6.71e-7 (unfavourable),Group enriched,Tissue enhanced,,cerebral cortex: 14.9;skin: 22.1,spleen: 12.0,Cell line enhanced,,HaCaT: 25.0;RT4: 14.8;T-47d: 10.9;U-2 OS: 10.7
624,SALL3,ZNF796,ENSG00000256463,Spalt like transcription factor 3,18,78980275-79002677,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA016656,Uncertain,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 4.1;prostate: 2.0,kidney: 0.9,Group enriched,29.0,HAP1: 4.8;HEK93: 2.5;NTERA-2: 9.5
625,SAMD14,FLJ36890,ENSG00000167100,Sterile alpha motif domain containing 14,17,50110040-50129882,Predicted intracellular proteins,Evidence at protein level,HPA051916,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.2,testis: 1.8,Cell line enhanced,,HDLM-2: 12.8;HEL: 7.8;HMC-1: 24.7;SH-SY5Y: 14.0
626,SAPCD2,"C9orf140, p42.3",ENSG00000186193,Suppressor APC domain containing 2,9,137062124-137070588,Predicted intracellular proteins,Evidence at protein level,HPA044154,Approved,,Supported,Nucleus<br>Nucleoli<br>Cytosol,Lung cancer:5.88e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 12.6,small intestine: 4.8,Mixed,,
627,SBK1,Sbk,ENSG00000188322,SH3 domain binding kinase 1,16,28292519-28323849,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,Cervical cancer:6.88e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 10.9;skeletal muscle: 12.0,parathyroid gland: 4.1,Cell line enhanced,,AF22: 27.9;NTERA-2: 29.2;REH: 29.2;SCLC-21H: 52.5;SH-SY5Y: 44.5
628,SCAMP5,MGC24969,ENSG00000198794,Secretory carrier membrane protein 5,15,74957219-75021496,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046645,Enhanced,,,,"Renal cancer:1.34e-6 (favourable), Pancreatic cancer:5.67e-5 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 275.5,parathyroid gland: 81.7,Cell line enhanced,,SCLC-21H: 103.1;SH-SY5Y: 51.9
629,SCD5,"ACOD4, FADS4, FLJ21032, HSCD5, SCD4",ENSG00000145284,Stearoyl-CoA desaturase 5,4,82629539-82798857,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA042380,Uncertain,,,,Renal cancer:2.32e-5 (favourable),Group enriched,Tissue enhanced,,adrenal gland: 200.6;cerebral cortex: 500.3,epididymis: 117.0,Mixed,,
630,SCG5,"7B2, SGNE1, SgV",ENSG00000166922,Secretogranin V,15,32641676-32697098,Predicted secreted proteins,Evidence at protein level,"HPA013136, HPA074618",Enhanced,,,,"Renal cancer:4.51e-9 (unfavourable), Head and neck cancer:9.64e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 233.7;parathyroid gland: 192.7,adrenal gland: 80.4,Group enriched,6.0,HHSteC: 22.6;HSkMC: 24.3;NTERA-2: 15.6;SCLC-21H: 37.1;SH-SY5Y: 38.6;U-87 MG: 46.3
631,SCHIP1,SCHIP-1,ENSG00000151967,Schwannomin interacting protein 1,3,159839861-159897360,Predicted intracellular proteins,Evidence at protein level,"HPA003243, HPA069824",Uncertain,,Approved,Nucleus<br>Nuclear bodies<br>Plasma membrane<br>Cell Junctions<br>Cytosol,Glioma:3.78e-4 (favourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 102.8;heart muscle: 53.1,skeletal muscle: 25.5,Cell line enhanced,,AN3-CA: 45.4;HUVEC TERT2: 48.7;NTERA-2: 29.7;SH-SY5Y: 177.1
632,SCRG1,SCRG-1,ENSG00000164106,Stimulator of chondrogenesis 1,4,173384701-173406380,Predicted secreted proteins,Evidence at protein level,HPA012882,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 24.4;testis: 15.5,smooth muscle: 11.0,Group enriched,13.0,HSkMC: 4.3;WM-115: 17.6
633,SCRN1,KIAA0193,ENSG00000136193,Secernin 1,7,29920103-29990289,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA024517,Enhanced,,Approved,Cytosol,"Renal cancer:1.15e-5 (favourable), Endometrial cancer:4.00e-5 (unfavourable), Urothelial cancer:2.60e-4 (unfavourable), Ovarian cancer:7.27e-4 (unfavourable), Breast cancer:8.32e-4 (unfavourable), Cervical cancer:8.46e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 172.0,parathyroid gland: 129.1,Mixed,,
634,SEC61A2,FLJ10578,ENSG00000065665,Sec61 translocon alpha 2 subunit,10,12129637-12169961,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,"Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:1.08e-5 (favourable), Urothelial cancer:8.75e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 51.3,testis: 32.5,Expressed in all,,
635,SEMA5B,"FLJ10372, KIAA1445, SEMAG, SemG",ENSG00000082684,Semaphorin 5B,3,122909193-123028605,Predicted membrane proteins,Evidence at protein level,HPA066548,Enhanced,,Supported,Cytosol,Renal cancer:7.57e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 11.4,heart muscle: 4.2,Cell line enhanced,,AF22: 79.6;NTERA-2: 15.7;SH-SY5Y: 22.6
636,SEMA6B,"SEM-SEMA-Y, SEMA-VIB, SEMAN, semaZ",ENSG00000167680,Semaphorin 6B,19,4542593-4559808,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB025157, HPA055778, HPA058523",Enhanced,,,,"Renal cancer:3.29e-5 (unfavourable), Thyroid cancer:1.45e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 65.5,spleen: 24.5,Cell line enhanced,,Hep G2: 88.4;HMC-1: 180.6;HUVEC TERT2: 71.3;TIME: 88.7
637,SEPT4,"ARTS, CE5B3, H5, hCDCREL-2, hucep-7, MART, PNUTL2",ENSG00000108387,Septin 4,17,58520250-58540818,Predicted intracellular proteins,Evidence at protein level,"CAB006855, HPA021587, HPA022905",Enhanced,,Supported,Nucleoplasm,Renal cancer:3.28e-7 (unfavourable),Expressed in all,Tissue enhanced,,adrenal gland: 217.2;cerebral cortex: 287.9,spleen: 56.8,Cell line enhanced,,HHSteC: 11.8;SK-MEL-30: 25.2
638,SERP2,"bA269C23.1, C13orf21",ENSG00000151778,Stress associated endoplasmic reticulum protein family member 2,13,44373665-44397714,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA038970,Uncertain,,,,Renal cancer:1.94e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 52.7;testis: 23.7,epididymis: 11.3,Cell line enhanced,,LHCN-M2: 3.2;SH-SY5Y: 5.6;U-2197: 4.5
639,SERTM1,C13orf36,ENSG00000180440,Serine rich and transmembrane domain containing 1,13,36673912-36697839,Predicted membrane proteins,Evidence at protein level,"HPA054814, HPA070485",Uncertain,,Supported,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 47.6;endometrium: 37.7;fallopian tube: 29.6,smooth muscle: 24.8,Cell line enhanced,,HAP1: 1.2;HEK93: 1.3;NTERA-2: 3.5;SH-SY5Y: 2.1
640,SEZ6L2,"FLJ90517, PSK-1",ENSG00000174938,Seizure related 6 homolog like 2,16,29871159-29899547,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA064471,Enhanced,,,,"Colorectal cancer:1.31e-4 (unfavourable), Glioma:7.27e-4 (unfavourable), Cervical cancer:7.46e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 82.4;parathyroid gland: 58.4,adrenal gland: 30.6,Cell line enhanced,,EFO-21: 72.2
641,SFXN5,BBG-TCC,ENSG00000144040,Sideroflexin 5,2,72942036-73075619,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA015473, HPA056866",Approved,,Approved,Nucleoplasm<br>Mitochondria,Pancreatic cancer:2.26e-6 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 39.4,epididymis: 18.6,Mixed,,
642,SGCZ,ZSG1,ENSG00000185053,Sarcoglycan zeta,8,14089864-15238339,Predicted membrane proteins,Evidence at transcript level,HPA017585,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.3;ovary: 3.4,breast: 0.7,Not detected,,
643,SGIP1,DKFZp761D221,ENSG00000118473,SH3 domain GRB2 like endophilin interacting protein 1,1,66533383-66748299,Predicted intracellular proteins,Evidence at protein level,HPA017963,Approved,,Approved,Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 36.2,endometrium: 16.9,Cell line enhanced,,BJ: 24.8;BJ hTERT+: 30.5;fHDF/TERT166: 18.7;RPTEC TERT1: 20.7;SH-SY5Y: 15.7;U-138 MG: 26.6
644,SGSM1,"KIAA1941, RUTBC2",ENSG00000167037,Small G protein signaling modulator 1,22,24806169-24927578,Predicted intracellular proteins,Evidence at protein level,HPA003986,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 14.8;parathyroid gland: 19.0,fallopian tube: 7.6,Cell line enhanced,,RPMI-8226: 1.5;SCLC-21H: 2.4;SH-SY5Y: 1.4
645,SGTB,"FLJ39002, Sgt2",ENSG00000197860,Small glutamine rich tetratricopeptide repeat containing beta,5,65665928-65723035,Predicted intracellular proteins,Evidence at protein level,"HPA044689, HPA063674",Enhanced,,Uncertain,Nucleus,,Expressed in all,Tissue enhanced,,cerebral cortex: 52.0,appendix: 10.4,Expressed in all,,
646,SHANK2,"CORTBP1, CTTNBP1, ProSAP1, SHANK, SPANK-3",ENSG00000162105,SH3 and multiple ankyrin repeat domains 2,11,70467856-71252577,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA008174,Approved,,,,Renal cancer:1.94e-6 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 20.9,thyroid gland: 11.6,Cell line enhanced,,Karpas-707: 16.4;RT4: 16.7;T-47d: 15.1
647,SHC3,"N-Shc, NSHC, SHCC",ENSG00000148082,SHC adaptor protein 3,9,89005771-89178767,"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA031427, HPA046656, HPA072448",Uncertain,,Enhanced,Nucleoplasm<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 45.3,parathyroid gland: 12.6,Cell line enhanced,,AF22: 20.5;SH-SY5Y: 8.1;U-87 MG: 11.2
648,SHISA4,"C1orf40, hShisa4, TMEM58",ENSG00000198892,Shisa family member 4,1,201888680-201892306,Predicted membrane proteins,Evidence at protein level,HPA061273,Uncertain,,,,,Expressed in all,Tissue enhanced,,cerebral cortex: 45.3;skeletal muscle: 94.4,adrenal gland: 23.6,Mixed,,
649,SHISA9,,ENSG00000237515,Shisa family member 9,16,12901620-13240413,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:1.53e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 22.8,prostate: 7.2,Cell line enhanced,,EFO-21: 46.5;LHCN-M2: 33.9
650,SHTN1,"KIAA1598, shootin-1, shootin1",ENSG00000187164,Shootin 1,10,116881482-117126586,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA037942, HPA037943",Enhanced,Approved,Approved,Nucleus<br>Plasma membrane<br>Cytosol,"Urothelial cancer:5.08e-6 (unfavourable), Prostate cancer:5.07e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 36.1,parathyroid gland: 18.7,Mixed,,
651,SLC10A4,MGC29802,ENSG00000145248,Solute carrier family 10 member 4,4,48483343-48489196,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA028835,Uncertain,Supported,,,,Tissue enhanced,Tissue enhanced,,adrenal gland: 6.2;cerebral cortex: 4.0,"cervix, uterine: 1.5",Cell line enhanced,,HAP1: 15.2;K-562: 13.9;SH-SY5Y: 41.0
652,SLC24A4,NCKX4,ENSG00000140090,Solute carrier family 24 member 4,14,92322581-92501483,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 7.1,spleen: 2.7,Cell line enhanced,,SCLC-21H: 1.5
653,SLC25A18,,ENSG00000182902,Solute carrier family 25 member 18,22,17563439-17590994,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 74.5;liver: 25.2,adipose tissue: 13.8,Cell line enhanced,,BEWO: 8.2
654,SLC25A41,"APC4, FLJ40442, MGC34725",ENSG00000181240,Solute carrier family 25 member 41,19,6426037-6433779,"Predicted intracellular proteins, Transporters",Evidence at transcript level,HPA043591,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.0;testis: 1.9,esophagus: 0.4,Cell line enhanced,,HMC-1: 2.4;U-937: 1.3
655,SLC25A48,"FLJ44862, HDMCP",ENSG00000145832,Solute carrier family 25 member 48,5,135834649-135888637,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA014674,Uncertain,,Approved,Intermediate filaments<br>Actin filaments,,Mixed,Tissue enhanced,,cerebral cortex: 17.7;kidney: 7.3,skeletal muscle: 2.7,Cell line enhanced,,HAP1: 2.4;HEK93: 1.6;SCLC-21H: 2.0;U-2 OS: 2.3
656,SLC2A13,HMIT,ENSG00000151229,Solute carrier family 2 member 13,12,39755021-40106089,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA006584,Approved,,Approved,Nuclear membrane,,Mixed,Tissue enhanced,,cerebral cortex: 49.3;parathyroid gland: 74.7,"cervix, uterine: 20.4",Mixed,,
657,SLC35F3,FLJ37712,ENSG00000183780,Solute carrier family 35 member F3,1,233904933-234324516,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA051327, HPA061582",Uncertain,,Approved,Nucleoli<br>Golgi apparatus,,Mixed,Tissue enhanced,,cerebral cortex: 10.1,breast: 3.0,Cell line enriched,7.0,HDLM-2: 103.6
658,SLC39A10,"DKFZp564L2123, FLJ90515, KIAA1265",ENSG00000196950,Solute carrier family 39 member 10,2,195575977-195737702,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA036512, HPA036513, HPA066087",Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Glioma:2.05e-5 (favourable), Liver cancer:4.39e-5 (unfavourable), Pancreatic cancer:3.23e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 77.7;thyroid gland: 79.2,prostate: 30.8,Expressed in all,,
659,SLC45A1,DNB5,ENSG00000162426,Solute carrier family 45 member 1,1,8317826-8344167,"Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 11.7,endometrium: 3.2,Cell line enhanced,,HHSteC: 4.1;U-87 MG: 6.3
660,SLC4A8,NBC3,ENSG00000050438,Solute carrier family 4 member 8,12,51391317-51515763,Predicted membrane proteins,Evidence at protein level,HPA031536,,,Uncertain,Actin filaments,,Group enriched,Tissue enhanced,,cerebral cortex: 14.5;testis: 15.4,ovary: 4.2,Cell line enhanced,,BEWO: 20.3;SCLC-21H: 18.5
661,SLC6A11,GAT3,ENSG00000132164,Solute carrier family 6 member 11,3,10816200-10940733,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA037981,Supported,Supported,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 18.1;skin: 6.7,esophagus: 5.5,Cell line enhanced,,HaCaT: 11.8;Hep G2: 10.7;hTCEpi: 8.5;NTERA-2: 6.6
662,SLC6A15,"FLJ10316, hv7-3, NTT73, SBAT1, V7-3",ENSG00000072041,Solute carrier family 6 member 15,12,84859488-84913615,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA008609,Uncertain,,Approved,Nucleoli<br>Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 23.0,placenta: 5.5,Cell line enhanced,,ASC diff: 62.0;hTERT-HME1: 99.4;SCLC-21H: 104.6
663,SLC6A7,PROT,ENSG00000011083,Solute carrier family 6 member 7,5,150189957-150222788,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA028907,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 16.9;rectum: 4.2,colon: 2.9,Not detected,,
664,SLC7A11,xCT,ENSG00000151012,Solute carrier family 7 member 11,4,138164097-138242349,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA064215,,,Supported,Vesicles,Ovarian cancer:1.77e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 22.4,epididymis: 8.2,Expressed in all,,
665,SLC7A5,"CD98, D16S469E, E16, LAT1, MPE16",ENSG00000103257,Solute carrier family 7 member 5,16,87830023-87869488,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA052673, HPA056077",Approved,,Supported,Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Lung cancer:2.43e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 90.3;testis: 84.3,bone marrow: 66.1,Expressed in all,,
666,SLC9A6,"KIAA0267, NHE6",ENSG00000198689,Solute carrier family 9 member A6,X,135973841-136047269,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA059445, HPA059590",Enhanced,,Supported,Vesicles,,Expressed in all,Tissue enhanced,,cerebral cortex: 67.9,parathyroid gland: 16.6,Mixed,,
667,SLC9B2,"FLJ23984, NHA2, NHEDC2",ENSG00000164038,Solute carrier family 9 member B2,4,103019868-103085829,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA047008,Uncertain,,Approved,Nucleoplasm<br>Cell Junctions,,Expressed in all,Tissue enhanced,,cerebral cortex: 32.5,liver: 20.4,Mixed,,
668,SLCO1A2,"OATP, OATP-A, OATP1A2, SLC21A3",ENSG00000084453,Solute carrier organic anion transporter family member 1A2,12,21264600-21419594,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA071152,,,Supported,Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 28.7,salivary gland: 6.6,Cell line enhanced,,NTERA-2: 16.5;RPMI-8226: 8.3;U-266/70: 18.6
669,SLITRK2,"CXorf2, KIAA1854, SLITL1",ENSG00000185985,SLIT and NTRK like family member 2,X,145817832-145825842,Predicted membrane proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 25.7,seminal vesicle: 7.4,Cell line enriched,39.0,HAP1: 36.6
670,SLITRK3,KIAA0848,ENSG00000121871,SLIT and NTRK like family member 3,3,165186720-165197109,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA017636, HPA048042",Enhanced,,Approved,Mitochondria,,Tissue enriched,Tissue enhanced,,cerebral cortex: 17.3;endometrium: 12.3,fallopian tube: 9.8,Cell line enhanced,,AF22: 2.6;HAP1: 2.3;SCLC-21H: 1.7
671,SLITRK4,DKFZp547M2010,ENSG00000179542,SLIT and NTRK like family member 4,X,143622790-143635777,Predicted membrane proteins,Evidence at protein level,HPA000431,Enhanced,,Uncertain,Microtubules,,Tissue enhanced,Tissue enhanced,,adrenal gland: 13.9;cerebral cortex: 12.8,"cervix, uterine: 8.4",Cell line enhanced,,HeLa: 3.9;HHSteC: 2.5;T-47d: 8.3;U-2 OS: 3.5
672,SLITRK5,"bA364G4.2, KIAA0918, LRRC11",ENSG00000165300,SLIT and NTRK like family member 5,13,87672615-87696272,Predicted membrane proteins,Evidence at protein level,HPA013843,Uncertain,,Supported,Nucleoplasm<br>Golgi apparatus,,Not detected,Tissue enhanced,,cerebral cortex: 4.9;fallopian tube: 4.7,seminal vesicle: 1.8,Cell line enhanced,,AF22: 6.9
673,SMIM10L2A,"LED, LINC00086, MGC39606, NCRNA00086",ENSG00000178947,Small integral membrane protein 10 like 2A,X,135421943-135428074,Predicted membrane proteins,Evidence at transcript level,,,,,,"Renal cancer:8.28e-8 (favourable), Endometrial cancer:6.78e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,adrenal gland: 21.8;cerebral cortex: 22.5,epididymis: 17.6,Cell line enhanced,,AN3-CA: 4.8;HAP1: 10.7;hTCEpi: 3.9
674,SMIM10L2B,"LINC00087, NCRNA00087, RP11-85L21.2",ENSG00000196972,Small integral membrane protein 10 like 2B,X,135094987-135098634,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:2.41e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 23.9,parathyroid gland: 7.4,Cell line enhanced,,HHSteC: 1.6;HSkMC: 2.2;NTERA-2: 1.6
675,SMIM13,C6orf228,ENSG00000224531,Small integral membrane protein 13,6,11094033-11138733,Predicted membrane proteins,Evidence at protein level,HPA065706,Enhanced,,Approved,Nucleus<br>Nuclear membrane<br>Golgi apparatus,Renal cancer:1.03e-5 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 47.1,placenta: 18.9,Expressed in all,,
676,SMIM17,,ENSG00000268182,Small integral membrane protein 17,19,56643145-56655766,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA071857, HPA071861",Enhanced,,Approved,Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 8.7,epididymis: 2.0,Cell line enhanced,,AF22: 2.3;HEK93: 2.1;SCLC-21H: 2.5
677,SMOC1,,ENSG00000198732,SPARC related modular calcium binding 1,14,69854131-70032366,"Disease related genes, Predicted secreted proteins",Evidence at protein level,"HPA004153, CAB034427",Approved,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 135.8,prostate: 66.2,Cell line enhanced,,AF22: 61.2;HeLa: 115.9;SiHa: 108.4;U-266/70: 48.2;U-87 MG: 61.4
678,SMOX,"C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO",ENSG00000088826,Spermine oxidase,20,4120980-4187747,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA047117, HPA060198",Approved,,Supported,Nucleoplasm<br>Nuclear membrane<br>Vesicles,"Liver cancer:3.33e-6 (unfavourable), Renal cancer:1.06e-4 (unfavourable), Lung cancer:1.36e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 49.7,gallbladder: 23.5,Cell line enhanced,,A549: 104.6;Karpas-707: 139.7
679,SNPH,bA314N13.5,ENSG00000101298,Syntaphilin,20,1266316-1309328,Predicted membrane proteins,Evidence at protein level,HPA049393,Approved,,Uncertain,Cytokinetic bridge<br>Mitochondria,Pancreatic cancer:6.97e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 33.6,seminal vesicle: 15.6,Mixed,,
680,SNTG1,"G1SYN, SYN4",ENSG00000147481,Syntrophin gamma 1,8,49909789-50794118,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA072282,Supported,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 8.6;spleen: 3.8,testis: 1.2,Not detected,,
681,SNX10,,ENSG00000086300,Sorting nexin 10,7,26291895-26374329,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA015605, HPA064782",Approved,,Approved,Nucleus<br>Nucleoli<br>Microtubules,"Renal cancer:8.06e-5 (unfavourable), Glioma:9.81e-5 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 94.3,lung: 60.1,Cell line enhanced,,WM-115: 291.7
682,SNX22,FLJ13952,ENSG00000157734,Sorting nexin 22,15,64151715-64157481,Predicted intracellular proteins,Evidence at protein level,HPA038470,Approved,,Approved,Nucleoplasm<br>Vesicles,"Breast cancer:2.89e-5 (favourable), Thyroid cancer:2.19e-4 (favourable)",Tissue enriched,Tissue enhanced,,cerebral cortex: 16.2;thyroid gland: 14.4,lymph node: 9.0,Cell line enhanced,,Daudi: 13.5;SCLC-21H: 4.9
683,SNX32,"FLJ30934, SNX6B",ENSG00000172803,Sorting nexin 32,11,65833641-65856896,Predicted intracellular proteins,Evidence at protein level,HPA041775,Uncertain,,Uncertain,Cell Junctions<br>Focal adhesion sites,,Mixed,Tissue enhanced,,cerebral cortex: 7.7,testis: 1.8,Cell line enhanced,,HHSteC: 3.0;HSkMC: 3.4;SH-SY5Y: 1.9;U-266/70: 4.3
684,SOBP,FLJ10159,ENSG00000112320,Sine oculis binding protein homolog,6,107489958-107660167,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA029242,Uncertain,,Approved,Nucleoplasm<br>Vesicles,Pancreatic cancer:1.55e-5 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 26.4,ovary: 13.7,Cell line enhanced,,AF22: 12.5;AN3-CA: 15.3
685,SORCS1,sorCS1,ENSG00000108018,Sortilin related VPS10 domain containing receptor 1,10,106573663-107164534,Predicted membrane proteins,Evidence at protein level,HPA011948,Approved,,Approved,Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 12.2;thyroid gland: 18.1,kidney: 4.8,Group enriched,12.0,RH-30: 78.2;SH-SY5Y: 111.4
686,SORCS2,KIAA1329,ENSG00000184985,Sortilin related VPS10 domain containing receptor 2,4,7192538-7742836,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA061916,,,Approved,Nucleus<br>Cytosol,"Renal cancer:3.09e-4 (unfavourable), Ovarian cancer:3.55e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 19.3,"cervix, uterine: 10.4",Cell line enhanced,,HaCaT: 17.3;HMC-1: 12.7;SiHa: 15.0
687,SORCS3,"KIAA1059, SORCS",ENSG00000156395,Sortilin related VPS10 domain containing receptor 3,10,104641101-105265235,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,Renal cancer:5.72e-4 (unfavourable),Group enriched,Tissue enhanced,,cerebral cortex: 11.9,adrenal gland: 2.6,Not detected,,
688,SOX10,"DOM, WS2E, WS4",ENSG00000100146,SRY-box 10,22,37970686-37987422,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB003171, HPA068898",Enhanced,,Supported,Nucleoplasm,,Not detected,Tissue enhanced,,cerebral cortex: 56.6;salivary gland: 50.5,breast: 24.0,Group enriched,686.0,SK-MEL-30: 236.8;WM-115: 425.1
689,SPOCK1,"SPOCK, testican-1, TIC1",ENSG00000152377,"SPARC/osteonectin, cwcv and kazal like domains proteoglycan 1",5,136975298-137598379,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA007450, HPA026770",Uncertain,,Approved,Vesicles,"Head and neck cancer:1.93e-5 (unfavourable), Renal cancer:3.77e-5 (unfavourable), Colorectal cancer:1.93e-4 (unfavourable), Ovarian cancer:4.72e-4 (unfavourable), Lung cancer:9.08e-4 (unfavourable), Stomach cancer:9.40e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,cerebral cortex: 209.2,prostate: 108.0,Cell line enhanced,,AF22: 299.3;ASC diff: 403.2;HUVEC TERT2: 508.1;U-138 MG: 298.1
690,SPOCK2,"KIAA0275, testican-2",ENSG00000107742,"SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2",10,72059035-72089032,Predicted secreted proteins,Evidence at protein level,HPA044605,Supported,,Uncertain,Nuclear speckles,"Head and neck cancer:1.95e-5 (favourable), Breast cancer:4.05e-4 (favourable), Melanoma:4.72e-4 (favourable), Ovarian cancer:7.19e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 161.8;lung: 127.8,lymph node: 75.1,Group enriched,8.0,Hep G2: 33.9;SCLC-21H: 79.9
691,SPRED3,,ENSG00000188766,Sprouty related EVH1 domain containing 3,19,38388421-38399587,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA071521,,,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.6,parathyroid gland: 2.6,Cell line enhanced,,TIME: 12.9
692,SPSB4,SSB-4,ENSG00000175093,SplA/ryanodine receptor domain and SOCS box containing 4,3,141051402-141148611,Predicted intracellular proteins,Evidence at protein level,HPA062793,,,Approved,Nucleoplasm<br>Golgi apparatus,Glioma:2.57e-4 (favourable),Group enriched,Tissue enhanced,,cerebral cortex: 1.3;spleen: 1.5;testis: 2.4,pancreas: 1.2,Cell line enhanced,,AF22: 12.9;NTERA-2: 3.7;RH-30: 4.3;SH-SY5Y: 3.9;U-2 OS: 3.1
693,SPTBN2,SCA5,ENSG00000173898,"Spectrin beta, non-erythrocytic 2",11,66685248-66729226,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009844, HPA039293, HPA043529",Enhanced,,Supported,Cell Junctions<br>Cytosol,Pancreatic cancer:3.14e-5 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 73.0;skin: 59.3;testis: 48.4,parathyroid gland: 24.6,Cell line enhanced,,NTERA-2: 49.7;SCLC-21H: 59.4
694,SRCIN1,"KIAA1684, p140Cap, SNIP",ENSG00000277363,SRC kinase signaling inhibitor 1,17,38530016-38605930,Predicted intracellular proteins,Evidence at protein level,"HPA009701, HPA063795",Enhanced,,Approved,Cell Junctions,Urothelial cancer:1.76e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 22.1,skin: 4.7,Cell line enriched,5.0,SCLC-21H: 14.7
695,SRGAP3,"ARHGAP14, KIAA0411, MEGAP, SRGAP2, WRP",ENSG00000196220,SLIT-ROBO Rho GTPase activating protein 3,3,8980591-9363053,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA036959, HPA044074",Enhanced,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,cerebral cortex: 26.5;fallopian tube: 17.4,"cervix, uterine: 7.9",Cell line enhanced,,AF22: 8.9;HBEC3-KT: 5.7;RT4: 8.6;T-47d: 9.6
696,SST,SMST,ENSG00000157005,Somatostatin,3,187668906-187670399,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000075, HPA019472, CAB034105",Enhanced,Supported,,,Endometrial cancer:1.93e-5 (unfavourable),Group enriched,Tissue enhanced,,cerebral cortex: 211.9;duodenum: 376.3;stomach: 305.7,small intestine: 142.4,Group enriched,5.0,EFO-21: 20.9;U-2 OS: 42.8
697,SSTR1,,ENSG00000139874,Somatostatin receptor 1,14,38207999-38213067,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA031506,Approved,,,,Renal cancer:4.28e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 13.6;duodenum: 14.2;stomach: 21.4,small intestine: 9.1,Cell line enhanced,,BJ: 102.5;BJ hTERT+: 27.1;fHDF/TERT166: 56.0
698,SSTR2,,ENSG00000180616,Somatostatin receptor 2,17,73165012-73176633,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA007264,Uncertain,,Supported,Cytosol,"Renal cancer:9.04e-7 (unfavourable), Pancreatic cancer:6.63e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 22.9,spleen: 5.8,Cell line enriched,9.0,SCLC-21H: 14.9
699,ST6GAL2,"KIAA1877, SIAT2, St6gal2, St6GalII",ENSG00000144057,"ST6 beta-galactoside alpha-2,6-sialyltransferase 2",2,106801600-106887108,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014459,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center,,Tissue enriched,Tissue enhanced,,cerebral cortex: 22.1;thyroid gland: 47.9,testis: 9.8,Cell line enhanced,,A549: 4.8;PC-3: 5.5;RPMI-8226: 6.7;SCLC-21H: 7.2;U-138 MG: 7.4;U-266/70: 7.5
700,ST8SIA2,"HsT19690, SIAT8B, ST8SIA-II, STX",ENSG00000140557,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2",15,92393828-92468728,Predicted secreted proteins,Evidence at protein level,HPA054518,Approved,,Approved,Microtubule organizing center,,Mixed,Tissue enhanced,,cerebral cortex: 2.1;heart muscle: 2.4,"cervix, uterine: 1.2",Cell line enhanced,,AF22: 25.4;LHCN-M2: 6.4;RH-30: 11.3;RPMI-8226: 6.1;WM-115: 7.1
701,ST8SIA5,SIAT8E,ENSG00000101638,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5",18,46667821-46759257,Predicted membrane proteins,Evidence at protein level,"HPA043813, HPA046771",Approved,,Approved,Plasma membrane<br>Midbody,,Tissue enriched,Tissue enhanced,,adrenal gland: 5.5;cerebral cortex: 11.4,parathyroid gland: 3.4,Cell line enriched,7.0,WM-115: 121.0
702,STH,MAPTIT,ENSG00000256762,Saitohin,17,45999250-45999694,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.4,placenta: 0.5,Not detected,,
703,STMN3,SCLIP,ENSG00000197457,Stathmin 3,20,63639705-63657682,Predicted intracellular proteins,Evidence at protein level,HPA012947,Enhanced,,,,,Expressed in all,Tissue enhanced,,cerebral cortex: 225.7,thyroid gland: 52.6,Cell line enhanced,,SCLC-21H: 225.8;SH-SY5Y: 155.0
704,STOX2,DKFZp762K222,ENSG00000173320,Storkhead box 2,4,183797692-184023526,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA049776, HPA065002",Uncertain,,Uncertain,Nucleoplasm<br>Actin filaments<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 17.4,parathyroid gland: 11.5,Cell line enhanced,,AF22: 13.0;NTERA-2: 16.8;SH-SY5Y: 16.8
705,STRC,DFNB16,ENSG00000242866,Stereocilin,15,43599398-43618800,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048083,Enhanced,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.4;epididymis: 1.6;testis: 1.7,skin: 0.8,Not detected,,
706,STRIP2,"FAM40B, FAR11B, KIAA1170",ENSG00000128578,Striatin interacting protein 2,7,129434433-129488399,Predicted intracellular proteins,Evidence at protein level,HPA019657,Uncertain,,Supported,Cytosol,"Stomach cancer:5.41e-4 (favourable), Lung cancer:6.78e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 13.9;testis: 23.5,skeletal muscle: 9.7,Mixed,,
707,STUM,"C1orf95, DKFZp761P211",ENSG00000203685,"Stum, mechanosensory transduction mediator homolog",1,226548800-226609214,Predicted membrane proteins,Evidence at protein level,HPA074381,,,Approved,Cytosol,Renal cancer:6.40e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 35.7,smooth muscle: 8.4,Cell line enriched,5.0,HEL: 26.9
708,STXBP5L,"KIAA1006, LLGL4",ENSG00000145087,Syntaxin binding protein 5 like,3,120908072-121424761,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 15.7;ovary: 12.3;thyroid gland: 14.1,seminal vesicle: 4.8,Cell line enhanced,,AF22: 6.5;MOLT-4: 5.3;SCLC-21H: 10.6;SH-SY5Y: 4.2
709,SV2A,"KIAA0736, SV2",ENSG00000159164,Synaptic vesicle glycoprotein 2A,1,149903318-149917882,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB002226, HPA007863",Enhanced,,Approved,Cytosol,Renal cancer:3.22e-4 (unfavourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 166.9;parathyroid gland: 72.0,epididymis: 28.2,Cell line enhanced,,NTERA-2: 65.6;SCLC-21H: 63.2
710,SV2C,,ENSG00000122012,Synaptic vesicle glycoprotein 2C,5,76083172-76353939,Predicted membrane proteins,Evidence at protein level,"HPA040722, HPA040770",Supported,,Supported,Nucleoplasm<br>Vesicles,,Not detected,Tissue enhanced,,adrenal gland: 1.6;cerebral cortex: 3.4,"fallopian tube,ovary: 0.6",Cell line enhanced,,Karpas-707: 6.5;SCLC-21H: 4.3;SH-SY5Y: 9.0
711,SYBU,"FLJ20366, GOLSYN, KIAA1472, OCSYN, SNPHL",ENSG00000147642,Syntabulin,8,109573978-109691791,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA053057,Uncertain,,Supported,Vesicles,Liver cancer:7.74e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 76.0,adrenal gland: 40.7,Cell line enhanced,,HaCaT: 20.2;PC-3: 23.7;SCLC-21H: 20.0;SK-BR-3: 38.8
712,SYN3,,ENSG00000185666,Synapsin III,22,32512552-33058372,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA034566,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 9.5;testis: 7.9,placenta: 4.2,Cell line enhanced,,HAP1: 5.8;NTERA-2: 3.7;SCLC-21H: 8.6
713,SYNDIG1,"C20orf39, FLJ14220, IFITMD5, SynDIG1, TMEM90B",ENSG00000101463,Synapse differentiation inducing 1,20,24469199-24666616,Predicted membrane proteins,Evidence at protein level,"HPA044271, HPA059267",,,Supported,Vesicles,Thyroid cancer:6.16e-6 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 26.9,heart muscle: 14.4,Group enriched,9.0,Karpas-707: 9.0;RH-30: 34.5;RPMI-8226: 24.4;SCLC-21H: 9.7;U-87 MG: 21.0
714,SYNGAP1,"KIAA1938, RASA5, SYNGAP",ENSG00000197283,Synaptic Ras GTPase activating protein 1,6,33419661-33457541,"Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA038373,Enhanced,,Approved,Nucleus,"Renal cancer:1.34e-6 (unfavourable), Head and neck cancer:2.80e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 26.3,endometrium: 12.5,Cell line enhanced,,AF22: 28.5
715,SYNJ1,"INPP5G, PARK20",ENSG00000159082,Synaptojanin 1,21,32628759-32728048,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA011916,Enhanced,,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,"Prostate cancer:2.58e-4 (unfavourable), Head and neck cancer:4.43e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 65.9,testis: 18.4,Expressed in all,,
716,SYT13,KIAA1427,ENSG00000019505,Synaptotagmin 13,11,45240301-45286319,Predicted intracellular proteins,Evidence at protein level,"HPA046224, HPA056602",Uncertain,,Supported,Vesicles,Endometrial cancer:7.79e-5 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 69.9;gallbladder: 32.9,small intestine: 14.4,Group enriched,9.0,A549: 17.3;NTERA-2: 8.8;RPTEC TERT1: 43.3;SCLC-21H: 17.8
717,SYT17,,ENSG00000103528,Synaptotagmin 17,16,19167971-19268334,Predicted intracellular proteins,Evidence at protein level,HPA042059,,,Approved,Nucleus<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 39.8;parathyroid gland: 32.6,prostate: 14.9,Cell line enhanced,,BEWO: 13.7;CAPAN-2: 24.6;MCF7: 16.6
718,SYT2,,ENSG00000143858,Synaptotagmin 2,1,202590596-202710417,"Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"HPA030372, HPA063655",Enhanced,Supported,Approved,Vesicles,,Tissue enriched,Tissue enhanced,,adrenal gland: 1.8;cerebral cortex: 2.1,"epididymis,testis: 1.0",Cell line enhanced,,AF22: 8.4;NTERA-2: 5.8;U-2 OS: 1.8
719,SYT4,"HsT1192, KIAA1342",ENSG00000132872,Synaptotagmin 4,18,43267878-43277650,Predicted intracellular proteins,Evidence at protein level,HPA010574,Approved,,Supported,Vesicles<br>Plasma membrane,,Tissue enhanced,Tissue enhanced,,adrenal gland: 20.4;cerebral cortex: 82.5,seminal vesicle: 11.3,Cell line enriched,10.0,SH-SY5Y: 251.0
720,SYT6,,ENSG00000134207,Synaptotagmin 6,1,114089291-114153919,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058362,,,Uncertain,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.5,kidney: 1.5,Group enriched,7.0,NTERA-2: 23.0;WM-115: 16.3
721,SYT7,"IPCA-7, MGC150517, PCANAP7, SYT-VII",ENSG00000011347,Synaptotagmin 7,11,61515313-61581148,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012869,Enhanced,,,,"Renal cancer:1.16e-4 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 108.7;prostate: 84.8,placenta: 26.6,Cell line enhanced,,hTERT-HME1: 68.9;RT4: 30.1;SCLC-21H: 34.3;SK-BR-3: 31.0;T-47d: 38.2
722,SYT9,,ENSG00000170743,Synaptotagmin 9,11,7238778-7469042,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.1;seminal vesicle: 5.1,adrenal gland: 2.7,Cell line enhanced,,HEK93: 9.6;RT4: 14.7;SH-SY5Y: 14.3;TIME: 16.8
723,TAC1,"NKNA, NPK, TAC2",ENSG00000006128,Tachykinin precursor 1,7,97731908-97740472,Predicted secreted proteins,Evidence at protein level,"CAB004588, HPA014429",Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 77.7;spleen: 47.0,appendix: 13.2,Cell line enriched,14.0,U-266/70: 16.5
724,TCEAL2,"my048, MY0876G05, WEX1",ENSG00000184905,Transcription elongation factor A like 2,X,102125688-102127711,Predicted intracellular proteins,Evidence at protein level,HPA076317,,,Approved,Nuclear speckles<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 191.7,ovary: 77.7,Cell line enhanced,,HAP1: 6.0;SCLC-21H: 7.3;U-2 OS: 11.7
725,TCEAL7,"MGC23947, WEX5",ENSG00000182916,Transcription elongation factor A like 7,X,103330196-103332326,Predicted intracellular proteins,Evidence at protein level,"HPA051507, HPA065080",Enhanced,,Supported,Nucleus,"Stomach cancer:3.53e-4 (unfavourable), Renal cancer:4.31e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,cerebral cortex: 145.6,endometrium: 76.7,Cell line enhanced,,hTEC/SVTERT24-B: 81.8;SCLC-21H: 242.8
726,TECTA,"DFNA12, DFNA8, DFNB21",ENSG00000109927,Tectorin alpha,11,121101173-121191493,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA018870,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 2.7,parathyroid gland: 2.0,Cell line enhanced,,SH-SY5Y: 1.5
727,TENM2,"KIAA1127, ODZ2, Ten-M2",ENSG00000145934,Teneurin transmembrane protein 2,5,167284799-168264157,Predicted membrane proteins,Evidence at protein level,"HPA038018, HPA038420, HPA068691",Uncertain,,Approved,Nucleoli,Urothelial cancer:7.52e-4 (unfavourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 9.0;heart muscle: 17.1,prostate: 3.6,Cell line enhanced,,fHDF/TERT166: 51.2;HBEC3-KT: 30.8;HDLM-2: 40.1;U-138 MG: 73.5;U-2 OS: 67.5;U-251 MG: 41.3
728,THY1,CD90,ENSG00000154096,Thy-1 cell surface antigen,11,119417378-119424985,"CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA003733, CAB068243, CAB068244",Enhanced,,Approved,Nucleus<br>Plasma membrane,"Renal cancer:2.40e-6 (unfavourable), Glioma:9.64e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 421.8;smooth muscle: 434.2,gallbladder: 161.0,Cell line enhanced,,BJ: 643.3;BJ hTERT+: 686.4;fHDF/TERT166: 1040.5
729,TIAM2,STEF,ENSG00000146426,T-cell lymphoma invasion and metastasis 2,6,154832697-155257723,Predicted intracellular proteins,Evidence at protein level,"HPA011134, HPA013903",Approved,,Supported,Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 18.0;testis: 24.4,thyroid gland: 10.2,Cell line enhanced,,AF22: 62.0;HDLM-2: 27.3;RH-30: 39.8
730,TLL2,,ENSG00000095587,Tolloid like 2,10,96364606-96513918,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 1.9,heart muscle: 1.0,Cell line enriched,8.0,RPTEC TERT1: 15.3
731,TLN2,"ILWEQ, KIAA0320",ENSG00000171914,Talin 2,15,62390526-62844631,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017194, HPA051828, HPA054787",Enhanced,,Supported,Focal adhesion sites<br>Cytosol,"Renal cancer:1.81e-6 (favourable), Breast cancer:6.53e-4 (favourable), Stomach cancer:7.74e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 41.2;kidney: 41.1,thyroid gland: 21.7,Mixed,,
732,TMCC2,"FLJ38497, HUCEP11",ENSG00000133069,Transmembrane and coiled-coil domain family 2,1,205228176-205273343,Predicted membrane proteins,Evidence at protein level,HPA014254,Approved,,,,,Mixed,Tissue enhanced,,bone marrow: 52.4;cerebral cortex: 15.1,placenta: 7.8,Cell line enhanced,,SCLC-21H: 41.5
733,TMEFF2,"CT120.2, HPP1, TENB2, TPEF, TR",ENSG00000144339,Transmembrane protein with EGF like and two follistatin like domains 2,2,191949043-192195709,Predicted membrane proteins,Evidence at protein level,HPA015587,Uncertain,,Uncertain,Microtubules<br>Cytokinetic bridge,,Tissue enriched,Tissue enhanced,,cerebral cortex: 41.0;prostate: 64.1,seminal vesicle: 19.6,Group enriched,6.0,AF22: 38.8;LHCN-M2: 94.7
734,TMEM108,"CT124, MGC3040",ENSG00000144868,Transmembrane protein 108,3,133038391-133397792,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA063350,Uncertain,,Approved,Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 21.9;testis: 25.8,adrenal gland: 15.0,Cell line enhanced,,HMC-1: 21.3;SCLC-21H: 24.8;SH-SY5Y: 98.2
735,TMEM121,"hole, MGC4659",ENSG00000184986,Transmembrane protein 121,14,105526603-105530202,Predicted membrane proteins,Evidence at transcript level,HPA049857,Uncertain,,Approved,Cytosol,Thyroid cancer:5.87e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 4.8,spleen: 2.4,Cell line enhanced,,EFO-21: 7.7;MCF7: 6.1;PC-3: 9.5;REH: 6.1;SCLC-21H: 6.2
736,TMEM132A,"FLJ20539, GBP, HSPA5BP1",ENSG00000006118,Transmembrane protein 132A,11,60924463-60937159,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA051979, HPA060492",Enhanced,,Approved,Mitochondria,"Renal cancer:1.55e-9 (unfavourable), Endometrial cancer:1.98e-5 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 94.2,placenta: 25.0,Cell line enhanced,,EFO-21: 167.6
737,TMEM144,FLJ11155,ENSG00000164124,Transmembrane protein 144,4,158201604-158255411,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA063554,,,Approved,Mitochondria,"Endometrial cancer:2.89e-4 (favourable), Pancreatic cancer:8.48e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 90.5,testis: 46.9,Cell line enhanced,,BEWO: 32.7
738,TMEM169,FLJ34263,ENSG00000163449,Transmembrane protein 169,2,216081866-216102783,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA062462, HPA062797, HPA070657",Uncertain,,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 12.0,thyroid gland: 4.8,Cell line enhanced,,AF22: 8.9;RPTEC TERT1: 10.0;SCLC-21H: 13.4;SH-SY5Y: 17.3
739,TMEM170B,,ENSG00000205269,Transmembrane protein 170B,6,11538278-11583524,Predicted membrane proteins,Evidence at transcript level,HPA055134,Uncertain,,Approved,Centrosome,,Mixed,Tissue enhanced,,cerebral cortex: 21.3,bone marrow: 16.8,Cell line enhanced,,THP-1: 15.8
740,TMEM178A,"MGC33926, TMEM178",ENSG00000152154,Transmembrane protein 178A,2,39664982-39717963,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at transcript level,HPA052128,Uncertain,,Approved,Nucleus<br>Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 55.4,kidney: 19.3,Cell line enhanced,,AF22: 137.1;NTERA-2: 17.7;SCLC-21H: 30.2
741,TMEM178B,DKFZp547G036,ENSG00000261115,Transmembrane protein 178B,7,141074232-141480380,Predicted membrane proteins,Evidence at protein level,HPA048771,Uncertain,,Uncertain,Nucleoli<br>Vesicles,Renal cancer:4.10e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 19.3;parathyroid gland: 28.9;thyroid gland: 14.4,heart muscle: 7.2,Cell line enhanced,,HAP1: 6.3;RPTEC TERT1: 6.3;SCLC-21H: 7.7;WM-115: 8.9
742,TMEM196,MGC42090,ENSG00000173452,Transmembrane protein 196,7,19719310-19773598,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA043163,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.2,endometrium: 2.2,Group enriched,7.0,ASC diff: 3.1;ASC TERT1: 3.1
743,TMEM198,"MGC99813, TMEM198A",ENSG00000188760,Transmembrane protein 198,2,219543663-219550595,Predicted membrane proteins,Evidence at protein level,"HPA042385, HPA056598",Uncertain,,Approved,Vesicles,Pancreatic cancer:6.89e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 15.7,duodenum: 8.9,Cell line enhanced,,SCLC-21H: 23.4;SH-SY5Y: 18.3
744,TMEM200C,TTMA,ENSG00000206432,Transmembrane protein 200C,18,5882072-5895955,Predicted membrane proteins,Evidence at protein level,"HPA047253, HPA050490",Uncertain,,Approved,Microtubules,,Tissue enhanced,Tissue enhanced,,adrenal gland: 3.1;cerebral cortex: 3.5,salivary gland: 1.7,Cell line enhanced,,AF22: 6.1;NTERA-2: 4.7;PC-3: 20.4;U-2 OS: 11.5
745,TMEM206,"C1orf75, FLJ10874",ENSG00000065600,Transmembrane protein 206,1,212363931-212414901,Predicted membrane proteins,Evidence at protein level,HPA008540,Uncertain,,,,Liver cancer:3.71e-5 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 25.4,kidney: 10.7,Expressed in all,,
746,TMEM229A,,ENSG00000234224,Transmembrane protein 229A,7,124030916-124033023,Predicted membrane proteins,Evidence at protein level,HPA056391,Uncertain,,Approved,Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 7.1;duodenum: 8.6;testis: 10.4,small intestine: 4.4,Cell line enriched,46.0,SH-SY5Y: 141.7
747,TMEM240,"C1orf70, SCA21",ENSG00000205090,Transmembrane protein 240,1,1535174-1540453,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA066721,Supported,,,,Pancreatic cancer:2.52e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 18.6,endometrium: 7.7,Cell line enhanced,,SCLC-21H: 12.1;SH-SY5Y: 13.3
748,TMEM244,"bA174C7.4, C6orf191",ENSG00000203756,Transmembrane protein 244,6,129831244-129861547,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.7,lymph node: 0.6,Cell line enhanced,,HDLM-2: 4.4;LHCN-M2: 4.4;U-251 MG: 3.4;U-266/70: 2.9;WM-115: 2.6
749,TMEM266,"C15orf27, FLJ38190",ENSG00000169758,Transmembrane protein 266,15,76059837-76229121,Predicted membrane proteins,Evidence at protein level,"HPA041921, HPA049425",Enhanced,,Supported,Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 1.9;skeletal muscle: 1.5,placenta: 1.2,Cell line enhanced,,NTERA-2: 1.0
750,TMEM35A,"FLJ14084, TMEM35",ENSG00000126950,Transmembrane protein 35A,X,101078720-101096364,Predicted membrane proteins,Evidence at protein level,HPA048583,Enhanced,,Supported,Vesicles<br>Focal adhesion sites<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 42.4;seminal vesicle: 65.5,prostate: 33.7,Cell line enhanced,,HUVEC TERT2: 40.2;SH-SY5Y: 12.9
751,TMEM63C,"C14orf171, CSC1, DKFZp434P0111, hsCSC1",ENSG00000165548,Transmembrane protein 63C,14,77116568-77259495,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA030657,Uncertain,,Approved,Centrosome,,Mixed,Tissue enhanced,,adrenal gland: 12.9;cerebral cortex: 18.5;testis: 13.8,epididymis: 5.6,Cell line enhanced,,Daudi: 13.3;Karpas-707: 17.4;SCLC-21H: 38.5;SK-BR-3: 21.9
752,TMEM74,"FLJ30668, NET36",ENSG00000164841,Transmembrane protein 74,8,108606850-108787615,Predicted membrane proteins,Evidence at protein level,HPA015672,Uncertain,,Approved,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 6.2,heart muscle: 1.6,Cell line enhanced,,HEK93: 3.6;NTERA-2: 4.9;SCLC-21H: 12.4
753,TMIE,DFNB6,ENSG00000181585,Transmembrane inner ear,3,46701333-46710886,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA038298,Uncertain,,Uncertain,Vesicles<br>Cytosol,,Tissue enriched,Tissue enhanced,,adrenal gland: 7.4;cerebral cortex: 5.2,testis: 1.6,Cell line enhanced,,CAPAN-2: 2.2;EFO-21: 2.1;SH-SY5Y: 2.3
754,TMPRSS5,"MGC141886, MGC148044",ENSG00000166682,"Transmembrane protease, serine 5",11,113687550-113706373,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA010992,,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 10.1,salivary gland: 3.0,Cell line enhanced,,CAPAN-2: 2.9;WM-115: 2.6
755,TNFSF18,"AITRL, hGITRL, TL6",ENSG00000120337,Tumor necrosis factor superfamily member 18,1,173039960-173050963,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 2.8;gallbladder: 3.0,parathyroid gland: 1.4,Group enriched,11.0,EFO-21: 48.3;HUVEC TERT2: 65.6;TIME: 89.7
756,TPBGL,,ENSG00000261594,Trophoblast glycoprotein-like,11,75240905-75243697,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 3.1;testis: 5.0,adrenal gland: 2.3,Cell line enhanced,,AF22: 1.5;HMC-1: 1.7;SCLC-21H: 2.2
757,TPH2,"FLJ37295, NTPH",ENSG00000139287,Tryptophan hydroxylase 2,12,71938846-72186618,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA046274, CAB078198",Enhanced,Supported,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.0,testis: 0.2,Not detected,,
758,TREM2,"TREM-2, Trem2a, Trem2b, Trem2c",ENSG00000095970,Triggering receptor expressed on myeloid cells 2,6,41158506-41163186,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA010917, HPA012571",Approved,,,,Liver cancer:4.24e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 37.0;lung: 40.5,adrenal gland: 16.1,Cell line enhanced,,HBEC3-KT: 9.0;hTCEpi: 49.6;THP-1: 26.6
759,TRIL,KIAA0644,ENSG00000255690,TLR4 interactor with leucine rich repeats,7,28953358-28958292,Predicted membrane proteins,Evidence at protein level,,,,,,"Endometrial cancer:3.23e-4 (unfavourable), Ovarian cancer:8.52e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 24.9,kidney: 5.7,Cell line enhanced,,AF22: 22.0;SH-SY5Y: 42.6;SK-BR-3: 26.9;T-47d: 14.9
760,TRIM2,"CMT2R, KIAA0517, RNF86",ENSG00000109654,Tripartite motif containing 2,4,153152342-153339320,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035853, HPA035854",Enhanced,,Approved,Centrosome,Renal cancer:6.58e-14 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 155.1,thyroid gland: 110.7,Cell line enhanced,,AF22: 68.3
761,TRIM46,"FLJ23229, TRIFIC",ENSG00000163462,Tripartite motif containing 46,1,155173787-155184971,Predicted intracellular proteins,Evidence at protein level,"HPA030389, HPA055583",Enhanced,,Approved,Intermediate filaments<br>Cytosol,Endometrial cancer:2.61e-7 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 7.9;epididymis: 4.0,smooth muscle: 1.5,Cell line enhanced,,SH-SY5Y: 11.1
762,TRO,"KIAA1114, MAGE-D3, MAGED3",ENSG00000067445,Trophinin,X,54920462-54931431,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA053358,,,Approved,Nucleus<br>Nucleoli fibrillar center,"Endometrial cancer:4.41e-5 (unfavourable), Pancreatic cancer:1.93e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 30.0,endometrium: 22.2,Cell line enhanced,,AF22: 36.8;SCLC-21H: 29.3;SH-SY5Y: 35.5
763,TRPC5,PPP1R159,ENSG00000072315,Transient receptor potential cation channel subfamily C member 5,X,111774315-112082776,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 1.9,liver: 0.4,Cell line enriched,5.0,NTERA-2: 1.7
764,TSPAN5,"NET-4, TM4SF9, Tspan-5",ENSG00000168785,Tetraspanin 5,4,98470367-98658629,Predicted membrane proteins,Evidence at protein level,,,,,,"Renal cancer:7.83e-5 (unfavourable), Stomach cancer:8.56e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 75.9,ovary: 57.2,Mixed,,
765,TTLL7,FLJ23033,ENSG00000137941,Tubulin tyrosine ligase like 7,1,83865028-83999150,Predicted intracellular proteins,Evidence at protein level,"HPA052249, HPA059321",Uncertain,,Approved,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 46.8,smooth muscle: 10.8,Cell line enhanced,,HDLM-2: 26.3;RH-30: 21.3;SCLC-21H: 16.4
766,TUBB4A,"beta-5, DYT4, TUBB4",ENSG00000104833,Tubulin beta 4A class IVa,19,6494319-6502848,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB010768, HPA043640, HPA046280",Approved,,Supported,Microtubules,Endometrial cancer:8.42e-7 (unfavourable),Group enriched,Tissue enhanced,,adrenal gland: 137.6;cerebral cortex: 554.4,testis: 102.4,Cell line enhanced,,AN3-CA: 82.5;HAP1: 52.9;HEL: 69.1
767,TUNAR,"HI-LNC78, LINC00617, TUNA",ENSG00000250366,TCL1 upstream neural differentiation-associated RNA,14,95876392-95925571,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:1.55e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 4.0;endometrium: 1.8;fallopian tube: 2.5,seminal vesicle: 1.3,Cell line enhanced,,AF22: 3.2;NTERA-2: 6.8;SCLC-21H: 7.9
768,TVP23A,"FAM18A, YDR084C",ENSG00000166676,Trans-golgi network vesicle protein 23 homolog A,16,10760919-10818794,Predicted membrane proteins,Evidence at transcript level,HPA060582,Uncertain,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.3,ovary: 3.2,Cell line enhanced,,SH-SY5Y: 2.2
769,TYRO3,"Brt, Dtk, Etk-2, Rek, RSE, Sky, Tif",ENSG00000092445,TYRO3 protein tyrosine kinase,15,41557675-41583586,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA071245,Approved,,,,,Expressed in all,Tissue enhanced,,cerebral cortex: 67.4;ovary: 61.6,testis: 37.0,Cell line enhanced,,BEWO: 66.6
770,UBE2QL1,FLJ25076,ENSG00000215218,Ubiquitin conjugating enzyme E2 Q family like 1,5,6448623-6494909,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA057414,,,Supported,Nucleus<br>Plasma membrane,Renal cancer:6.81e-8 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 41.8,seminal vesicle: 10.4,Cell line enhanced,,Karpas-707: 29.4;PC-3: 32.0;SCLC-21H: 37.2;U-266/70: 57.9;U-266/84: 50.5
771,UGT8,CGT,ENSG00000174607,UDP glycosyltransferase 8,4,114598455-114678224,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA014405, HPA065785",Approved,,Approved,Mitochondria,Renal cancer:8.55e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 101.0,kidney: 29.8,Cell line enhanced,,CAPAN-2: 44.4;RPTEC TERT1: 37.0;SCLC-21H: 32.8
772,UNC5D,"KIAA1777, Unc5h4",ENSG00000156687,Unc-5 netrin receptor D,8,35235457-35796550,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA042940,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.2;duodenum: 6.1;prostate: 8.3,"cervix, uterine: 3.4",Cell line enhanced,,HEK93: 2.7;NTERA-2: 9.6;SH-SY5Y: 3.5;U-251 MG: 2.5
773,UNC79,KIAA1409,ENSG00000133958,Unc-79 homolog (C. elegans),14,93333219-93707876,Predicted membrane proteins,Evidence at protein level,HPA071881,,,Approved,Nucleus<br>Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 5.2;testis: 3.0,adrenal gland: 1.0,Cell line enhanced,,REH: 3.9;SCLC-21H: 3.6;SH-SY5Y: 2.0;U-937: 1.2
774,UNC80,"C2orf21, FLJ33496, KIAA1843, UNC-80",ENSG00000144406,"Unc-80 homolog, NALCN activator",2,209771993-209999300,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA042472,Enhanced,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,adrenal gland: 5.1;cerebral cortex: 15.8;testis: 5.2,gallbladder: 1.9,Cell line enhanced,,AF22: 2.4;SCLC-21H: 4.7;SH-SY5Y: 2.4
775,VAX1,,ENSG00000148704,Ventral anterior homeobox 1,10,117128521-117138301,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA028946,Uncertain,,Approved,Nucleus<br>Nucleoli,,Not detected,Tissue enhanced,,cerebral cortex: 1.4,testis: 0.4,Group enriched,8.0,A-431: 2.9;WM-115: 2.4
776,VAX2,DRES93,ENSG00000116035,Ventral anterior homeobox 2,2,70900590-70933446,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA009708,,,Approved,Nuclear speckles,,Mixed,Tissue enhanced,,cerebral cortex: 3.2,"adipose tissue,adrenal gland,breast,endometrium: 0.7",Cell line enhanced,,SH-SY5Y: 7.0
777,VSTM2A,"MGC33530, VSTM2",ENSG00000170419,V-set and transmembrane domain containing 2A,7,54542325-54571080,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA021404, HPA024134",Uncertain,,,,Renal cancer:5.34e-4 (favourable),Tissue enhanced,Tissue enhanced,,adrenal gland: 12.7;cerebral cortex: 40.8;prostate: 15.5,stomach: 4.8,Cell line enhanced,,Karpas-707: 1.3;SCLC-21H: 6.9;SH-SY5Y: 4.3
778,VSTM2L,"C20orf102, dJ1118M15.2",ENSG00000132821,V-set and transmembrane domain containing 2 like,20,37903104-37945350,Predicted secreted proteins,Evidence at protein level,HPA043832,Uncertain,,,,"Endometrial cancer:1.63e-5 (unfavourable), Urothelial cancer:8.14e-4 (unfavourable)",Group enriched,Tissue enhanced,,cerebral cortex: 55.1,gallbladder: 26.8,Cell line enhanced,,CAPAN-2: 58.1;HDLM-2: 86.5;SK-BR-3: 59.9
779,WASF3,"KIAA0900, SCAR3, WAVE3",ENSG00000132970,WAS protein family member 3,13,26557703-26688948,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,CAB037086,Approved,,,,Pancreatic cancer:2.21e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 86.4,thyroid gland: 28.1,Cell line enhanced,,ASC diff: 56.8
780,WBSCR17,"GalNAc-T5L, GALNTL3",ENSG00000185274,Williams-Beuren syndrome chromosome region 17,7,71132169-71713600,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA013624, HPA047986",Approved,,Uncertain,Nucleus<br>Nucleoli<br>Nuclear bodies<br>Golgi apparatus,"Testis cancer:3.91e-4 (favourable), Ovarian cancer:4.60e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 76.4,ovary: 29.1,Cell line enhanced,,AF22: 14.1;NTERA-2: 10.8;RPMI-8226: 8.6;SK-BR-3: 34.1
781,WDR17,,ENSG00000150627,WD repeat domain 17,4,176065834-176182818,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA042766, HPA054501",Approved,,Approved,Nuclear speckles,,Mixed,Tissue enhanced,,cerebral cortex: 25.2;parathyroid gland: 19.3,thyroid gland: 11.0,Cell line enhanced,,AF22: 7.7;SCLC-21H: 10.5
782,WDR7,"KIAA0541, TRAG",ENSG00000091157,WD repeat domain 7,18,56651343-57036606,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042074, HPA051057",Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:1.13e-5 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 38.6,parathyroid gland: 17.0,Expressed in all,,
783,WNT1,INT1,ENSG00000125084,Wnt family member 1,12,48978453-48981676,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.3,lymph node: 1.0,Not detected,,
784,WNT10B,"SHFM6, WNT-12",ENSG00000169884,Wnt family member 10B,12,48965340-48971763,"Disease related genes, Predicted secreted proteins",Evidence at protein level,"HPA055048, HPA062539",Enhanced,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,cerebral cortex: 11.6,skin: 3.0,Cell line enhanced,,T-47d: 7.6
785,WNT7A,,ENSG00000154764,Wnt family member 7A,3,13816258-13880121,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA015719, CAB025894",Approved,,,,"Pancreatic cancer:3.03e-6 (unfavourable), Endometrial cancer:2.96e-5 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.7;gallbladder: 3.6;placenta: 3.9,lung: 3.0,Group enriched,5.0,BEWO: 56.9;EFO-21: 52.0;PC-3: 18.2;RPTEC TERT1: 74.6
786,WSCD1,KIAA0523,ENSG00000179314,WSC domain containing 1,17,5772234-6124427,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA015919,Uncertain,,Approved,Nucleoplasm<br>Golgi apparatus,,Group enriched,Tissue enhanced,,cerebral cortex: 30.3;spleen: 19.0,testis: 14.9,Cell line enhanced,,AF22: 39.4;HUVEC TERT2: 20.9;PC-3: 23.1;RH-30: 61.0;SCLC-21H: 18.5
787,YJEFN3,"FLJ44968, hYjeF_N3-19p13.11",ENSG00000250067,YjeF N-terminal domain containing 3,19,19528861-19537581,Predicted intracellular proteins,Evidence at protein level,HPA060789,Approved,,Approved,Mitochondria,"Renal cancer:1.30e-7 (unfavourable), Pancreatic cancer:7.25e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 15.6;testis: 5.6,epididymis: 3.0,Cell line enhanced,,BEWO: 8.5;HEK93: 9.6
788,YPEL4,FLJ30213,ENSG00000166793,Yippee like 4,11,57645087-57649944,Predicted intracellular proteins,Evidence at transcript level,HPA045621,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 19.0,ovary: 4.3,Cell line enhanced,,AF22: 3.2;SK-MEL-30: 3.1
789,ZC3H12B,"CXorf32, MCPIP2",ENSG00000102053,Zinc finger CCCH-type containing 12B,X,65366638-65507887,Predicted intracellular proteins,Evidence at transcript level,HPA000836,Uncertain,,Approved,Endoplasmic reticulum<br>Golgi apparatus<br>Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 4.6,endometrium: 2.2,Cell line enhanced,,AF22: 2.1
790,ZCCHC18,"PNMA7B, SIZN2",ENSG00000166707,Zinc finger CCHC-type containing 18,X,104112131-104115846,Predicted intracellular proteins,Evidence at transcript level,HPA034940,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.6,ovary: 4.2,Cell line enhanced,,Karpas-707: 3.3;SH-SY5Y: 3.2
791,ZNF365,"KIAA0844, UAN",ENSG00000138311,Zinc finger protein 365,10,62374192-62672011,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA052446,Enhanced,,Supported,Vesicles<br>Microtubule organizing center,,Mixed,Tissue enhanced,,cerebral cortex: 54.5,parathyroid gland: 10.9,Cell line enhanced,,HaCaT: 18.7;PC-3: 12.7;U-251 MG: 14.7
792,ZNF385D,"FLJ22419, ZNF659",ENSG00000151789,Zinc finger protein 385D,3,21412222-22373321,Predicted intracellular proteins,Evidence at protein level,HPA036190,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 4.8,adipose tissue: 3.1,Cell line enhanced,,ASC TERT1: 2.2;RPTEC TERT1: 3.3;U-87 MG: 8.1
793,ZNF536,KIAA0390,ENSG00000198597,Zinc finger protein 536,19,30228290-30713538,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA077341,,,Approved,Nucleus<br>Cell Junctions,,Mixed,Tissue enhanced,,cerebral cortex: 19.0,thyroid gland: 5.3,Cell line enhanced,,HAP1: 11.4;SH-SY5Y: 31.3;WM-115: 12.5
794,ZNF804A,C2orf10,ENSG00000170396,Zinc finger protein 804A,2,184598366-184939492,Predicted intracellular proteins,Evidence at protein level,HPA029195,Uncertain,,Approved,Endoplasmic reticulum,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.4,thyroid gland: 2.7,Cell line enhanced,,Daudi: 21.5;RH-30: 19.3;U-698: 15.3
